

# CITATION REPORT

List of articles citing

## Alzheimer's disease: genes, proteins, and therapy

DOI: 10.1152/physrev.2001.81.2.741  
Physiological Reviews, 2001, 81, 741-66.

**Source:** <https://exaly.com/paper-pdf/32650344/citation-report.pdf>

**Version:** 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2266	Brain Dysfunction Associated with Amyloid Fibrils and Other Aggregated Proteins. 355-382		
2265	Role of free radicals in the neurodegenerative diseases: therapeutic implications for antioxidant treatment. <b>2001</b> , 18, 685-716		1059
2264	Identification of a new synaptic vesicle protein 2B mRNA transcript which is up-regulated in neurons by amyloid beta peptide fragment (1-42). <b>2001</b> , 289, 924-8		14
2263	Wild-type and mutated nicastrins do not display aminopeptidase M- and B-like activities. <b>2001</b> , 289, 678-80		11
2262	Reactive astrocytes and alpha1-antichymotrypsin in Alzheimer's disease. <b>2001</b> , 22, 931-6		67
2261	Visualizing the growth of Alzheimer's A beta amyloid-like fibrils. <b>2001</b> , 7, 582		15
2260	Interaction with telencephalin and the amyloid precursor protein predicts a ring structure for presenilins. <b>2001</b> , 32, 579-89		176
2259	Neuroinflammation and the genetics of Alzheimer's disease: the search for a pro-inflammatory phenotype. <b>2001</b> , 13, 163-70		28
2258	Clinical aspects of Alzheimer's disease. <b>2001</b> , 13, 221-30		11
2257	Psychogenomics: opportunities for understanding addiction. <b>2001</b> , 21, 8324-7		50
2256	Production of reactive oxygen species from aggregating proteins implicated in Alzheimer's disease, Parkinson's disease and other neurodegenerative diseases. <b>2001</b> , 1, 507-17		135
2255	Die Alzheimer Krankheit - von den molekularen Mechanismen zu potentiellen Therapien. <b>2001</b> , 7, 127-136		
2254	Molecular and cell biological aspects of Alzheimer disease. <b>2001</b> , 46, 609-18		8
2253	Introduction: Special issue on the genetics of bipolar disorder. <b>2001</b> , 3, 267-9		1
2252	Brain metabolism and brain disease: is metabolic deficiency the proximate cause of Alzheimer dementia?. <b>2001</b> , 66, 851-6		127
2251	Alzheimer's amyloid-beta as a preventive antioxidant for brain lipoproteins. <b>2001</b> , 21, 299-315		19
2250	Intracellular mechanisms of amyloid accumulation and pathogenesis in Alzheimer's disease. <b>2001</b> , 17, 137-45		169

2249	The beta-secretase, BACE: a prime drug target for Alzheimer's disease. <b>2001</b> , 17, 157-70	137
2248	Implication of APP secretases in notch signaling. <b>2001</b> , 17, 171-81	57
2247	Lewy body pathology in Alzheimer's disease. <b>2001</b> , 17, 225-32	108
2246	Targeting A $\beta$ 2. <b>2001</b> , 2, 856-856	
2245	Transgenic mouse models of Alzheimer's disease. <b>2001</b> , 17, S7-12	73
2244	The molecular bases of Alzheimer's disease and other neurodegenerative disorders. <b>2001</b> , 32, 367-81	331
2243	The cell biology of Alzheimer's disease: uncovering the secrets of secretases. <b>2001</b> , 11, 585-90	154
2242	Apolipoprotein E: a major piece in the Alzheimer's disease puzzle. <b>2001</b> , 5, 254-66	89
2241	Alzheimer's beta-secretase, beta-site amyloid precursor protein-cleaving enzyme, is responsible for cleavage secretion of a Golgi-resident sialyltransferase. <b>2001</b> , 98, 13554-9	223
2240	Phosphorylation-dependent regulation of the interaction of amyloid precursor protein with Fe65 affects the production of beta-amyloid. <b>2001</b> , 276, 40353-61	198
2239	Distinct intramembrane cleavage of the beta-amyloid precursor protein family resembling gamma-secretase-like cleavage of Notch. <b>2001</b> , 276, 35235-8	237
2238	The intracellular domain of the beta-amyloid precursor protein is stabilized by Fe65 and translocates to the nucleus in a notch-like manner. <b>2001</b> , 276, 40288-92	346
2237	4th Annual Pharmacogenomics and Medicine Lectures. <b>2001</b> , 2, 291-6	16
2236	beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. <b>2001</b> , 98, 12245-50	465
2235	Signal transduction through tyrosine-phosphorylated C-terminal fragments of amyloid precursor protein via an enhanced interaction with Shc/Grb2 adaptor proteins in reactive astrocytes of Alzheimer's disease brain. <b>2002</b> , 277, 35282-8	92
2234	Methionine 35 oxidation reduces fibril assembly of the amyloid abeta-(1-42) peptide of Alzheimer's disease. <b>2002</b> , 277, 40173-6	172
2233	The JNK/c-Jun cascade and Alzheimer's disease. <b>2002</b> , 17, 79-88	55
2232	Fe65, a ligand of the Alzheimer's beta-amyloid precursor protein, blocks cell cycle progression by down-regulating thymidylate synthase expression. <b>2002</b> , 277, 35481-8	66

2231	Inclusion body myositis-like phenotype induced by transgenic overexpression of beta APP in skeletal muscle. <b>2002</b> , 99, 6334-9	91
2230	Biosynthesis and cellular trafficking of the convertase SKI-1/S1P: ectodomain shedding requires SKI-1 activity. <b>2002</b> , 277, 11265-75	90
2229	The integration of neurology, psychiatry, and neuroscience in the 21st century. <b>2002</b> , 159, 695-704	116
2228	Deciphering the genetic basis of Alzheimer's disease. <b>2002</b> , 3, 67-99	226
2227	Studies of the aggregation of mutant proteins in vitro provide insights into the genetics of amyloid diseases. <b>2002</b> , 99 Suppl 4, 16419-26	246
2226	Beta-amyloid precursor protein transgenic mice that harbor diffuse A beta deposits but do not form plaques show increased ischemic vulnerability: role of inflammation. <b>2002</b> , 99, 1610-5	145
2225	Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. <b>2002</b> , 277, 32046-53	1117
2224	The mechanism of gamma-secretase activities through high molecular weight complex formation of presenilins is conserved in <i>Drosophila melanogaster</i> and mammals. <b>2002</b> , 277, 50198-205	36
2223	Presenilin-dependent gamma-secretase-like intramembrane cleavage of ErbB4. <b>2002</b> , 277, 6318-23	237
2222	Oxidative nerve cell death in Alzheimer's disease and stroke: antioxidants as neuroprotective compounds. <b>2002</b> , 383, 521-36	151
2221	Complex N-linked glycosylated nicastrin associates with active gamma-secretase and undergoes tight cellular regulation. <b>2002</b> , 277, 35113-7	99
2220	The disintegrin/metalloprotease ADAM 10 is essential for Notch signalling but not for alpha-secretase activity in fibroblasts. <b>2002</b> , 11, 2615-24	525
2219	Understanding the pathology of schizophrenia: recent advances from the study of the molecular architecture of postmortem CNS tissue. <b>2002</b> , 78, 142-8	21
2218	Apolipoprotein E structural requirements for the formation of SDS-stable complexes with beta-amyloid-(1-40): the role of salt bridges. <b>2002</b> , 366, 273-9	31
2217	Molecular cloning and characterization of CALP/KChIP4, a novel EF-hand protein interacting with presenilin 2 and voltage-gated potassium channel subunit Kv4. <b>2002</b> , 277, 14965-75	125
2216	A beta 17-42 in Alzheimer's disease activates JNK and caspase-8 leading to neuronal apoptosis. <b>2002</b> , 125, 2036-43	100
2215	Cytoskeleton expression in Alzheimer disease. <b>2002</b> , 61, 230-6	
2214	Sex hormones, neuroprotection and cognition. <b>2002</b> , 138, 135-42	11

2213	Iron: a pathological mediator of Alzheimer disease?. <b>2002</b> , 24, 184-7	106
2212	Cerebrovascular autoregulation is profoundly impaired in mice overexpressing amyloid precursor protein. <b>2002</b> , 283, H315-23	220
2211	Inhibition of BACE, a promising approach to Alzheimer's disease therapy. <b>2002</b> , 2, 359-70	51
2210	Sequential assistance of molecular chaperones and transient formation of covalent complexes during protein degradation from the ER. <b>2002</b> , 158, 247-57	186
2209	Mapping the Progress of Alzheimer's and Parkinson's Disease. <b>2002</b> ,	2
2208	A common protein interaction domain links two recently identified epilepsy genes. <b>2002</b> , 11, 1757-62	97
2207	Drug therapy in human and experimental transmissible spongiform encephalopathy. <b>2002</b> , 58, 1720-5	44
2206	Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer's disease. <b>2002</b> , 99, 10843-8	273
2205	Stimulation of enveloped virus infection by beta-amyloid fibrils. <b>2002</b> , 277, 35019-24	65
2204	Interaction of intracellular beta amyloid peptide with chaperone proteins. <b>2002</b> , 99, 9439-44	176
2203	Heme deficiency may be a factor in the mitochondrial and neuronal decay of aging. <b>2002</b> , 99, 14807-12	161
2202	A candidate molecular mechanism for the association of an intronic polymorphism of FE65 with resistance to very late onset dementia of the Alzheimer type. <b>2002</b> , 11, 465-75	24
2201	Signaling events in amyloid beta-peptide-induced neuronal death and insulin-like growth factor I protection. <b>2002</b> , 277, 17649-56	152
2200	The novel presenilin-1-associated protein is a proapoptotic mitochondrial protein. <b>2002</b> , 277, 48913-22	43
2199	The gamma-secretase-generated intracellular domain of beta-amyloid precursor protein binds Numb and inhibits Notch signaling. <b>2002</b> , 99, 7102-7	169
2198	Genetic polymorphisms and cerebrospinal fluid levels of tissue inhibitor of metalloproteinases 1 in sporadic Alzheimer's disease. <b>2002</b> , 12, 155-60	11
2197	Amyloid beta peptide induces cytochrome C release from isolated mitochondria. <b>2002</b> , 13, 1989-93	108
2196	Gene-Environment Interactions in Cognitive Disorders. 377-385	

2195	Glutamate exacerbates amyloid beta1-42-induced impairment of long-term potentiation in rat hippocampal slices. <b>2002</b> , 88, 223-6	16
2194	The 4,752 C/T polymorphism in the presenilin 1 gene increases the risk of Alzheimer's disease in apolipoprotein E4 carriers. <b>2002</b> , 41, 823-8	7
2193	Alzheimer transgenic models. <b>2002</b> , 15, 433-439	1
2192	Diet-induced hypercholesterolemia enhances brain A beta accumulation in transgenic mice. <b>2002</b> , 13, 455-9	196
2191	Antioxidants and Alzheimer's disease: from bench to bedside (and back again). <b>2002</b> , 5, 645-51	35
2190	Engineering of metallothionein-3 neuroinhibitory activity into the inactive isoform metallothionein-1. <b>2002</b> , 277, 37023-8	52
2189	The Economic and Social Burden of Bipolar Disorder. <b>2002</b> , 441-501	3
2188	Presenilin-1 mutations alter K+ currents in the human neuroblastoma cell line, SH-SY5Y. <b>2002</b> , 13, 1553-6	9
2187	Glu11 site cleavage and N-terminally truncated A beta production upon BACE overexpression. <b>2002</b> , 41, 3128-36	98
2186	TaqMan systems for genotyping of disease-related polymorphisms present in the gene encoding apolipoprotein E. <b>2002</b> , 40, 1123-31	110
2185	Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. <b>2002</b> , 295, 2264-7	495
2184	Crystal structure of memapsin 2 (beta-secretase) in complex with an inhibitor OM00-3. <b>2002</b> , 41, 10963-7	184
2183	Intraneuronal Alzheimer abeta42 accumulates in multivesicular bodies and is associated with synaptic pathology. <b>2002</b> , 161, 1869-79	573
2182	Alzheimer's disease is a synaptic failure. <b>2002</b> , 298, 789-91	3246
2181	Beta-amyloid plaques in a model for sporadic Alzheimer's disease based on transgenic anti-nerve growth factor antibodies. <i>Molecular and Cellular Neurosciences</i> , <b>2002</b> , 21, 15-28	4.8 85
2180	Alterations in cerebral blood flow and glucose utilization in mice overexpressing the amyloid precursor protein. <b>2002</b> , 9, 61-8	164
2179	Acetylcholinesterase inhibitors in the context of therapeutic strategies to combat Alzheimer's disease. <b>2002</b> , 12, 1853-1865	12
2178	The molecular basis of copper homeostasis copper-related disorders. <b>2002</b> , 21, 259-70	117

2177	The search for an amyloid solution. <b>2002</b> , 298, 962-4; author reply 962-4	26
2176	Genetics of dementia. <b>2002</b> , 86, 591-614	19
2175	Inherited dementias. <b>2002</b> , 20, 779-808, vii	10
2174	The intramembrane cleavage site of the amyloid precursor protein depends on the length of its transmembrane domain. <b>2002</b> , 99, 1365-70	66
2173	Pharmacogenomics for the treatment of dementia. <b>2002</b> , 34, 357-79	39
2172	Protein phosphatase 2A methylation: a link between elevated plasma homocysteine and Alzheimer's Disease. <b>2002</b> , 518, 1-4	89
2171	Complex N-glycosylated form of nicastrin is stabilized and selectively bound to presenilin fragments. <b>2002</b> , 520, 117-21	56
2170	Memapsin 2 (beta-secretase) cytosolic domain binds to the VHS domains of GGA1 and GGA2: implications on the endocytosis mechanism of memapsin 2. <b>2002</b> , 524, 183-7	101
2169	Mutations that reduce aggregation of the Alzheimer's Abeta42 peptide: an unbiased search for the sequence determinants of Abeta amyloidogenesis. <b>2002</b> , 319, 1279-90	198
2168	Lipoprotein receptors in the nervous system. <b>2002</b> , 71, 405-34	346
2167	Altered metabolism of the amyloid beta precursor protein is associated with mitochondrial dysfunction in Down's syndrome. <b>2002</b> , 33, 677-88	313
2166	Protein misfolding, amyloid formation, and neurodegeneration: a critical role for molecular chaperones?. <b>2002</b> , 35, 9-12	262
2165	Inflammation in neurodegenerative disease--a double-edged sword. <b>2002</b> , 35, 419-32	927
2164	CD40-CD40L interaction in Alzheimer's disease. <b>2002</b> , 2, 445-51	44
2163	Alzheimer's and Parkinson's disease--overlapping or synergistic pathologies?. <b>2002</b> , 8, 3-5	47
2162	Dementia, the fate of brain? Neuropathological point of view. <b>2002</b> , 325, 655-64	5
2161	Benzofuran derivatives as Abeta-aggregate-specific imaging agents for Alzheimer's disease. <b>2002</b> , 29, 633-42	118
2160	Abeta-degrading endopeptidase, neprilysin, in mouse brain: synaptic and axonal localization inversely correlating with Abeta pathology. <b>2002</b> , 43, 39-56	121

2159	Muscarine enhances soluble amyloid precursor protein secretion in human neuroblastoma SH-SY5Y by a pathway dependent on protein kinase C(alpha), src-tyrosine kinase and extracellular signal-regulated kinase but not phospholipase C. <b>2002</b> , 102, 62-72	47
2158	Beta-amyloid (Abeta) protein in cerebrospinal fluid as a biomarker for Alzheimer's disease. <b>2002</b> , 23, 1205-14	64
2157	ADDLs & protofibrils--the missing links?. <b>2002</b> , 23, 231-5	71
2156	Gene action in the aging brain: an evolutionary biological perspective. <b>2002</b> , 23, 647-54	20
2155	Abeta as a bioflocculant: implications for the amyloid hypothesis of Alzheimer's disease. <b>2002</b> , 23, 1051-72	115
2154	Alzheimer's disease and Alzheimer's dementia: distinct but overlapping entities. <b>2002</b> , 23, 1077-84	53
2153	Abeta conformational change is central to Alzheimer's disease. <b>2002</b> , 23, 1085-8	10
2152	The amyloid hypothesis: let sleeping dogmas lie?. <b>2002</b> , 23, 1101-5	53
2151	Characterization of neuronal dystrophy induced by fibrillar amyloid beta: implications for Alzheimer's disease. <b>2002</b> , 114, 265-73	144
2150	Expression of the Fe65 adapter protein in adult and developing mouse brain. <b>2002</b> , 115, 951-60	46
2149	Alzheimer's disease and the basal forebrain cholinergic system: relations to beta-amyloid peptides, cognition, and treatment strategies. <b>2002</b> , 68, 209-45	527
2148	Elevated levels of Abeta1-40 and Abeta1-42 do not alter the binding sites of nicotinic receptor subtypes in the brain of APP <sup>swe</sup> and PS1 double transgenic mice. <b>2002</b> , 328, 269-72	19
2147	Chapter 4. Emerging themes in Alzheimer's disease research: Paradigm shift in drug discovery. <b>2002</b> , 37, 31-40	1
2146	Diagnostic testing in neurogenetics. Principles, limitations, and ethical considerations. <b>2002</b> , 20, 627-43, v	13
2145	Métabolisme du précurseur du peptide amyloïde et préβilines. <b>2002</b> , 18, 717-724	2
2144	Beta-amyloid-induced synthesis of the ganglioside GD3 is a requisite for cell cycle reactivation and apoptosis in neurons. <b>2002</b> , 22, 3963-8	80
2143	Amyloid precursor protein, presenilins, and alpha-synuclein: molecular pathogenesis and pharmacological applications in Alzheimer's disease. <b>2002</b> , 54, 469-525	354
2142	Nicotine lowers the secretion of the Alzheimer's amyloid beta-protein precursor that contains amyloid beta-peptide in rat. <b>2002</b> , 4, 405-15	42



2141	Abeta deposition is essential to AD neuropathology. <b>2002</b> , 4, 133-8	6
2140	Neuronal deficiency of presenilin 1 inhibits amyloid plaque formation and corrects hippocampal long-term potentiation but not a cognitive defect of amyloid precursor protein [V717I] transgenic mice. <b>2002</b> , 22, 3445-53	207
2139	The relationship between Abeta and memory in the Tg2576 mouse model of Alzheimer's disease. <b>2002</b> , 22, 1858-67	600
2138	. <b>2002</b> ,	7
2137	Effect of reactive oxygen species on NH4+ permeation in <i>Xenopus laevis</i> oocytes. <b>2002</b> , 282, C1445-53	20
2136	Searching for an in vivo site for nascent amyloid fibril formation. <b>2002</b> , 4, 105-14	6
2135	Association of novel and established polymorphisms in neuronal nicotinic acetylcholine receptors with sporadic Alzheimer's disease. <b>2002</b> , 4, 71-6	35
2134	Evidence that synaptically released beta-amyloid accumulates as extracellular deposits in the hippocampus of transgenic mice. <b>2002</b> , 22, 9785-93	255
2133	Modulation of Alzheimer-like synaptic and cholinergic deficits in transgenic mice by human apolipoprotein E depends on isoform, aging, and overexpression of amyloid beta peptides but not on plaque formation. <b>2002</b> , 22, 10539-48	165
2132	Expression of human apolipoprotein E downregulates amyloid precursor protein-induced ischemic susceptibility. <b>2002</b> , 33, 1905-10	8
2131	Implications of amyloid precursor protein and subsequent beta-amyloid production to the pharmacotherapy of Alzheimer's disease. <b>2002</b> , 22, 1547-63	8
2130	A novel compound RS-0466 reverses beta-amyloid-induced cytotoxicity through the Akt signaling pathway in vitro. <b>2002</b> , 457, 11-7	22
2129	Ageing of the brain. <b>2002</b> , 123, 811-7	124
2128	Prostaglandins and other lipid mediators in Alzheimer's disease. <b>2002</b> , 68-69, 197-210	119
2127	CD45 isoform alteration in CD4+ T cells as a potential diagnostic marker of Alzheimer's disease. <b>2002</b> , 132, 164-72	40
2126	Molecular mechanisms underlying cyclic AMP inhibition of macrophage dependent TNF-alpha production and neurotoxicity in response to amyloidogenic C-terminal fragment of Alzheimer's amyloid precursor protein. <b>2002</b> , 133, 160-74	19
2125	Amyloidosis and Alzheimer's disease. <b>2002</b> , 54, 1539-51	137
2124	Beta-secretase (BACE) as a drug target for Alzheimer's disease. <b>2002</b> , 54, 1589-602	179

2123	Neuroinflammation and anti-inflammatory therapy for Alzheimer's disease. <b>2002</b> , 54, 1627-56	108
2122	Apolipoprotein E modulates Alzheimer's Abeta(1-42)-induced oxidative damage to synaptosomes in an allele-specific manner. <b>2002</b> , 924, 90-7	111
2121	Ca(2+) stores and capacitative Ca(2+) entry in human neuroblastoma (SH-SY5Y) cells expressing a familial Alzheimer's disease presenilin-1 mutation. <b>2002</b> , 949, 105-11	40
2120	IMPY: an improved thioflavin-T derivative for in vivo labeling of beta-amyloid plaques. <b>2002</b> , 956, 202-10	184
2119	The potential of anti-inflammatory drugs for the treatment of Alzheimer's disease. <b>2002</b> , 1, 279-84	163
2118	Role of neuroproteomics in CNS drug discovery. <b>2002</b> , 1, 95-101	4
2117	Tissue-type plasminogen activator is a multiligand cross-beta structure receptor. <b>2002</b> , 12, 1833-9	93
2116	Alzheimer disease gamma-secretase: a complex story of GxGD-type presenilin proteases. <b>2002</b> , 12, 556-62	155
2115	Substitution of isoleucine-31 by helical-breaking proline abolishes oxidative stress and neurotoxic properties of Alzheimer's amyloid beta-peptide. <b>2002</b> , 32, 1205-11	81
2114	Antioxidant neuroprotection in Alzheimer's disease as preventive and therapeutic approach. <b>2002</b> , 33, 182-91	211
2113	Molecular evidence of presenilin 1 mutation in familial early onset dementia. <b>2002</b> , 114, 292-8	15
2112	Evaluation of multiple presenilin 2 SNPs for association with early-onset sporadic Alzheimer disease. <b>2002</b> , 111, 157-63	7
2111	Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: A 26-week randomized, placebo-controlled, double-blind trial. <b>2002</b> , 52, 346-50	304
2110	Paradigm shifts in Alzheimer's disease and other neurodegenerative disorders: the emerging role of oligomeric assemblies. <b>2002</b> , 69, 567-77	493
2109	Region-specific reduction of A beta-degrading endopeptidase, neprilysin, in mouse hippocampus upon aging. <b>2002</b> , 70, 493-500	164
2108	Urokinase-type plasminogen activator inhibits amyloid-beta neurotoxicity and fibrillogenesis via plasminogen. <b>2002</b> , 70, 249-55	44
2107	Age-related deficits in long-term potentiation are insensitive to hydrogen peroxide: coincidence with enhanced autophosphorylation of Ca2+/calmodulin-dependent protein kinase II. <b>2002</b> , 70, 298-308	36
2106	Familial conformational diseases and dementias. <b>2002</b> , 20, 1-14	46

2105	Therapeutic strategies of Alzheimer's disease through manipulation of A $\beta$ metabolism: a focus on A $\beta$ degrading peptidase, neprilysin. <b>2002</b> , 56, 171-183	4
2104	Targeting intracellular A $\beta$ 2 for Alzheimer's disease drug discovery. <b>2002</b> , 56, 194-200	15
2103	Secretases as targets for beta-amyloid lowering drugs. <b>2002</b> , 56, 201-210	7
2102	Targeting APP metabolism for the treatment of Alzheimer's disease. <b>2002</b> , 56, 211-227	13
2101	Role of amyloid $\beta$ peptides in the regulation of central cholinergic function and its relevance to Alzheimer's disease pathology. <b>2002</b> , 56, 248-263	8
2100	Role of GSK-3 $\beta$ in Alzheimer's disease pathology. <b>2002</b> , 56, 491-510	71
2099	Effects of beta-amyloid on proliferation and morphology of yeast <i>Saccharomyces cerevisiae</i> . <b>2002</b> , 9, 197-201	2
2098	Development of indole-3-propionic acid (OXIGON) for Alzheimer's disease. <b>2002</b> , 19, 213-7	95
2097	The biological role of the Alzheimer amyloid precursor protein in epithelial cells. <b>2002</b> , 117, 171-80	56
2096	Cytosolic and nuclear aggregation of the amyloid beta-peptide following its expression in the endoplasmic reticulum. <b>2002</b> , 118, 353-60	61
2095	Pathology, diagnosis and pathogenesis of AA amyloidosis. <b>2002</b> , 440, 111-122	165
2094	The beta-amyloid precursor protein (APP) and Alzheimer's disease: does the tail wag the dog?. <b>2002</b> , 3, 763-70	60
2093	Enriched early experiences of mice underexpressing the beta-amyloid precursor protein restore spatial learning capabilities but not normal openfield behavior of adult animals. <b>2002</b> , 1, 230-41	18
2092	Expression of human beta-secretase in the mouse brain increases the steady-state level of beta-amyloid. <b>2002</b> , 80, 799-806	108
2091	The disulphide bonds in the catalytic domain of BACE are critical but not essential for amyloid precursor protein processing activity. <b>2002</b> , 80, 1079-88	26
2090	Characterizing CGI-94 (comparative gene identification-94) which is down-regulated in the hippocampus of early stage Alzheimer's disease brain. <b>2002</b> , 15, 79-86	6
2089	Nutritional approaches to combat oxidative stress in Alzheimer's disease. <b>2002</b> , 13, 444	293
2088	Potential novel targets for Alzheimer pharmacotherapy: I. Secretases. <b>2002</b> , 27, 169-83	23

2087	Plaque-associated disruption of CSF and plasma amyloid-beta (Abeta) equilibrium in a mouse model of Alzheimer's disease. <b>2002</b> , 81, 229-36	208
2086	Divergent pathways account for two distinct effects of amyloid beta peptides on exocytosis and Ca(2+) currents: involvement of ROS and NF-kappaB. <b>2002</b> , 81, 1043-51	29
2085	Low-density lipoprotein receptor-related protein levels and endocytic function are reduced by overexpression of the FE65 adaptor protein, FE65L1. <b>2002</b> , 82, 755-62	21
2084	Prostaglandin H2 (PGH2) accelerates formation of amyloid beta1-42 oligomers. <b>2002</b> , 82, 1003-6	51
2083	Pyroglutamate-modified amyloid beta-peptides--AbetaN3(pE)--strongly affect cultured neuron and astrocyte survival. <b>2002</b> , 82, 1480-9	155
2082	Involvement of Gadd153 in the pathogenic action of presenilin-1 mutations. <b>2002</b> , 83, 673-81	62
2081	The neuropathogenic contributions of lysosomal dysfunction. <b>2002</b> , 83, 481-9	170
2080	Altered processing of amyloid precursor protein in the human neuroblastoma SH-SY5Y by chronic hypoxia. <b>2002</b> , 83, 1262-71	52
2079	Disruption of neurogenesis by amyloid beta-peptide, and perturbed neural progenitor cell homeostasis, in models of Alzheimer's disease. <b>2002</b> , 83, 1509-24	398
2078	Hypoxia potentiates exocytosis and Ca2+ channels in PC12 cells via increased amyloid beta peptide formation and reactive oxygen species generation. <b>2002</b> , 541, 1013-23	42
2077	Inflammation and therapeutic vaccination in CNS diseases. <b>2002</b> , 420, 879-84	218
2076	Medicine: danger--misfolding proteins. <b>2002</b> , 416, 483-4	136
2075	Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. <b>2002</b> , 416, 535-9	3560
2074	Amyloid diseases: small drugs lead the attack. <b>2002</b> , 417, 231-3	11
2073	Inflammation takes on Alzheimer disease. <b>2002</b> , 8, 936-8	39
2072	Generation of antibodies specific for beta-amyloid by vaccination of patients with Alzheimer disease. <b>2002</b> , 8, 1270-5	243
2071	Genetically engineered mouse models of neurodegenerative diseases. <b>2002</b> , 5, 633-9	190
2070	Role of CD40 ligand in amyloidosis in transgenic Alzheimer's mice. <b>2002</b> , 5, 1288-93	179

2069	Serpinopathies and the conformational dementias. <b>2002</b> , 3, 759-68	188
2068	The comeback of immunization. <b>2002</b> , 3, 330-330	1
2067	Oestrogen as a neuroprotective hormone. <b>2002</b> , 3, 433-42	381
2066	A novel beta-sheet breaker, RS-0406, reverses amyloid beta-induced cytotoxicity and impairment of long-term potentiation in vitro. <b>2002</b> , 137, 676-82	75
2065	Signal transduction through tyrosine-phosphorylated carboxy-terminal fragments of APP via an enhanced interaction with Shc/Grb2 adaptor proteins in reactive astrocytes of Alzheimer's disease brain. <b>2002</b> , 973, 323-33	31
2064	Regulation of promoter activity of the APP gene by cytokines and growth factors: implications in Alzheimer's disease. <b>2002</b> , 973, 463-7	69
2063	Cerebrovascular disease is a major factor in the failure of elimination of Abeta from the aging human brain: implications for therapy of Alzheimer's disease. <b>2002</b> , 977, 162-8	75
2062	The G. L. Brown Prize Lecture. Hypoxic regulation of ion channel function and expression. <b>2002</b> , 87, 413-22	14
2061	Decreased concentration of human kallikrein 6 in brain extracts of Alzheimer's disease patients. <b>2002</b> , 35, 225-31	47
2060	Kinetic modeling and determination of reaction constants of Alzheimer's beta-amyloid fibril extension and dissociation using surface plasmon resonance. <b>2002</b> , 41, 13489-98	114
2059	Progress in focus: recent advances in histochemistry and cell biology. <b>2002</b> , 118, 507-25	4
2058	Thermodynamics of single peptide bond cleavage in bovine pancreatic trypsin inhibitor (BPTI). <b>2002</b> , 11, 924-32	24
2057	The hydrophobic environment of Met35 of Alzheimer's Abeta(1-42) is important for the neurotoxic and oxidative properties of the peptide. <b>2002</b> , 4, 219-23	46
2056	Human alcoholism studies of genes identified through mouse quantitative trait locus analysis. <b>2002</b> , 7, 365-71	1
2055	CLAC: a novel Alzheimer amyloid plaque component derived from a transmembrane precursor, CLAC-P/collagen type XXV. <b>2002</b> , 21, 1524-34	159
2054	A presenilin-1/gamma-secretase cleavage releases the E-cadherin intracellular domain and regulates disassembly of adherens junctions. <b>2002</b> , 21, 1948-56	560
2053	Presenilins mediate a dual intramembranous gamma-secretase cleavage of Notch-1. <b>2002</b> , 21, 5408-16	178
2052	Loss of spr-5 bypasses the requirement for the C.elegans presenilin sel-12 by derepressing hop-1. <b>2002</b> , 21, 5787-96	47

2051	Gamma-secretase: substrates and inhibitors. <b>2002</b> , 26, 81-95	19
2050	Intracellular A-beta amyloid, a sign for worse things to come?. <b>2002</b> , 26, 299-316	63
2049	Advances in the cellular and molecular biology of the beta-amyloid protein in Alzheimer's disease. <b>2002</b> , 1, 1-31	147
2048	Disruption of neurogenesis in the subventricular zone of adult mice, and in human cortical neuronal precursor cells in culture, by amyloid beta-peptide: implications for the pathogenesis of Alzheimer's disease. <b>2002</b> , 1, 125-35	192
2047	Effects of lipophilicity on the affinity and nonspecific binding of iodinated benzothiazole derivatives. <b>2003</b> , 20, 255-60	40
2046	Antioxidant treatment in Alzheimer's disease: current state. <b>2003</b> , 21, 1-11	89
2045	Impact of aging: sporadic, and genetic risk factors on vulnerability to apoptosis in Alzheimer's disease. <b>2003</b> , 4, 161-78	26
2044	Structure-activity relationship of imidazo[1,2-a]pyridines as ligands for detecting beta-amyloid plaques in the brain. <b>2003</b> , 46, 237-43	197
2043	Enhancer regulation/endogenous and synthetic enhancer compounds: a neurochemical concept of the innate and acquired drives. <b>2003</b> , 28, 1275-97	13
2042	Cerebrovascular effects of amyloid-beta peptides: mechanisms and implications for Alzheimer's dementia. <b>2003</b> , 23, 681-9	79
2041	Alzheimer's beta-secretase cleaves a glycosyltransferase as a physiological substrate. <b>2004</b> , 20, 59-62	11
2040	In vitro cultured neurons for molecular studies correlating apoptosis with events related to Alzheimer disease. <b>2003</b> , 2, 270-8	23
2039	DSCR1(Adapt78)--a Janus gene providing stress protection but causing Alzheimer's disease?. <b>2003</b> , 55, 29-31	20
2038	Methionine oxidation: Implications for the mechanism of toxicity of the $\beta$ amyloid peptide from Alzheimer's disease. <b>2003</b> , 10, 413-417	13
2037	Increased fibrillar beta-amyloid in response to human clq injections into hippocampus and cortex of APP+PS1 transgenic mice. <b>2003</b> , 28, 83-93	26
2036	Beta-amyloid and cholinergic neurons. <b>2003</b> , 28, 499-506	23
2035	XB51 isoforms mediate Alzheimer's beta-amyloid peptide production by X11L (X11-like protein)-dependent and -independent mechanisms. <b>2003</b> , 374, 261-8	19
2034	Cerebral amyloid angiopathy: pathogenesis and effects on the ageing and Alzheimer brain. <b>2003</b> , 25, 611-6	94

2033	Distinct mechanisms account for beta-amyloid toxicity in PC12 and differentiated PC12 neuronal cells. <b>2003</b> , 10, 379-88	4
2032	The role of the N-methyl-D-aspartate receptor in Alzheimer's disease: therapeutic potential. <b>2003</b> , 3, 373-8	9
2031	Protein aggregation and aggregate toxicity: new insights into protein folding, misfolding diseases and biological evolution. <b>2003</b> , 81, 678-99	1272
2030	Deposits of fibrillar A beta do not cause neuronal loss or ferritin expression in adult rat brain. <b>2003</b> , 110, 381-400	11
2029	Brain region-dependent increases in beta-amyloid and apolipoprotein E levels in hypercholesterolemic rabbits. <b>2003</b> , 110, 641-9	35
2028	Characterization of the effect of ganstigmine (CHF2819) on amyloid precursor protein metabolism in SH-SY5Y neuroblastoma cells. <b>2003</b> , 110, 935-47	22
2027	Emerging ideas on the molecular basis of protein and peptide aggregation. <b>2003</b> , 13, 146-59	289
2026	Intramembrane-cleaving proteases: controlled liberation of proteins and bioactive peptides. <b>2003</b> , 13, 71-8	187
2025	Heparan sulphate proteoglycans in Alzheimer's disease and amyloid-related disorders. <b>2003</b> , 2, 482-92	168
2024	The pharmacology of amyloid precursor protein processing. <b>2003</b> , 38, 145-57	42
2023	Protective effect of resveratrol on beta-amyloid-induced oxidative PC12 cell death. <b>2003</b> , 34, 1100-10	316
2022	Multiple signaling events in amyloid beta-induced, oxidative stress-dependent neuronal apoptosis. <b>2003</b> , 35, 45-58	101
2021	Mitochondrial dysfunction, apoptotic cell death, and Alzheimer's disease. <b>2003</b> , 66, 1627-34	258
2020	PDAPP; YFP double transgenic mice: a tool to study amyloid-beta associated changes in axonal, dendritic, and synaptic structures. <b>2003</b> , 456, 375-83	57
2019	Effects of tumor necrosis factor-alpha central administration on hippocampal damage in rat induced by amyloid beta-peptide (25-35). <b>2003</b> , 71, 110-20	41
2018	Overexpression of amyloid precursor protein is associated with degeneration, decreased viability, and increased damage caused by neurotoxins (prostaglandins A1 and E2, hydrogen peroxide, and nitric oxide) in differentiated neuroblastoma cells. <b>2003</b> , 74, 148-59	16
2017	Identity and function of gamma-secretase. <b>2003</b> , 74, 353-60	84
2016	Proteolytic processing of the Alzheimer's disease amyloid precursor protein in brain and platelets. <b>2003</b> , 74, 386-92	119

2015	Distinct presenilin-dependent and presenilin-independent gamma-secretases are responsible for total cellular Abeta production. <b>2003</b> , 74, 361-9	39
2014	Cysteine proteases are the major beta-secretase in the regulated secretory pathway that provides most of the beta-amyloid in Alzheimer's disease: role of BACE 1 in the constitutive secretory pathway. <b>2003</b> , 74, 393-405	35
2013	Anatomopathological spectrum of tauopathies. <b>2003</b> , 18 Suppl 6, S13-20	18
2012	Specific BACE1 genotypes provide additional risk for late-onset Alzheimer disease in APOE epsilon 4 carriers. <b>2003</b> , 119B, 44-7	33
2011	Influence of prednisolone on Bsecretase enzyme activity in vitro. <b>2003</b> , 32, 83-87	
2010	Outsourcing in the brain: do neurons depend on cholesterol delivery by astrocytes?. <b>2003</b> , 25, 72-8	230
2009	Alzheimer vaccine: amyloid-beta on trial. <b>2003</b> , 25, 283-8	22
2008	Pinacyanol as effective probe of fibrillar beta-amyloid peptide: comparative study with Congo Red. <b>2003</b> , 72, 455-63	30
2007	Green tea catechins as a BACE1 (beta-secretase) inhibitor. <b>2003</b> , 13, 3905-8	139
2006	Measuring human beta-secretase (BACE1) activity using homogeneous time-resolved fluorescence. <b>2003</b> , 319, 49-55	48
2005	A new series of potent benzodiazepine gamma-secretase inhibitors. <b>2003</b> , 13, 179-83	55
2004	RS-4252 inhibits amyloid beta-induced cytotoxicity in HeLa cells. <b>2003</b> , 93, 29-32	9
2003	LDL receptor-related proteins in neurodevelopment. <b>2003</b> , 4, 291-301	51
2002	Presenilin-1 exists in both pre- and post-Golgi compartments and recycles via COPI-coated membranes. <b>2003</b> , 4, 553-65	46
2001	Capillary and arterial cerebral amyloid angiopathy in Alzheimer's disease: defining the perivascular route for the elimination of amyloid beta from the human brain. <b>2003</b> , 29, 106-17	181
2000	Selecting cells with different Alzheimer's disease gamma-secretase activity using FACS. Differential effect on presenilin exon 9 gamma- and epsilon-cleavage. <b>2003</b> , 270, 495-506	4
1999	Co-incorporation of A beta 40 and A beta 42 to form mixed pre-fibrillar aggregates. <b>2003</b> , 270, 654-63	35
1998	Stabilization of the cyclin-dependent kinase 5 activator, p35, by paclitaxel decreases beta-amyloid toxicity in cortical neurons. <b>2003</b> , 84, 347-62	59



1997	Cystatin C colocalizes with amyloid-beta and coimmunoprecipitates with amyloid-beta precursor protein in sporadic inclusion-body myositis muscles. <b>2003</b> , 85, 1539-46	36
1996	Presenilin endoproteolysis mediated by an aspartyl protease activity pharmacologically distinct from gamma-secretase. <b>2003</b> , 85, 1563-74	39
1995	Potent anti-amyloidogenic and fibril-destabilizing effects of polyphenols in vitro: implications for the prevention and therapeutics of Alzheimer's disease. <b>2003</b> , 87, 172-81	524
1994	Acetylcholinesterase induces neuronal cell loss, astrocyte hypertrophy and behavioral deficits in mammalian hippocampus. <b>2003</b> , 87, 195-204	47
1993	The amyloid precursor protein protects PC12 cells against endoplasmic reticulum stress-induced apoptosis. <b>2003</b> , 87, 248-56	51
1992	Apolipoprotein E and beta-amyloid (1-42) regulation of glycogen synthase kinase-3beta. <b>2003</b> , 87, 1152-64	72
1991	Hypoxic remodelling of Ca <sup>2+</sup> mobilization in type I cortical astrocytes: involvement of ROS and pro-amyloidogenic APP processing. <b>2004</b> , 88, 869-77	22
1990	Fast anterograde transport of herpes simplex virus: role for the amyloid precursor protein of Alzheimer's disease. <b>2003</b> , 2, 305-18	81
1989	Age-dependent cognitive decline in the APP23 model precedes amyloid deposition. <b>2003</b> , 17, 388-96	197
1988	Oxygen-induced DNA damage in freshly isolated brain cells compared with cultured astrocytes in the Comet assay. <b>2003</b> , Suppl 2, 43-52	5
1987	Tyrosine nitration of a synaptic protein synaptophysin contributes to amyloid beta-peptide-induced cholinergic dysfunction. <b>2003</b> , 8, 407-12	62
1986	Genetic association of acyl-coenzyme A: cholesterol acyltransferase with cerebrospinal fluid cholesterol levels, brain amyloid load, and risk for Alzheimer's disease. <b>2003</b> , 8, 635-8	55
1985	A decade of caspases. <b>2003</b> , 22, 8543-67	915
1984	Elevated beta-secretase expression and enzymatic activity detected in sporadic Alzheimer disease. <b>2003</b> , 9, 3-4	606
1983	A welcoming environment for amyloid plaques. <b>2003</b> , 6, 328-30	9
1982	Extracellular amyloid formation and associated pathology in neural grafts. <b>2003</b> , 6, 370-7	104
1981	Clinical biomarkers in drug discovery and development. <b>2003</b> , 2, 566-80	583
1980	Dying for a cause: invertebrate genetics takes on human neurodegeneration. <b>2003</b> , 4, 181-94	137

1979	Conformational restriction via cyclization in beta-amyloid peptide Abeta(1-28) leads to an inhibitor of Abeta(1-28) amyloidogenesis and cytotoxicity. <b>2003</b> , 10, 149-59	34
1978	Colloids for Encoding Chemical Libraries: Applications in Biological Screening. 507-560	1
1977	Design and synthesis of highly potent benzodiazepine gamma-secretase inhibitors: preparation of (2S,3R)-3-(3,4-difluorophenyl)-2-(4-fluorophenyl)-4-hydroxy-N-((3S)-1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)butyramide by use of an asymmetric Ireland-Claisen rearrangement. <b>2003</b> , 46, 2275-8	60
1976	A peptide motif consisting of glycine, alanine, and valine is required for the fibrillization and cytotoxicity of human alpha-synuclein. <b>2003</b> , 42, 8870-8	133
1975	The calpain system. <i>Physiological Reviews</i> , <b>2003</b> , 83, 731-801	47.9 2232
1974	Notch and the amyloid precursor protein are cleaved by similar gamma-secretase(s). <b>2003</b> , 42, 137-44	105
1973	Distinct mechanisms by mutant presenilin 1 and 2 leading to increased intracellular levels of amyloid beta-protein 42 in Chinese hamster ovary cells. <b>2003</b> , 42, 1042-52	37
1972	Biochemical and structural characterization of the interaction of memapsin 2 (beta-secretase) cytosolic domain with the VHS domain of GGA proteins. <b>2003</b> , 42, 12174-80	74
1971	Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts. <b>2003</b> , 160, 113-23	899
1970	Humoral immune response to fibrillar beta-amyloid peptide. <b>2003</b> , 42, 11682-92	30
1969	Use of YFP to study amyloid-beta associated neurite alterations in live brain slices. <b>2003</b> , 24, 1071-7	21
1968	Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease. <b>2003</b> , 24, 1063-70	736
1967	Regulation of hippocampal synaptic plasticity by cyclic AMP-dependent protein kinases. <b>2003</b> , 71, 401-37	256
1966	Evidence that nonsteroidal anti-inflammatory drugs decrease amyloid beta 42 production by direct modulation of gamma-secretase activity. <b>2003</b> , 278, 31831-7	226
1965	Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics. <b>2003</b> , 43, 545-84	717
1964	NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. <b>2003</b> , 112, 440-9	382
1963	A CBP binding transcriptional repressor produced by the PS1/epsilon-cleavage of N-cadherin is inhibited by PS1 FAD mutations. <b>2003</b> , 114, 635-45	433
1962	Methionine oxidation: Implications for the mechanism of toxicity of the $\beta$ amyloid peptide from Alzheimer's disease. <b>2003</b> , 10, 413-417	3

1961	BACE1 and BACE2 in pathologic and normal human muscle. <b>2003</b> , 179, 150-8	35
1960	H <sub>2</sub> O <sub>2</sub> and 4-hydroxynonenal mediate amyloid beta-induced neuronal apoptosis by activating JNKs and p38MAPK. <b>2003</b> , 180, 144-55	154
1959	P38 MAP kinase is activated at early stages in Alzheimer's disease brain. <b>2003</b> , 183, 394-405	146
1958	Recombinant endostatin forms amyloid fibrils that bind and are cytotoxic to murine neuroblastoma cells in vitro. <b>2003</b> , 539, 149-55	42
1957	Alzheimer's disease and angiogenesis. <b>2003</b> , 361, 1298-9; author reply 1299-300	2
1956	Alzheimer's disease and angiogenesis. <b>2003</b> , 361, 1299; author reply 1299-300	2
1955	Role of cholesterol in synapse formation and function. <b>2003</b> , 1610, 271-80	209
1954	Amyloid beta-protein interactions with membranes and cholesterol: causes or casualties of Alzheimer's disease. <b>2003</b> , 1610, 281-90	124
1953	Putative function of ADAM9, ADAM10, and ADAM17 as APP alpha-secretase. <b>2003</b> , 301, 231-5	245
1952	Peptide-based, irreversible inhibitors of gamma-secretase activity. <b>2003</b> , 305, 529-33	2
1951	Corticotropin-releasing factor (CRF) and related peptides confer neuroprotection via type 1 CRF receptors. <b>2003</b> , 45, 623-36	60
1950	APP intracellular domain formation and unaltered signaling in the presence of familial Alzheimer's disease mutations. <b>2003</b> , 287, 1-9	24
1949	Proapoptotic protein glyceraldehyde-3-phosphate dehydrogenase: a possible site of action of antiapoptotic drugs. <b>2003</b> , 27, 291-301	37
1948	Human neprilysin is capable of degrading amyloid beta peptide not only in the monomeric form but also the pathological oligomeric form. <b>2003</b> , 350, 113-6	186
1947	ABCA1 modulates CSF cholesterol levels and influences the age at onset of Alzheimer's disease. <b>2003</b> , 24, 421-6	131
1946	Oxidative stress precedes fibrillar deposition of Alzheimer's disease amyloid beta-peptide (1-42) in a transgenic <i>Caenorhabditis elegans</i> model. <b>2003</b> , 24, 415-20	297
1945	Reduction of beta-amyloid plaques in brain of transgenic mouse model of Alzheimer's disease by EFRH-phage immunization. <b>2003</b> , 21, 1060-5	66
1944	Egr-1 upregulates the Alzheimer's disease presenilin-2 gene in neuronal cells. <b>2003</b> , 318, 113-24	36

1943	Human beta-secretase activity in yeast detected by a novel cellular growth selection system. <b>2003</b> , 1620, 167-78		19
1942	Comparative gene identification-94--a pivotal regulator of apoptosis. <b>2003</b> , 116, 321-4		1
1941	Diffuse amyloid deposition, but not plaque number, is reduced in amyloid precursor protein/presenilin 1 double-transgenic mice by pathway lesions. <b>2003</b> , 119, 1185-97		32
1940	Induction of tyrosine kinase receptor b by retinoic acid allows brain-derived neurotrophic factor-induced amyloid precursor protein gene expression in human SH-SY5Y neuroblastoma cells. <b>2003</b> , 120, 1019-26		33
1939	Apolipoprotein E4 decreases whereas apolipoprotein E3 increases the level of secreted amyloid precursor protein after closed head injury. <b>2003</b> , 121, 315-25		11
1938	Single intracerebroventricular administration of amyloid-beta (25-35) peptide induces impairment in short-term rather than long-term memory in rats. <b>2003</b> , 61, 197-205		90
1937	Phosphorylation of calsenilin at Ser63 regulates its cleavage by caspase-3. <i>Molecular and Cellular Neurosciences</i> , <b>2003</b> , 23, 495-506	4.8	19
1936	Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. <b>2003</b> , 38, 547-54		677
1935	Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. <b>2003</b> , 39, 409-21		3031
1934	Amyloid precursor protein (APP) and the biology of proteolytic processing: relevance to Alzheimer's disease. <b>2003</b> , 35, 1505-35		152
1933	A new role for astrocytes: beta-amyloid homeostasis and degradation. <b>2003</b> , 9, 281-2		46
1932	No alterations of hippocampal neuronal number and synaptic bouton number in a transgenic mouse model expressing the beta-cleaved C-terminal APP fragment. <b>2003</b> , 12, 110-20		37
1931	Presenilin-1 interacts directly with the beta-site amyloid protein precursor cleaving enzyme (BACE1). <b>2003</b> , 13, 238-45		37
1930	Identification of peptides that specifically bind Abeta1-40 amyloid in vitro and amyloid plaques in Alzheimer's disease brain using phage display. <b>2003</b> , 14, 146-56		21
1929	Dehydroepiandrosterone reduces expression and activity of BACE in NT2 neurons exposed to oxidative stress. <b>2003</b> , 14, 291-301		39
1928	The amyloid beta peptide (Abeta(1-40)) is thermodynamically soluble at physiological concentrations. <b>2003</b> , 42, 10506-13		154
1927	New amide-bearing benzolactam-based protein kinase C modulators induce enhanced secretion of the amyloid precursor protein metabolite sAPPalpha. <b>2003</b> , 46, 364-73		45
1926	A vision for the future of genomics research. <b>2003</b> , 422, 835-47		1390

1925	Cholesterol homeostasis and function in neurons of the central nervous system. <b>2003</b> , 60, 1158-71	273
1924	Increased T cell reactivity to amyloid $\beta$ protein in older humans and patients with Alzheimer disease. <b>2003</b> , 112, 415-422	221
1923	The Notch ligands, Jagged and Delta, are sequentially processed by alpha-secretase and presenilin/gamma-secretase and release signaling fragments. <b>2003</b> , 278, 34427-37	269
1922	Reduction in levels of 24S-hydroxycholesterol by statin treatment in patients with Alzheimer disease. <b>2003</b> , 60, 510-5	135
1921	The transmembrane domain of the amyloid precursor protein in microsomal membranes is on both sides shorter than predicted. <b>2003</b> , 278, 6803-8	39
1920	Cyclic AMP inhibition of tumor necrosis factor alpha production induced by amyloidogenic C-terminal peptide of Alzheimer's amyloid precursor protein in macrophages: involvement of multiple intracellular pathways and cyclic AMP response element binding protein. <b>2003</b> , 63, 690-8	31
1919	Serum lipids and memory in a population based cohort of middle age women. <b>2003</b> , 74, 1530-5	60
1918	Disease-specific accumulation of mutant ubiquitin as a marker for proteasomal dysfunction in the brain. <b>2003</b> , 17, 2014-24	124
1917	DNA damage in nasal and brain tissues of canines exposed to air pollutants is associated with evidence of chronic brain inflammation and neurodegeneration. <b>2003</b> , 31, 524-38	229
1916	The cell adhesion protein P-selectin glycoprotein ligand-1 is a substrate for the aspartyl protease BACE1. <b>2003</b> , 278, 48713-9	209
1915	Identification of a beta-secretase activity, which truncates amyloid beta-peptide after its presenilin-dependent generation. <b>2003</b> , 278, 5531-8	51
1914	C-terminal fragments of amyloid precursor protein exert neurotoxicity by inducing glycogen synthase kinase-3beta expression. <b>2003</b> , 17, 1951-3	212
1913	Syndecan 3 intramembrane proteolysis is presenilin/gamma-secretase-dependent and modulates cytosolic signaling. <b>2003</b> , 278, 48651-7	79
1912	Specific compositions of amyloid-beta peptides as the determinant of toxic beta-aggregation. <b>2003</b> , 278, 23648-55	81
1911	Alzheimer beta-amyloid homodimers facilitate A beta fibrillization and the generation of conformational antibodies. <b>2003</b> , 278, 35317-24	60
1910	Two suppressors of sel-12 encode C2H2 zinc-finger proteins that regulate presenilin transcription in <i>Caenorhabditis elegans</i> . <b>2003</b> , 130, 2117-28	28
1909	Increased vulnerability of brain mitochondria in diabetic (Goto-Kakizaki) rats with aging and amyloid-beta exposure. <b>2003</b> , 52, 1449-56	96
1908	Dietary Cu stabilizes brain superoxide dismutase 1 activity and reduces amyloid A beta production in APP23 transgenic mice. <b>2003</b> , 100, 14187-92	307

1907	Potential link between amyloid beta-protein 42 and C-terminal fragment gamma 49-99 of beta-amyloid precursor protein. <b>2003</b> , 278, 24294-301	120
1906	Partial purification and characterization of gamma-secretase from post-mortem human brain. <b>2003</b> , 278, 24277-84	129
1905	Impaired modulation of GABAergic transmission by muscarinic receptors in a mouse transgenic model of Alzheimer's disease. <b>2003</b> , 278, 26888-96	61
1904	Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid. <b>2003</b> , 15, 505-14	218
1903	Overexpression of nicastrin increases Abeta production. <b>2003</b> , 17, 1138-40	31
1902	Allele-specific silencing of a pathogenic mutant acetylcholine receptor subunit by RNA interference. <b>2003</b> , 12, 2637-44	55
1901	Drugs targeting Alzheimer's disease: some things old and some things new. <b>2003</b> , 304, 897-904	73
1900	Atherosclerosis and neurodegeneration: unexpected conspirators in Alzheimer's dementia. <b>2003</b> , 23, 1951-3	32
1899	Carboxyl-terminal-truncated apolipoprotein E4 causes Alzheimer's disease-like neurodegeneration and behavioral deficits in transgenic mice. <b>2003</b> , 100, 10966-71	268
1898	Transforming growth factor-beta 1 potentiates amyloid-beta generation in astrocytes and in transgenic mice. <b>2003</b> , 278, 18408-18	100
1897	Sulindac sulfide is a noncompetitive gamma-secretase inhibitor that preferentially reduces Abeta 42 generation. <b>2003</b> , 278, 18664-70	155
1896	Amyloid beta-protein stimulates the expression of urokinase-type plasminogen activator (uPA) and its receptor (uPAR) in human cerebrovascular smooth muscle cells. <b>2003</b> , 278, 19054-61	43
1895	Managing Alzheimer dementia tomorrow. <b>2003</b> , 16, 423-34	1
1894	Targeting presenilin-type aspartic protease signal peptide peptidase with gamma-secretase inhibitors. <b>2003</b> , 278, 16528-33	109
1893	Gamma-secretase is a membrane protein complex comprised of presenilin, nicastrin, Aph-1, and Pen-2. <b>2003</b> , 100, 6382-7	665
1892	Immunotherapeutic approaches to Alzheimer's disease. <b>2003</b> , 302, 834-8	253
1891	The application of functional genomics to Alzheimer's disease. <b>2003</b> , 4, 597-621	64
1890	Abeta42-lowering nonsteroidal anti-inflammatory drugs preserve intramembrane cleavage of the amyloid precursor protein (APP) and ErbB-4 receptor and signaling through the APP intracellular domain. <b>2003</b> , 278, 30748-54	105

1889	Stereoselective interactions of peptide inhibitors with the beta-amyloid peptide. <b>2003</b> , 278, 34874-81	117
1888	Neurotoxic, redox-competent Alzheimer's beta-amyloid is released from lipid membrane by methionine oxidation. <b>2003</b> , 278, 42959-65	156
1887	Characterization of alpha 2,6-sialyltransferase cleavage by Alzheimer's beta -secretase (BACE1). <b>2003</b> , 278, 14865-71	87
1886	The C-terminal fragment of presenilin 2 triggers p53-mediated staurosporine-induced apoptosis, a function independent of the presenilinase-derived N-terminal counterpart. <b>2003</b> , 278, 12064-9	43
1885	Selective neuronal degeneration induced by soluble oligomeric amyloid beta protein. <b>2003</b> , 17, 118-20	179
1884	The kinetics of beta-amyloid protein polymerization using surface plasmon resonance biosensor.	
1883	Secretion and intracellular generation of truncated Abeta in beta-site amyloid-beta precursor protein-cleaving enzyme expressing human neurons. <b>2003</b> , 278, 4458-66	67
1882	The neuronal adaptor protein X11alpha reduces Abeta levels in the brains of Alzheimer's APPswe Tg2576 transgenic mice. <b>2003</b> , 278, 47025-9	60
1881	The non-cyclooxygenase targets of non-steroidal anti-inflammatory drugs, lipoxygenases, peroxisome proliferator-activated receptor, inhibitor of kappa B kinase, and NF kappa B, do not reduce amyloid beta 42 production. <b>2003</b> , 278, 31825-30	63
1880	Novel cadherin-related membrane proteins, Alcadeins, enhance the X11-like protein-mediated stabilization of amyloid beta-protein precursor metabolism. <b>2003</b> , 278, 49448-58	104
1879	Elucidation of primary structure elements controlling early amyloid beta-protein oligomerization. <b>2003</b> , 278, 34882-9	246
1878	The apolipoprotein E phenotype is not a visual loss susceptibility gene in Leber hereditary optic neuropathy. <b>2003</b> , 74, 1535-1535	78
1877	Frameshifted beta-amyloid precursor protein (APP+1) is a secretory protein, and the level of APP+1 in cerebrospinal fluid is linked to Alzheimer pathology. <b>2003</b> , 278, 39637-43	9
1876	Rab5-stimulated up-regulation of the endocytic pathway increases intracellular beta-cleaved amyloid precursor protein carboxyl-terminal fragment levels and Abeta production. <b>2003</b> , 278, 31261-8	174
1875	Spherical aggregates of beta-amyloid (amylospheroid) show high neurotoxicity and activate tau protein kinase I/glycogen synthase kinase-3beta. <b>2003</b> , 100, 6370-5	417
1874	A reporter for amyloid precursor protein gamma-secretase activity in Drosophila. <b>2003</b> , 12, 2669-78	23
1873	Intramembrane-cleaving aspartic proteases and disease: presenilins, signal peptide peptidase and their homologs. <b>2003</b> , 12 Spec No 2, R201-6	85
1872	Will caloric restriction and folate protect against AD and PD?. <b>2003</b> , 60, 690-5	96

1871	Cerebral amyloid angiopathies: a pathologic, biochemical, and genetic view. <b>2003</b> , 62, 885-98	207
1870	Human amylin actions on rat cholinergic basal forebrain neurons: antagonism of beta-amyloid effects. <b>2003</b> , 89, 2923-30	25
1869	An Alzheimer's disease hypothesis based on transcriptional dysregulation. <b>2003</b> , 10, 80-5	30
1868	A critical analysis of new molecular targets and strategies for drug developments in Alzheimer's disease. <b>2003</b> , 4, 97-112	170
1867	The risk of dementia in relation to statins and other lipid lowering agents. <b>2003</b> , 25, 601-4	18
1866	The cholinergic deficiency syndrome and its therapeutic implications. <b>2003</b> , 49, 55-60	51
1865	Pharmakotherapie der Demenzen. <b>2003</b> , 30, 512-518	
1864	24S-hydroxycholesterol: a marker of brain cholesterol metabolism. <b>2003</b> , 36 Suppl 2, S102-6	50
1863	Sport und das leichte Schel-Hirn-Trauma. <b>2003</b> , 30, 519-524	
1862	Physiologic and pathologic events mediated by intramembranous and juxtamembranous proteolysis. <b>2003</b> , 2003, RE4	27
1861	Molecular identification of AMY, an Alzheimer disease amyloid-associated protein. <b>2003</b> , 62, 1108-17	14
1860	Amyloid beta peptide-induced corpus callosum damage and glial activation in vivo. <b>2003</b> , 14, 1429-33	59
1859	Toward an early diagnosis and treatment of Alzheimer's disease. <b>2003</b> , 15, 223-37	20
1858	Distinct Mechanisms Account for $\beta$ -Amyloid Toxicity in PC12 and Differentiated PC12 Neuronal Cells. <b>2003</b> , 10, 379-388	7
1857	Short-term beta-amyloid vaccinations do not improve cognitive performance in cognitively impaired APP + PS1 mice. <b>2003</b> , 117, 478-84	38
1856	Tauroursodeoxycholic acid prevents amyloid-beta peptide-induced neuronal death via a phosphatidylinositol 3-kinase-dependent signaling pathway. <b>2003</b> , 9, 226-34	95
1855	. <b>2003</b> ,	41
1854	Aberrant activation of focal adhesion proteins mediates fibrillar amyloid beta-induced neuronal dystrophy. <b>2003</b> , 23, 493-502	107



1853	Beta-amyloid peptide activates non-alpha7 nicotinic acetylcholine receptors in rat basal forebrain neurons. <b>2003</b> , 90, 3130-6	54
1852	In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-beta metabolism and half-life. <b>2003</b> , 23, 8844-53	369
1851	PS2APP transgenic mice, coexpressing hPS2mut and hAPPswe, show age-related cognitive deficits associated with discrete brain amyloid deposition and inflammation. <b>2003</b> , 23, 8989-9003	163
1850	Role of cytokines in the gene expression of amyloid beta-protein precursor: identification of a 5'-UTR-binding nuclear factor and its implications in Alzheimer's disease. <b>2003</b> , 5, 81-90	71
1849	Insulin receptor substrate-2 deficiency impairs brain growth and promotes tau phosphorylation. <b>2003</b> , 23, 7084-92	378
1848	[New aspects of cholesterol in the central nervous system]. <b>2003</b> , 19, 601-5	3
1847	Alzheimer's Disease: Molecular Genetics. <b>2004</b> , 265-267	
1846	A comparative study of amyloid-beta (1-42) as a cofactor for plasminogen activation by vampire bat plasminogen activator and recombinant human tissue-type plasminogen activator. <b>2004</b> , 92, 559-67	9
1845	. <b>2004</b> ,	2
1844	Alterações genéticas na doença de Alzheimer. <b>2004</b> , 31, 19-25	8
1843	Cerebral hypoperfusion and amyloid-induced synergistic impairment of hippocampal CA1 synaptic efficacy and spatial memory in young adult rats. <b>2004</b> , 6, 355-66; discussion 443-9	11
1842	Alzheimer disease: mechanistic understanding predicts novel therapies. <b>2004</b> , 140, 627-38	206
1841	Binding sites of amyloid beta-peptide in cell plasma membrane and implications for Alzheimer's disease. <b>2004</b> , 5, 19-31	91
1840	ApoE: crossroads between Alzheimer's disease and atherosclerosis. <b>2004</b> , 4, 279-85	7
1839	Hormone therapy and Alzheimer's disease: benefit or harm?. <b>2004</b> , 5, 389-406	32
1838	The extreme C terminus of presenilin 1 is essential for gamma-secretase complex assembly and activity. <b>2004</b> , 279, 45564-72	39
1837	An overview of the current and novel drugs for Alzheimer's disease with particular reference to anti-cholinesterase compounds. <b>2004</b> , 10, 3121-30	64
1836	Abnormalities of peptide metabolism in Alzheimer disease. <b>2004</b> , 1, 317-23	8

1835	Alzheimer's disease: interactions between cholinergic functions and beta-amyloid. <b>2004</b> , 1, 241-8	66
1834	A beta-secretase (BACE1) inhibitor hispidin from the mycelial cultures of <i>Phellinus linteus</i> . <b>2004</b> , 70, 143-6	63
1833	Immunotherapy for Alzheimer's disease. <b>2004</b> , 101 Suppl 2, 14657-62	142
1832	Ginger extract inhibits beta-amyloid peptide-induced cytokine and chemokine expression in cultured THP-1 monocytes. <b>2004</b> , 10, 1009-13	62
1831	Modulation of notch processing by gamma-secretase inhibitors causes intestinal goblet cell metaplasia and induction of genes known to specify gut secretory lineage differentiation. <b>2004</b> , 82, 341-58	466
1830	Self-assembly of peptides into a beta-barrel motif. <b>2004</b> , 120, 5809-23	30
1829	The human amyloid-beta precursor protein770 mutation V717F generates peptides longer than amyloid-beta-(40-42) and flocculent amyloid aggregates. <b>2004</b> , 279, 5829-36	24
1828	Ganstigmine and donepezil improve neurodegeneration in AD11 antinerve growth factor transgenic mice. <b>2004</b> , 19, 153-60	21
1827	Tyrosine gated electron transfer is key to the toxic mechanism of Alzheimer's disease beta-amyloid. <b>2004</b> , 18, 1427-9	231
1826	Amyloid beta-induced changes in nitric oxide production and mitochondrial activity lead to apoptosis. <b>2004</b> , 279, 50310-20	219
1825	Phosphorylation of presenilin 1 at the caspase recognition site regulates its proteolytic processing and the progression of apoptosis. <b>2004</b> , 279, 1585-93	53
1824	Fatty acids increase presenilin-1 levels and [gamma]-secretase activity in PSwt-1 cells. <b>2004</b> , 45, 2368-76	25
1823	Dysregulated IP3 signaling in cortical neurons of knock-in mice expressing an Alzheimer's-linked mutation in presenilin1 results in exaggerated Ca <sup>2+</sup> signals and altered membrane excitability. <b>2004</b> , 24, 508-13	215
1822	Coordinated metabolism of Alcadein and amyloid beta-protein precursor regulates FE65-dependent gene transactivation. <b>2004</b> , 279, 24343-54	61
1821	Consensus analysis of signal peptide peptidase and homologous human aspartic proteases reveals opposite topology of catalytic domains compared with presenilins. <b>2004</b> , 279, 50790-8	84
1820	Microtransplantation of functional receptors and channels from the Alzheimer's brain to frog oocytes. <b>2004</b> , 101, 1760-3	39
1819	A nontransgenic mouse model shows inducible amyloid-beta (Abeta) peptide deposition and elucidates the role of apolipoprotein E in the amyloid cascade. <b>2004</b> , 101, 13909-14	93
1818	Mouse models of Alzheimer's disease: insight into treatment. <b>2004</b> , 15, 353-69	87

1817	A system for enhancing genome-wide coexpression dynamics study. <b>2004</b> , 101, 15561-6	53
1816	Effects of RNA interference-mediated silencing of gamma-secretase complex components on cell sensitivity to caspase-3 activation. <b>2004</b> , 279, 34130-7	24
1815	Requirement of PEN-2 for stabilization of the presenilin N-/C-terminal fragment heterodimer within the gamma-secretase complex. <b>2004</b> , 279, 23255-61	102
1814	Association of gamma-secretase with lipid rafts in post-Golgi and endosome membranes. <b>2004</b> , 279, 44945-54	341
1813	Amyloid beta peptides and central cholinergic neurons: functional interrelationship and relevance to Alzheimer's disease pathology. <b>2004</b> , 145, 261-74	27
1812	Gene expression profiles of transcripts in amyloid precursor protein transgenic mice: up-regulation of mitochondrial metabolism and apoptotic genes is an early cellular change in Alzheimer's disease. <b>2004</b> , 13, 1225-40	259
1811	Impact of APOE in mild cognitive impairment. <b>2004</b> , 63, 1898-901	167
1810	Brain inflammation and Alzheimer's-like pathology in individuals exposed to severe air pollution. <b>2004</b> , 32, 650-8	376
1809	Fe65 is not involved in the platelet-derived growth factor-induced processing of Alzheimer's amyloid precursor protein, which activates its caspase-directed cleavage. <b>2004</b> , 279, 16161-9	20
1808	Phenotypic profiles and functional genomics in Alzheimer's disease and in dementia with a vascular component. <b>2004</b> , 26, 459-80	30
1807	Aspirin, NSAIDs, risk of dementia, and influence of the apolipoprotein E epsilon 4 allele in an elderly population. <b>2004</b> , 23, 135-43	55
1806	The biochemical and genetic odyssey to the function of a nicastrin-like protein. <b>2004</b> , 1, 192-5	4
1805	Plasmin deficiency in Alzheimer's disease brains: causal or casual?. <b>2004</b> , 1, 205-12	20
1804	Lithium decreases secretion of Abeta1-42 and C-truncated species Abeta1-37/38/39/40 in chicken telencephalic cultures but specifically increases intracellular Abeta1-38. <b>2004</b> , 1, 236-41	17
1803	Translational regulation of BACE-1 expression in neuronal and non-neuronal cells. <b>2004</b> , 32, 1808-17	71
1802	Calcium dyshomeostasis in beta-amyloid and tau-bearing skeletal myotubes. <b>2004</b> , 279, 53524-32	25
1801	Effects of neprilysin chimeric proteins targeted to subcellular compartments on amyloid beta peptide clearance in primary neurons. <b>2004</b> , 279, 30259-64	41
1800	Early-onset and robust cerebral microvascular accumulation of amyloid beta-protein in transgenic mice expressing low levels of a vasculotropic Dutch/Iowa mutant form of amyloid beta-protein precursor. <b>2004</b> , 279, 20296-306	261

1799	Binding sites of gamma-secretase inhibitors in rodent brain: distribution, postnatal development, and effect of deafferentation. <b>2004</b> , 24, 2942-52	40
1798	Demonstration of BACE (beta-secretase) phosphorylation and its interaction with GGA1 in cells by fluorescence-lifetime imaging microscopy. <b>2004</b> , 117, 5437-45	97
1797	Tumor necrosis factor-alpha, interleukin-1beta, and interferon-gamma stimulate gamma-secretase-mediated cleavage of amyloid precursor protein through a JNK-dependent MAPK pathway. <b>2004</b> , 279, 49523-32	247
1796	EDEM contributes to maintenance of protein folding efficiency and secretory capacity. <b>2004</b> , 279, 44600-5	36
1795	Dimeric amyloid beta protein rapidly accumulates in lipid rafts followed by apolipoprotein E and phosphorylated tau accumulation in the Tg2576 mouse model of Alzheimer's disease. <b>2004</b> , 24, 3801-9	287
1794	Dissecting the pathological effects of human Abeta40 and Abeta42 in Drosophila: a potential model for Alzheimer's disease. <b>2004</b> , 101, 6623-8	380
1793	The C-terminal tail of presenilin regulates Omi/HtrA2 protease activity. <b>2004</b> , 279, 45844-54	62
1792	Degradation of BACE by the ubiquitin-proteasome pathway. <b>2004</b> , 18, 1571-3	129
1791	Nerve growth factor (NGF) induces mRNA expression of the new transcription factor protein p48ZnF. <b>2004</b> , 36, 130-4	5
1790	The role of test accuracy in predicting acceptance of genetic susceptibility testing for Alzheimer's disease. <b>2004</b> , 8, 120-6	5
1789	In Vitro Neurotoxicology. <b>2004</b> ,	3
1788	Therapeutic effects of PKC activators in Alzheimer's disease transgenic mice. <b>2004</b> , 101, 11141-6	277
1787	Identification of a new presenilin-dependent zeta-cleavage site within the transmembrane domain of amyloid precursor protein. <b>2004</b> , 279, 50647-50	111
1786	Single transmembrane spanning heterotrimeric G protein-coupled receptors and their signaling cascades. <b>2004</b> , 56, 371-85	92
1785	A phosphorylated, carboxy-terminal fragment of beta-amyloid precursor protein localizes to the splicing factor compartment. <b>2004</b> , 13, 475-88	45
1784	Genome wide identification and classification of alternative splicing based on EST data. <b>2004</b> , 20, 2579-85	68
1783	Retinol-binding protein gene is highly expressed in higher-order association areas of the primate neocortex. <b>2005</b> , 15, 96-108	45
1782	Genomic characterization of Alzheimer's disease and genotype-related phenotypic analysis of biological markers in dementia. <b>2004</b> , 5, 1049-105	26

1781	Soluble Arctic amyloid beta protein inhibits hippocampal long-term potentiation in vivo. <b>2004</b> , 19, 2839-46	103
1780	The beta-amyloid precursor protein controls a store-operated Ca <sup>2+</sup> entry in cortical neurons. <b>2004</b> , 20, 2071-8	23
1779	Altered circadian locomotor activity in APP23 mice: a model for BPSD disturbances. <b>2004</b> , 20, 2757-66	71
1778	Protein misfolding in neurodegenerative diseases. <b>2004</b> , 30, 215-24	80
1777	Enhanced G-protein activation by a mixture of Abeta(25-35), Abeta(1-40/42) and zinc. <b>2004</b> , 89, 1215-23	8
1776	Inhibition of the E2F-1/p53/Bax pathway by tauroursodeoxycholic acid in amyloid beta-peptide-induced apoptosis of PC12 cells. <b>2004</b> , 90, 567-75	58
1775	Frame-shifted amyloid precursor protein found in Alzheimer's disease and Down's syndrome increases levels of secreted amyloid beta40. <b>2004</b> , 90, 712-23	11
1774	Pathophysiological concentrations of amyloid beta proteins directly inhibit rat brain and recombinant human type II phosphatidylinositol 4-kinase activity. <b>2004</b> , 91, 1164-70	17
1773	Intracellularly generated amyloid-beta peptide counteracts the antiapoptotic function of its precursor protein and primes proapoptotic pathways for activation by other insults in neuroblastoma cells. <b>2004</b> , 91, 1260-74	26
1772	Melatonin alleviates behavioral deficits associated with apoptosis and cholinergic system dysfunction in the APP 695 transgenic mouse model of Alzheimer's disease. <b>2004</b> , 37, 129-36	143
1771	Endoplasmic reticulum-localized amyloid beta-peptide is degraded in the cytosol by two distinct degradation pathways. <b>2004</b> , 5, 89-101	63
1770	Time-controlled transcatheter perfusion cross-linking for the study of protein interactions in complex tissues. <b>2004</b> , 22, 724-31	136
1769	Nicalin and its binding partner Nomo are novel Nodal signaling antagonists. <b>2004</b> , 23, 3041-50	45
1768	Protection from cytosolic prion protein toxicity by modulation of protein translocation. <b>2004</b> , 23, 4550-9	105
1767	Expression of the Alzheimer protease BACE1 is suppressed via its 5'-untranslated region. <b>2004</b> , 5, 620-5	97
1766	Baculoviruses expressing the human familial Alzheimer's disease presenilin 1 mutation lacking exon 9 increase levels of an amyloid beta-like protein in Sf9 cells. <b>2004</b> , 9, 594-602	5
1765	Transgenic animal models of Alzheimer's disease and related disorders: histopathology, behavior and therapy. <b>2004</b> , 9, 664-83	228
1764	GM1 ganglioside regulates the proteolysis of amyloid precursor protein. <b>2004</b> , 9, 946-52	85

1763	Differential qualitative responses to rivastigmine in APOE epsilon 4 carriers and noncarriers. <b>2004</b> , 4, 332-5	38
1762	Neurodegenerative disease and the neuroimmune axis (Alzheimer's and Parkinson's disease, and viral infections). <b>2004</b> , 147, 43-9	59
1761	Mimotopes of conformational epitopes in fibrillar beta-amyloid. <b>2004</b> , 156, 10-20	10
1760	Targeting JNK3 for the treatment of neurodegenerative disorders. <b>2004</b> , 9, 932-9	100
1759	Differences between recognition memory and remote memory for olfactory and visual stimuli in nondemented elderly individuals genetically at risk for Alzheimer's disease. <b>2004</b> , 39, 433-41	29
1758	Preliminary studies of a novel bifunctional metal chelator targeting Alzheimer's amyloidogenesis. <b>2004</b> , 39, 1641-9	118
1757	One-electron oxidation of beta-amyloid peptide: sequence modulation of reactivity. <b>2004</b> , 37, 881-91	36
1756	Nilvadipine antagonizes both Abeta vasoactivity in isolated arteries, and the reduced cerebral blood flow in APPsw transgenic mice. <b>2004</b> , 999, 53-61	62
1755	Proteomics: a new approach to investigate oxidative stress in Alzheimer's disease brain. <b>2004</b> , 1000, 1-7	191
1754	Magnetic resonance spectroscopic analysis of Alzheimer's disease mouse brain that express mutant human APP shows altered neurochemical profile. <b>2004</b> , 1012, 60-5	131
1753	Multi-metric behavioral comparison of APPsw and P301L models for Alzheimer's disease: linkage of poorer cognitive performance to tau pathology in forebrain. <b>2004</b> , 1012, 29-41	97
1752	Behavioral effects of CD40-CD40L pathway disruption in aged PSAPP mice. <b>2004</b> , 1015, 161-8	32
1751	Proteases and lipoprotein receptors in Alzheimer's disease. <b>2004</b> , 41, 139-78	4
1750	BACE1: the beta-secretase enzyme in Alzheimer's disease. <b>2004</b> , 23, 105-14	252
1749	ApoE and Abeta1-42 interactions: effects of isoform and conformation on structure and function. <b>2004</b> , 23, 235-46	72
1748	Apolipoprotein E dose-dependent modulation of beta-amyloid deposition in a transgenic mouse model of Alzheimer's disease. <b>2004</b> , 23, 255-62	39
1747	The splicing regulatory protein p18SRP is down-regulated in Alzheimer's disease brain. <b>2004</b> , 24, 269-76	4
1746	Loss of apolipoprotein E receptor LR11 in Alzheimer disease. <b>2004</b> , 61, 1200-5	236

1745	De novo proteins from designed combinatorial libraries. <b>2004</b> , 13, 1711-23	178
1744	Involvement of proteases in glycosyltransferase secretion: Alzheimer's beta-secretase-dependent cleavage and a following processing by an aminopeptidase. <b>2004</b> , 21, 25-9	10
1743	Identification of rTid-1, the rat homologue of the drosophila tumor suppressor l(2)tid gene. <b>2004</b> , 258, 183-9	2
1742	Redox-active metals, oxidative stress, and Alzheimer's disease pathology. <b>2004</b> , 1012, 153-63	329
1741	Magnetic iron compounds in neurological disorders. <b>2004</b> , 1012, 183-92	52
1740	New therapeutic strategies and drug candidates for neurodegenerative diseases: p53 and TNF-alpha inhibitors, and GLP-1 receptor agonists. <b>2004</b> , 1035, 290-315	76
1739	Variants of CYP46A1 may interact with age and APOE to influence CSF Abeta42 levels in Alzheimer's disease. <b>2004</b> , 114, 581-7	57
1738	Glial reactions and the clearance of amyloid beta protein in the brains of patients with hereditary cerebral hemorrhage with amyloidosis-Dutch type. <b>2004</b> , 107, 389-98	26
1737	Altered kallikrein 7 and 10 concentrations in cerebrospinal fluid of patients with Alzheimer's disease and frontotemporal dementia. <b>2004</b> , 37, 230-7	36
1736	Antibodies from a DNA peptide vaccination decrease the brain amyloid burden in a mouse model of Alzheimer's disease. <b>2004</b> , 82, 706-14	24
1735	Beta-hairpin conformation of fibrillogenic peptides: structure and alpha-beta transition mechanism revealed by molecular dynamics simulations. <b>2004</b> , 57, 198-204	78
1734	Early events in protein aggregation: molecular flexibility and hydrophobicity/charge interaction in amyloid peptides as studied by molecular dynamics simulations. <b>2005</b> , 58, 110-8	32
1733	Amyloid beta-peptide interactions with neuronal and glial cell plasma membrane: binding sites and implications for Alzheimer's disease. <b>2004</b> , 10, 229-48	231
1732	In vitro anti-beta-secretase and dual anti-cholinesterase activities of Camellia sinensis L. (tea) relevant to treatment of dementia. <b>2004</b> , 18, 624-7	76
1731	Advanced glycation endproducts and pro-inflammatory cytokines in transgenic Tg2576 mice with amyloid plaque pathology. <b>2003</b> , 86, 283-9	30
1730	X11alpha impairs gamma- but not beta-cleavage of amyloid precursor protein. <b>2004</b> , 88, 971-82	35
1729	Co-expressed presenilin 1 NTF and CTF form functional gamma-secretase complexes in cells devoid of full-length protein. <b>2004</b> , 89, 44-53	45
1728	Plasma amyloid beta, apolipoprotein E, lacunar infarcts, and white matter lesions. <b>2004</b> , 55, 570-5	91

1727	Presenilin mutations associated with fronto-temporal dementia. <b>2004</b> , 55, 604-6	17
1726	Characterizing the new transcription regulator protein p60TRP. <b>2004</b> , 91, 1030-42	30
1725	Isoform-specific knockout of FE65 leads to impaired learning and memory. <b>2004</b> , 75, 12-24	58
1724	Inhibition of histone deacetylation enhances the neurotoxicity induced by the C-terminal fragments of amyloid precursor protein. <b>2004</b> , 75, 117-24	50
1723	alpha1 Integrin activation: a link between beta-amyloid deposition and neuronal death in aging hippocampal neurons. <b>2004</b> , 75, 688-97	33
1722	Curcumin has potent anti-amyloidogenic effects for Alzheimer's beta-amyloid fibrils in vitro. <b>2004</b> , 75, 742-50	844
1721	Overexpression of alpha-synuclein decreased viability and enhanced sensitivity to prostaglandin E(2), hydrogen peroxide, and a nitric oxide donor in differentiated neuroblastoma cells. <b>2004</b> , 76, 415-22	15
1720	Alzheimer's disease and immune activation: A translational perspective. <b>2004</b> , 35, 193-201	
1719	The use of real-time PCR analysis in a gene expression study of Alzheimer's disease post-mortem brains. <b>2004</b> , 132, 101-7	95
1718	Ginkgo biloba extract (Egb 761) inhibits beta-amyloid production by lowering free cholesterol levels. <b>2004</b> , 15, 749-56	80
1717	Probing pockets S2-S4' of the gamma-secretase active site with (hydroxyethyl)urea peptidomimetics. <b>2004</b> , 14, 1935-8	39
1716	Modeling the binding affinities of beta-secretase inhibitors: application to subsite specificity. <b>2004</b> , 14, 4843-6	16
1715	Amyloid beta peptide load is correlated with increased beta-secretase activity in sporadic Alzheimer's disease patients. <b>2004</b> , 101, 3632-7	432
1714	Oligomerization of Alzheimer's beta-amyloid within processes and synapses of cultured neurons and brain. <b>2004</b> , 24, 3592-9	377
1713	Prefibrillar amyloid protein aggregates share common features of cytotoxicity. <b>2004</b> , 279, 31374-82	315
1712	Truncated carboxyl-terminal fragments of beta-amyloid precursor protein are processed to amyloid beta-proteins 40 and 42. <b>2004</b> , 43, 13532-40	118
1711	Synthesis and evaluation of two 18F-labeled 6-iodo-2-(4'-N,N-dimethylamino)phenylimidazo[1,2-a]pyridine derivatives as prospective radioligands for beta-amyloid in Alzheimer's disease. <b>2004</b> , 47, 2208-18	86
1710	Purification and characterization of the human gamma-secretase complex. <b>2004</b> , 43, 9774-89	206



1709	Rapid photochemical cross-linking--a new tool for studies of metastable, amyloidogenic protein assemblies. <b>2004</b> , 37, 357-64	183
1708	Acetylcholinesterase inhibitors: novel activities of old molecules. <b>2004</b> ,	
1707	The role of beta amyloid in Alzheimer's disease: still a cause of everything or the only one who got caught?. <b>2004</b> ,	
1706	Acetylcholinesterase inhibitors: novel activities of old molecules. <b>2004</b> , 50, 441-51	222
1705	The role of beta amyloid in Alzheimer's disease: still a cause of everything or the only one who got caught?. <b>2004</b> , 50, 397-409	136
1704	Nicotinic acetylcholine receptor immunohistochemistry in Alzheimer's disease and dementia with Lewy bodies: differential neuronal and astroglial pathology. <b>2004</b> , 225, 39-49	51
1703	Modeling amyloid beta-peptide insertion into lipid bilayers. <b>2004</b> , 86, 3585-97	47
1702	Hypocapnia induces caspase-3 activation and increases Abeta production. <b>2004</b> , 1, 29-37	31
1701	Lithium, a common drug for bipolar disorder treatment, regulates amyloid-beta precursor protein processing. <b>2004</b> , 43, 6899-908	263
1700	Transthyretin aggregation under partially denaturing conditions is a downhill polymerization. <b>2004</b> , 43, 7365-81	281
1699	Transferrin neutralization of amyloid beta 25-35 cytotoxicity. <b>2004</b> , 350, 129-36	22
1698	Therapeutic targets from a Drosophila model of Alzheimer's disease. <b>2004</b> , 4, 513-6	13
1697	Got RIP? Presenilin-dependent intramembrane proteolysis in growth factor receptor signaling. <b>2004</b> , 15, 337-51	72
1696	When enough is enough: genetic diseases associated with transcriptional derepression. <b>2004</b> , 14, 301-7	23
1695	Lineage-specific and ubiquitous biological roles of the mammalian transcription factor LSF. <b>2004</b> , 343, 23-40	47
1694	The insulin-like growth factor-II/mannose-6-phosphate receptor: structure, distribution and function in the central nervous system. <b>2004</b> , 44, 117-40	119
1693	Noradrenergic mechanisms in neurodegenerative diseases: a theory. <b>2004</b> , 45, 38-78	319
1692	Signal transduction during amyloid-beta-peptide neurotoxicity: role in Alzheimer disease. <b>2004</b> , 47, 275-89	105

1691	Adaptor protein interactions: modulators of amyloid precursor protein metabolism and Alzheimer's disease risk?. <b>2004</b> , 185, 208-19	121
1690	The presenilin-1 familial Alzheimer disease mutant P117L impairs neurogenesis in the hippocampus of adult mice. <b>2004</b> , 188, 224-37	147
1689	Vitamin A exhibits potent antiamyloidogenic and fibril-destabilizing effects in vitro. <b>2004</b> , 189, 380-92	82
1688	Increased caspase activation in peripheral blood mononuclear cells of patients with Alzheimer's disease. <b>2004</b> , 190, 254-62	33
1687	Yeast growth selection system for the identification of cell-active inhibitors of beta-secretase. <b>2004</b> , 1674, 29-39	17
1686	Stimulation of beta-amyloid precursor protein alpha-processing by phorbol ester involves calcium and calpain activation. <b>2004</b> , 316, 332-40	30
1685	Promoter polymorphism in fibroblast growth factor 1 gene increases risk of definite Alzheimer's disease. <b>2004</b> , 321, 320-3	22
1684	Wnt-3a overcomes beta-amyloid toxicity in rat hippocampal neurons. <b>2004</b> , 297, 186-96	175
1683	Living with the enemy: a physiological role for the beta-amyloid peptide. <b>2004</b> , 27, 1-3	49
1682	Amyloid-beta(25-35)-induced memory impairments correlate with cell loss in rat hippocampus. <b>2004</b> , 80, 647-55	115
1681	Structure and function of amyloid in Alzheimer's disease. <b>2004</b> , 74, 323-49	119
1680	Genetic discoveries and nursing implications for complex disease prevention and management. <b>2004</b> , 20, 222-9	18
1679	Cognitive impairment in PDAPP mice depends on ApoE and ACT-catalyzed amyloid formation. <b>2004</b> , 25, 1153-67	64
1678	So what if tangles precede plaques?. <b>2004</b> , 25, 721-3; discussion 743-6	29
1677	Lessons from the AN 1792 Alzheimer vaccine: lest we forget. <b>2004</b> , 25, 609-15	75
1676	Contribution of glial cells to the development of amyloid plaques in Alzheimer's disease. <b>2004</b> , 25, 663-74	395
1675	Docosahexaenoic acid protects from dendritic pathology in an Alzheimer's disease mouse model. <b>2004</b> , 43, 633-45	602
1674	Central cholinergic functions in human amyloid precursor protein knock-in/presenilin-1 transgenic mice. <b>2004</b> , 125, 1009-17	36

1673	Modulation of hippocampal cell proliferation, memory, and amyloid plaque deposition in APPsw (Tg2576) mutant mice by isolation stress. <b>2004</b> , 127, 601-9	284
1672	Differences in the immune response to long term Abeta vaccination in C57BL/6 and B6D2F1 mice. <b>2004</b> , 22, 4075-83	18
1671	Hippocampal neuron loss exceeds amyloid plaque load in a transgenic mouse model of Alzheimer's disease. <b>2004</b> , 164, 1495-502	212
1670	Subcellular topography of neuronal Abeta peptide in APPxPS1 transgenic mice. <b>2004</b> , 165, 1465-77	133
1669	Acetylcholinesterase-Abeta complexes are more toxic than Abeta fibrils in rat hippocampus: effect on rat beta-amyloid aggregation, laminin expression, reactive astrocytosis, and neuronal cell loss. <b>2004</b> , 164, 2163-74	117
1668	The endocytotic pathway is required for increased A beta 42 secretion during apoptosis. <b>2004</b> , 128, 201-11	12
1667	Altered processing of the amyloid precursor protein and decreased expression of ADAM 10 by chronic hypoxia in SH-SY5Y: no role for the stress-activated JNK and p38 signalling pathways. <b>2004</b> , 130, 161-9	27
1666	The X-ray structure of an antiparallel dimer of the human amyloid precursor protein E2 domain. <b>2004</b> , 15, 343-53	119
1665	Normal induction but accelerated decay of LTP in APP + PS1 transgenic mice. <b>2004</b> , 15, 188-95	98
1664	Conserved "PAL" sequence in presenilins is essential for gamma-secretase activity, but not required for formation or stabilization of gamma-secretase complexes. <b>2004</b> , 15, 654-66	51
1663	Deposition of amyloid fibrils promotes cell-surface accumulation of amyloid beta precursor protein. <b>2004</b> , 16, 617-29	26
1662	Mutations in APP have independent effects on Abeta and CTFgamma generation. <b>2004</b> , 17, 205-18	58
1661	Human single chain Fv antibodies and a complementarity determining region-derived peptide binding to amyloid-beta 1-42. <b>2004</b> , 17, 114-21	19
1660	M1 muscarinic receptor activation protects neurons from beta-amyloid toxicity. A role for Wnt signaling pathway. <b>2004</b> , 17, 337-48	68
1659	Longitudinal observation on CSF Abeta42 levels in young to middle-aged amyloid precursor protein/presenilin-1 doubly transgenic mice. <b>2004</b> , 17, 516-23	32
1658	Presenilin expression during induced differentiation of the human neuroblastoma SH-SY5Y cell line. <b>2004</b> , 44, 487-96	9
1657	Candidate gene association studies of the alpha 4 (CHRNA4) and beta 2 (CHRNA2) neuronal nicotinic acetylcholine receptor subunit genes in Alzheimer's disease. <b>2004</b> , 358, 142-6	34
1656	Tenuigenin treatment decreases secretion of the Alzheimer's disease amyloid beta-protein in cultured cells. <b>2004</b> , 367, 123-8	79

1655	Increased cerebrospinal fluid levels of transforming growth factor-beta1 in Alzheimer's disease. <b>2004</b> , 367, 194-6	83
1654	Plasmin deficiency does not alter endogenous murine amyloid beta levels in mice. <b>2004</b> , 368, 285-9	30
1653	Neural progenitor cells do not differentiate prematurely in presenilin-1 null mutant mice. <b>2004</b> , 371, 249-54	4
1652	In vivo labeling of amyloid with BF-108. <b>2004</b> , 48, 65-74	57
1651	Effects of beta-AP peptides on activation of the transcription factor NF-kappaB and in cell proliferation in glial cell cultures. <b>2004</b> , 48, 315-23	20
1650	Overexpression of tau leads to the stimulation of neurite outgrowth, the activation of caspase 3 activity, and accumulation and phosphorylation of tau in neuroblastoma cells on cAMP treatment. <b>2004</b> , 49, 363-71	17
1649	Age-related myelin breakdown: a developmental model of cognitive decline and Alzheimer's disease. <b>2004</b> , 25, 5-18; author reply 49-62	681
1648	Age- and sex-dependent development of adrenocortical hyperactivity in a transgenic mouse model of Alzheimer's disease. <b>2004</b> , 25, 893-904	62
1647	High carbohydrate diets and Alzheimer's disease. <b>2004</b> , 62, 689-700	51
1646	Effect of different anti-Abeta antibodies on Abeta fibrillogenesis as assessed by atomic force microscopy. <b>2004</b> , 335, 997-1006	88
1645	How small peptides block and reverse serpin polymerisation. <b>2004</b> , 342, 931-41	76
1644	Antagonist of the amylin receptor blocks beta-amyloid toxicity in rat cholinergic basal forebrain neurons. <b>2004</b> , 24, 5579-84	59
1643	Modeling the protonation states of the catalytic aspartates in beta-secretase. <b>2004</b> , 47, 5159-66	70
1642	ApoE and clusterin cooperatively suppress Abeta levels and deposition: evidence that ApoE regulates extracellular Abeta metabolism in vivo. <b>2004</b> , 41, 193-202	355
1641	Glutamyl cyclases unfold glutamyl cyclase activity under mild acid conditions. <b>2004</b> , 563, 191-6	130
1640	Non-steroidal anti-inflammatory drugs protect amyloid beta protein-induced increase in the intracellular Cl <sup>-</sup> concentration in cultured rat hippocampal neurons. <b>2004</b> , 367, 156-9	10
1639	A disintegrin-metalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer disease mouse model. <b>2004</b> , 113, 1456-64	438
1638	Three-dimensional structure of an independently folded extracellular domain of human amyloid-beta precursor protein. <b>2004</b> , 43, 9583-8	34

1637	Mutant presenilin (A260V) affects Rab8 in PC12D cell. <b>2004</b> , 44, 313-20	23
1636	Convergence of atherosclerosis and Alzheimer's disease: inflammation, cholesterol, and misfolded proteins. <b>2004</b> , 363, 1139-46	43 <sup>1</sup>
1635	Establishing In Vitro Models to Study Endogenous Neurotoxicants. <b>2004</b> , 291-314	
1634	Functional Analysis of the Presenilin Complex and $\gamma$ -Secretase Activity. <b>2004</b> , 84-93	
1633	A Functional Genomics Approach to the Analysis of Biological Markers in Alzheimer Disease. <b>2004</b> , 236-285	8
1632	Activity-dependent increase in beta-amyloid precursor protein mRNA expression in neurons. <b>2004</b> , 15, 1329-33	2
1631	Imaging beta-amyloid plaques and neurofibrillary tangles in the aging human brain. <b>2004</b> , 10, 1469-92	218
1630	Soluble oligomeric A $\beta$ disrupts the protein kinase C signaling pathway. <b>2004</b> , 15, 503-7	7
1629	Current concepts and future prospects for Alzheimer disease vaccines. <b>2004</b> , 18, 38-43	21
1628	Drug use in the elderly: risk or protection?. <b>2004</b> , 17, 443-447	2
1627	A family with Alzheimer disease and strokes associated with A713T mutation of the APP gene. <b>2004</b> , 63, 910-2	53
1626	Syntaxin 5 interacts with presenilin holoproteins, but not with their N- or C-terminal fragments, and affects beta-amyloid peptide production. <b>2004</b> , 381, 619-28	32
1625	Connection of lipid peroxide oxidation with the sphingomyelin pathway in the development of Alzheimer's disease. <b>2004</b> , 32, 144-6	65
1624	[Current status and perspectives on the development of therapeutic agents for Alzheimer's disease]. <b>2004</b> , 123, 421-7	3
1623	Gene vaccination to bias the immune response to amyloid-beta peptide as therapy for Alzheimer disease. <b>2004</b> , 61, 1859-64	72
1622	Protein markers for Alzheimer disease in the frontal cortex and cerebellum. <b>2004</b> , 63, 1385-92	26
1621	What is the rationale for new treatment strategies in Alzheimer's disease?. <b>2004</b> , 9, 6-12	13
1620	Pathogenesis of Alzheimer Disease: Metabolic Factors. <b>2004</b> , 303-353	

1619	Advanced glycation endproduct precursor alters intracellular amyloid-beta/A beta PP carboxy-terminal fragment aggregation and cytotoxicity. <b>2003</b> , 5, 467-76	49
1618	Pharmacogenomic Studies with a Combination Therapy in Alzheimer's Disease. <b>2004</b> , 94-107	10
1617	A novel highly pathogenic Alzheimer presenilin-1 mutation in codon 117 (Pro117Ser): Comparison of clinical, neuropathological and cell culture phenotypes of Pro117Leu and Pro117Ser mutations. <b>2004</b> , 6, 31-43	21
1616	Paradigm shift in NMDA receptor antagonist drug development: molecular mechanism of uncompetitive inhibition by memantine in the treatment of Alzheimer's disease and other neurologic disorders. <b>2004</b> , 6, S61-74	125
1615	Differential loss of synaptic proteins in Alzheimer's disease: implications for synaptic dysfunction. <b>2005</b> , 7, 103-17; discussion 173-80	282
1614	The role of caspase cleavage of tau in Alzheimer disease neuropathology. <b>2005</b> , 64, 104-12	139
1613	ADAM10. <b>2005</b> , 85-121	5
1612	Amyloid- $\beta$ As a Biologically Active Peptide in CNS. <b>2005</b> , 529-538	0
1611	Conclusion. <b>2005</b> , 141-145	
1610	APP23 mice as a model of Alzheimer's disease: an example of a transgenic approach to modeling a CNS disorder. <b>2005</b> , 10, 207-22	46
1609	Mitochondrial dysfunction, endoplasmic reticulum stress, and apoptosis in Alzheimer's disease. <b>2005</b> , 97, 312-6	107
1608	Excitotoxicity. <b>2005</b> , 291-313	
1607	Transgenic mouse models for APP processing and Alzheimer's disease: early and late defects. <b>2005</b> , 38, 45-63	20
1606	Induction of angiogenesis in the beta-amyloid peptide-injected rat hippocampus. <b>2005</b> , 16, 129-32	29
1605	Neuronal Ca <sup>2+</sup> /calmodulin-dependent protein kinase II--discovery, progress in a quarter of a century, and perspective: implication for learning and memory. <b>2005</b> , 28, 1342-54	160
1604	Amyloid pathology and protein kinase C (PKC): possible therapeutics effects of PKC activators. <b>2005</b> , 97, 1-5	18
1603	Pathophysiological roles of amyloidogenic carboxy-terminal fragments of the beta-amyloid precursor protein in Alzheimer's disease. <b>2005</b> , 97, 461-71	53
1602	Design and synthesis of N-benzylpiperidine-purine derivatives as new dual inhibitors of acetyl- and butyrylcholinesterase. <b>2005</b> , 13, 6795-802	43

1601	Choices for tissue visualization with IR microspectroscopy. <b>2005</b> , 38, 133-141	12
1600	Structure-based design of cycloamide-urethane-derived novel inhibitors of human brain memapsin 2 (beta-secretase). <b>2005</b> , 15, 15-20	80
1599	Molecular-modeling based design, synthesis, and activity of substituted piperidines as gamma-secretase inhibitors. <b>2005</b> , 15, 1891-4	20
1598	Chitooligosaccharides as a novel Bsecretase inhibitor. <b>2005</b> , 61, 198-202	47
1597	Transthyretin inhibition of amyloid beta aggregation and toxicity. <b>2005</b> , 38, 1112-9	30
1596	Role of formyl peptide receptor-like 1 (FPRL1/FPR2) in mononuclear phagocyte responses in Alzheimer disease. <b>2005</b> , 31, 165-76	72
1595	Calcium-regulated signaling pathways: role in amyloid beta-induced synaptic dysfunction. <b>2004</b> , 6, 53-64	48
1594	Embryonic stem cell models of CAG repeat disease. <b>2005</b> , 4, 25-30	
1593	Mitochondrial Abeta: a potential focal point for neuronal metabolic dysfunction in Alzheimer's disease. <b>2005</b> , 19, 2040-1	575
1592	Presenilin immunoreactivity in Alzheimer's disease. <b>2005</b> , 12, 700-6	2
1591	Reduced neuronal expression of synaptic transmission modulator HNK-1/neural cell adhesion molecule as a potential consequence of amyloid beta-mediated oxidative stress: a proteomic approach. <b>2005</b> , 92, 705-17	27
1590	Beta-site APP cleaving enzyme up-regulation induced by 4-hydroxynonenal is mediated by stress-activated protein kinases pathways. <b>2005</b> , 92, 628-36	275
1589	Expression of human FE65 in amyloid precursor protein transgenic mice is associated with a reduction in beta-amyloid load. <b>2005</b> , 93, 330-8	40
1588	Syntaxin 5 interacts specifically with presenilin holoproteins and affects processing of betaAPP in neuronal cells. <b>2005</b> , 94, 425-39	25
1587	Familial Alzheimer's disease mutations inhibit gamma-secretase-mediated liberation of beta-amyloid precursor protein carboxy-terminal fragment. <b>2005</b> , 94, 1189-201	57
1586	The N-terminal active centre of human angiotensin-converting enzyme degrades Alzheimer amyloid beta-peptide. <b>2005</b> , 21, 733-40	110
1585	Dietary n-3 polyunsaturated fatty acid depletion activates caspases and decreases NMDA receptors in the brain of a transgenic mouse model of Alzheimer's disease. <b>2005</b> , 22, 617-26	198
1584	Subtype-specific actions of beta-amyloid peptides on recombinant human neuronal nicotinic acetylcholine receptors (alpha7, alpha4beta2, alpha3beta4) expressed in <i>Xenopus laevis</i> oocytes. <b>2005</b> , 146, 964-71	35

1583	Killing pain, killing neurons?. <b>2005</b> , 11, 472-3	6
1582	Diverse compounds mimic Alzheimer disease-causing mutations by augmenting Abeta42 production. <b>2005</b> , 11, 545-50	254
1581	Regulation of gene expression by the amyloid precursor protein: inhibition of the JNK/c-Jun pathway. <b>2005</b> , 12, 1-9	53
1580	NF-kappaB factor c-Rel mediates neuroprotection elicited by mGlu5 receptor agonists against amyloid beta-peptide toxicity. <b>2005</b> , 12, 761-72	80
1579	The amyloid-beta precursor protein: integrating structure with biological function. <b>2005</b> , 24, 3996-4006	196
1578	Reconstitution of gamma-secretase by truncated presenilin (PS) fragments revealed that PS C-terminal transmembrane domain is critical for formation of gamma-secretase complex. <b>2006</b> , 11, 83-93	9
1577	Collagenous Alzheimer amyloid plaque component assembles amyloid fibrils into protease resistant aggregates. <b>2005</b> , 272, 2231-6	29
1576	A case for a non-transgenic animal model of Alzheimer's disease. <b>2005</b> , 4, 157-72	47
1575	Genetic and molecular aspects of Alzheimer's disease shed light on new mechanisms of transcriptional regulation. <b>2005</b> , 4, 134-46	60
1574	Concepts for the treatment of Alzheimer's disease: molecular mechanisms and clinical application. <b>2005</b> , 86, 173-85	41
1573	Expression and production of two selected beta-chemokines in peripheral blood mononuclear cells from patients with Alzheimer's disease. <b>2005</b> , 40, 605-11	37
1572	Chronic treatment with amyloid beta(1-42) inhibits non-cholinergic high-affinity choline transport in NG108-15 cells through protein kinase C signaling. <b>2005</b> , 1062, 101-10	14
1571	Can herbs provide a new generation of drugs for treating Alzheimer's disease?. <b>2005</b> , 50, 361-76	96
1570	Genetically engineered livestock: closer than we think?. <b>2005</b> , 23, 533-5	14
1569	En route to early diagnosis of Alzheimer's disease--are we there yet?. <b>2005</b> , 23, 531-3	20
1568	Cerebrospinal fluid of Alzheimer patients promotes beta-amyloid fibril formation in vitro. <b>2005</b> , 20, 233-40	22
1567	Metabolism of amyloid-beta peptide and Alzheimer's disease. <b>2005</b> , 108, 129-48	161
1566	The PDAPP mouse model of Alzheimer's disease: locus coeruleus neuronal shrinkage. <b>2005</b> , 492, 469-76	36



1565	Reversible assembly of helical filaments by de novo designed minimalist peptides. <b>2005</b> , 80, 26-33	30
1564	Candidate gene association studies of genes involved in neuronal cholinergic transmission in Alzheimer's disease suggests choline acetyltransferase as a candidate deserving further study. <b>2005</b> , 132B, 5-8	33
1563	Identification of hippocampus-related candidate genes for Alzheimer's disease. <b>2005</b> , 57, 585-8	40
1562	Subgroups of Alzheimer's disease based on cerebrospinal fluid molecular markers. <b>2005</b> , 58, 748-57	119
1561	Amyloid-beta aggregates formed at polar-nonpolar interfaces differ from amyloid-beta protofibrils produced in aqueous buffers. <b>2005</b> , 67, 164-74	30
1560	Quantification of the A beta peptide in Alzheimer's plaques by laser dissection microscopy combined with mass spectrometry. <b>2005</b> , 40, 193-201	36
1559	Cytoplasmic domain of the beta-amyloid protein precursor of Alzheimer's disease: function, regulation of proteolysis, and implications for drug development. <b>2005</b> , 80, 151-9	38
1558	Notch 1 interacts with the amyloid precursor protein in a Numb-independent manner. <b>2005</b> , 82, 214-24	30
1557	Inhibition of fibril formation of Abeta by guanidiniocarbonyl pyrrole receptors. <b>2005</b> , 6, 628-31	21
1556	Characterization of the ZnII binding to the peptide amyloid-beta1-16 linked to Alzheimer's disease. <b>2005</b> , 6, 1663-71	69
1555	[Sporadic cerebral amyloid angiopathy with ischemic leukoencephalopathy and microbleeds. Cause for a rapidly progressive dementia syndrome]. <b>2005</b> , 76, 1250-4	2
1554	Symptomatic effect of donepezil, rivastigmine, galantamine and memantine on cognitive deficits in the APP23 model. <b>2005</b> , 180, 177-90	100
1553	PEN-2 gene mutation in a familial Alzheimer's disease case. <b>2005</b> , 252, 1033-6	21
1552	Oxidative stress potentiates BACE1 gene expression and Abeta generation. <b>2005</b> , 112, 455-69	175
1551	Traumatic brain injury: cause or risk of Alzheimer's disease? A review of experimental studies. <b>2005</b> , 112, 1547-64	56
1550	beta-Secretase (BACE1) inhibitors from pomegranate ( <i>Punica granatum</i> ) husk. <b>2005</b> , 28, 1328-32	78
1549	What is the dominant Abeta species in human brain tissue? A review. <b>2005</b> , 7, 29-41	39
1548	Insoluble alpha-synuclein in Alzheimer's disease without Lewy body formation. <b>2005</b> , 7, 69-76	10

1547	Studies of the effects of fragment (25-35) of beta-amyloid peptide on the behavior of rats in a radial maze. <b>2005</b> , 35, 511-8	25
1546	Inhibition of dynamin-dependent endocytosis increases shedding of the amyloid precursor protein ectodomain and reduces generation of amyloid beta protein. <b>2005</b> , 6, 30	104
1545	Prediction of "hot spots" of aggregation in disease-linked polypeptides. <b>2005</b> , 5, 18	148
1544	Innate immunity and inflammation in ageing: a key for understanding age-related diseases. <b>2005</b> , 2, 8	323
1543	Genes involved in Alzheimer's disease, a survey of possible candidates. <b>2005</b> , 7, 331-53	29
1542	The role of inflammation in Alzheimer's disease neuropathology and clinical dementia. From epidemiology to treatment. <b>2005</b> , 166-175	1
1541	Selected genetically engineered models relevant to human neurodegenerative disease. <b>2005</b> , 176-195	1
1540	Amyloid-beta: acute-phase apolipoprotein with metal-binding activity. <b>2005</b> , 8, 129-37; discussion 209-15	2
1539	beta-Amyloid peptides impair PKC-dependent functions of metabotropic glutamate receptors in prefrontal cortical neurons. <b>2005</b> , 93, 3102-11	41
1538	. <b>2005</b> ,	1
1537	Is MTHFR polymorphism a risk factor for Alzheimer's disease like APOE?. <b>2005</b> , 63, 1-6	20
1536	Alzheimer's Disease: Clinical Features, Neuropathologies and Biochemical Abnormalities, Genetics, Models, and Experimental Therapeutics. <b>2005</b> , 445-458	2
1535	The molecular basis of memantine action in Alzheimer's disease and other neurologic disorders: low-affinity, uncompetitive antagonism. <b>2005</b> , 2, 155-65	199
1534	Flavonoids and the Brain: Evidences and Putative Mechanisms for a Protective Capacity. <b>2005</b> , 3, 193-205	17
1533	Oxidative stress, antioxidants and neurodegenerative diseases. <b>2005</b> , 11, 2033-52	108
1532	Postmenopausal hormone therapy and Alzheimer's disease risk: interaction with age. <b>2005</b> , 76, 103-5	165
1531	Evidence that the COOH terminus of human presenilin 1 is located in extracytoplasmic space. <b>2005</b> , 289, C576-81	17
1530	Drug library screen to identify compounds that decrease secreted Abeta from a human cell line. <b>2005</b> , 2, 255-9	7

1529	Development of novel amyloid imaging agents based upon thioflavin S. <b>2005</b> , 2, 109-14	10
1528	Immunization therapy for Alzheimer disease?. <b>2005</b> , 64, 10-2	8
1527	Characterization of Drosophila aspartic proteases that induce the secretion of a Golgi-resident transferase, heparan sulfate 6-O-sulfotransferase. <b>2005</b> , 137, 315-22	8
1526	GGA proteins mediate the recycling pathway of memapsin 2 (BACE). <b>2005</b> , 280, 11696-703	198
1525	CpG-containing oligodeoxynucleotide promotes microglial cell uptake of amyloid beta 1-42 peptide by up-regulating the expression of the G-protein- coupled receptor mFPR2. <b>2005</b> , 19, 2032-4	72
1524	Lipids as modulators of proteolytic activity of BACE: involvement of cholesterol, glycosphingolipids, and anionic phospholipids in vitro. <b>2005</b> , 280, 36815-23	228
1523	Peptide blockers of the inhibition of neuronal nicotinic acetylcholine receptors by amyloid beta. <b>2005</b> , 280, 31085-90	36
1522	Axonal transport, amyloid precursor protein, kinesin-1, and the processing apparatus: revisited. <b>2005</b> , 25, 2386-95	195
1521	Protease nexin-2/amyloid beta-protein precursor limits cerebral thrombosis. <b>2005</b> , 102, 18135-40	45
1520	Endoproteolytic cleavage of FE65 converts the adaptor protein to a potent suppressor of the sAPPalpha pathway in primates. <b>2005</b> , 280, 12548-58	21
1519	Interaction of N-terminal acetyltransferase with the cytoplasmic domain of beta-amyloid precursor protein and its effect on A beta secretion. <b>2005</b> , 137, 147-55	33
1518	Longer forms of amyloid beta protein: implications for the mechanism of intramembrane cleavage by gamma-secretase. <b>2005</b> , 25, 436-45	314
1517	Copper-dependent inhibition of human cytochrome c oxidase by a dimeric conformer of amyloid-beta1-42. <b>2005</b> , 25, 672-9	291
1516	Lead (Pb) exposure and its effect on APP proteolysis and Abeta aggregation. <b>2005</b> , 19, 2083-4	75
1515	Invasion of hematopoietic cells into the brain of amyloid precursor protein transgenic mice. <b>2005</b> , 25, 11125-32	148
1514	Genomic structure and functional characterization of the human ADAM10 promoter. <b>2005</b> , 19, 1522-4	111
1513	Rab6 interacts with the mint3 adaptor protein. <b>2005</b> , 386, 671-7	32
1512	Intracellular Abeta42 activates p53 promoter: a pathway to neurodegeneration in Alzheimer's disease. <b>2005</b> , 19, 255-7	182

1511	Changes in extracellular space size and geometry in APP23 transgenic mice: a model of Alzheimer's disease. <b>2005</b> , 102, 479-84	88
1510	CLAC binds to amyloid beta peptides through the positively charged amino acid cluster within the collagenous domain 1 and inhibits formation of amyloid fibrils. <b>2005</b> , 280, 8596-605	39
1509	Nigrostriatal dysfunction in familial Alzheimer's disease-linked APP <sup>swe</sup> /PS1 <sup>DeltaE9</sup> transgenic mice. <b>2005</b> , 25, 10220-9	67
1508	Peroxisomal proliferation protects from beta-amyloid neurodegeneration. <b>2005</b> , 280, 41057-68	115
1507	β-Secretase, APP and Aβ in Alzheimer's Disease. <b>2005</b> , 79-103	44
1506	Estrogen and selective estrogen receptor modulators exert neuroprotective effects and stimulate the expression of selective Alzheimer's disease indicator-1, a recently discovered antiapoptotic gene, in human neuroblast long-term cell cultures. <b>2005</b> , 90, 1775-82	74
1505	Transgenic <i>C. elegans</i> as a model in Alzheimer's research. <b>2005</b> , 2, 37-45	66
1504	P2Y2 nucleotide receptors enhance alpha-secretase-dependent amyloid precursor protein processing. <b>2005</b> , 280, 18696-702	99
1503	The absence of ABCA1 decreases soluble ApoE levels but does not diminish amyloid deposition in two murine models of Alzheimer disease. <b>2005</b> , 280, 43243-56	176
1502	A beta immunotherapy: Lessons learned for potential treatment of Alzheimer's disease. <b>2005</b> , 2, 255-60	58
1501	Reciprocal activity of ginsenosides in the production of proinflammatory repertoire, and their potential roles in neuroprotection in vivo. <b>2005</b> , 71, 476-81	56
1500	Estrogen and cognition, with a focus on Alzheimer's disease. <b>2005</b> , 23, 172-9	47
1499	The fetal basis of amyloidogenesis: exposure to lead and latent overexpression of amyloid precursor protein and beta-amyloid in the aging brain. <b>2005</b> , 25, 823-9	288
1498	Efficacy of rivastigmine in Alzheimer's disease patients with rapid disease progression: results of a meta-analysis. <b>2005</b> , 20, 192-7	38
1497	Characterization of the Alzheimer's disease-associated CLAC protein and identification of an amyloid beta-peptide-binding site. <b>2005</b> , 280, 1007-15	21
1496	Implications of the serine protease HtrA1 in amyloid precursor protein processing. <b>2005</b> , 102, 6021-6	158
1495	Gene delivery of human apolipoprotein E alters brain Aβ burden in a mouse model of Alzheimer's disease. <b>2005</b> , 102, 1211-6	156
1494	Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta. <b>2005</b> , 25, 629-36	278

1493	NMDA receptor activation inhibits alpha-secretase and promotes neuronal amyloid-beta production. <b>2005</b> , 25, 9367-77	162
1492	Reducing cerebral microvascular amyloid-beta protein deposition diminishes regional neuroinflammation in vasculotropic mutant amyloid precursor protein transgenic mice. <b>2005</b> , 25, 6271-7	54
1491	RNA interference-mediated silencing of X11alpha and X11beta attenuates amyloid beta-protein levels via differential effects on beta-amyloid precursor protein processing. <b>2005</b> , 280, 15413-21	43
1490	Conformational transition of amyloid beta-peptide. <b>2005</b> , 102, 5403-7	222
1489	Akt-dependent expression of NAIP-1 protects neurons against amyloid-{beta} toxicity. <b>2005</b> , 280, 24941-7	48
1488	Amyloid-beta protofibrils differ from amyloid-beta aggregates induced in dilute hexafluoroisopropanol in stability and morphology. <b>2005</b> , 280, 2471-80	86
1487	Inhibition of glycosphingolipid biosynthesis reduces secretion of the beta-amyloid precursor protein and amyloid beta-peptide. <b>2005</b> , 280, 28110-7	108
1486	In vivo cleavage of alpha2,6-sialyltransferase by Alzheimer beta-secretase. <b>2005</b> , 280, 8589-95	77
1485	Compounds that bind APP and inhibit Abeta processing in vitro suggest a novel approach to Alzheimer disease therapeutics. <b>2005</b> , 280, 17792-7	27
1484	Phosphorylation of p66Shc and forkhead proteins mediates Abeta toxicity. <b>2005</b> , 169, 331-9	83
1483	Nucleation-dependent polymerization is an essential component of amyloid-mediated neuronal cell death. <b>2005</b> , 25, 1071-80	185
1482	{beta}-Amyloid-induced neurodegeneration and protection by structurally diverse microtubule-stabilizing agents. <b>2005</b> , 312, 659-68	77
1481	Role of 14-3-3gamma in FE65-dependent gene transactivation mediated by the amyloid beta-protein precursor cytoplasmic fragment. <b>2005</b> , 280, 42364-74	46
1480	Methylation of the imidazole side chains of the Alzheimer disease amyloid-beta peptide results in abolition of superoxide dismutase-like structures and inhibition of neurotoxicity. <b>2005</b> , 280, 13355-63	101
1479	CD147 is a regulatory subunit of the gamma-secretase complex in Alzheimer's disease amyloid beta-peptide production. <b>2005</b> , 102, 7499-504	170
1478	Statins cause intracellular accumulation of amyloid precursor protein, beta-secretase-cleaved fragments, and amyloid beta-peptide via an isoprenoid-dependent mechanism. <b>2005</b> , 280, 18755-70	108
1477	gamma-Cleavage is dependent on zeta-cleavage during the proteolytic processing of amyloid precursor protein within its transmembrane domain. <b>2005</b> , 280, 37689-97	114
1476	Inhibition of amyloid precursor protein processing by beta-secretase through site-directed antibodies. <b>2005</b> , 102, 7718-23	71

1475	c-Jun NH2-terminal kinase-interacting protein-3 facilitates phosphorylation and controls localization of amyloid-beta precursor protein. <b>2005</b> , 25, 3741-51	70
1474	Lipid homeostasis and apolipoprotein E in the development and progression of Alzheimer's disease. <b>2005</b> , 46, 949-68	129
1473	Acute gamma-secretase inhibition improves contextual fear conditioning in the Tg2576 mouse model of Alzheimer's disease. <b>2005</b> , 25, 8898-902	189
1472	Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer's disease. <b>2005</b> , 25, 8843-53	514
1471	Beta-amyloid-induced neuronal apoptosis involves c-Jun N-terminal kinase-dependent downregulation of Bcl-w. <b>2005</b> , 25, 1149-58	178
1470	Distinct transcriptional regulation and function of the human BACE2 and BACE1 genes. <b>2005</b> , 19, 739-49	110
1469	Inhibition of cathepsin B reduces beta-amyloid production in regulated secretory vesicles of neuronal chromaffin cells: evidence for cathepsin B as a candidate beta-secretase of Alzheimer's disease. <b>2005</b> , 386, 931-40	110
1468	Driving cellular plasticity and survival through the signal transduction pathways of metabotropic glutamate receptors. <b>2005</b> , 2, 425-46	49
1467	LRP and Alzheimer's disease. <b>2005</b> , 16, 123-35	50
1466	Disruption of the MAP1B-related protein FUTSCH leads to changes in the neuronal cytoskeleton, axonal transport defects, and progressive neurodegeneration in Drosophila. <b>2005</b> , 16, 2433-42	72
1465	The amyloid precursor protein (APP) of Alzheimer disease and its paralog, APLP2, modulate the Cu/Zn-Nitric Oxide-catalyzed degradation of glypican-1 heparan sulfate in vivo. <b>2005</b> , 280, 13913-20	40
1464	gamma-Secretase substrate selectivity can be modulated directly via interaction with a nucleotide-binding site. <b>2005</b> , 280, 41987-96	90
1463	Sequence determinants of enhanced amyloidogenicity of Alzheimer A{beta}42 peptide relative to A{beta}40. <b>2005</b> , 280, 35069-76	95
1462	Gene clustering by latent semantic indexing of MEDLINE abstracts. <b>2005</b> , 21, 104-15	113
1461	Physicochemical characteristics of soluble oligomeric Abeta and their pathologic role in Alzheimer's disease. <b>2005</b> , 27, 869-81	100
1460	Metales de transición y enfermedad de Alzheimer. <b>2005</b> , 40, 365-370	1
1459	Pharmacogenomics and therapeutic prospects in Alzheimer's disease. <b>2005</b> , 6, 1967-87	40
1458	Refining an Alzheimer's vaccine to avoid an inflammatory response. <b>2005</b> , 5, 809-16	5

1457	Structural locations and functional roles of new subsites S5, S6, and S7 in memapsin 2 (beta-secretase). <b>2005</b> , 44, 105-12	66
1456	Trolox and 17beta-estradiol protect against amyloid beta-peptide neurotoxicity by a mechanism that involves modulation of the Wnt signaling pathway. <b>2005</b> , 280, 11615-25	97
1455	RAC1 inhibition targets amyloid precursor protein processing by gamma-secretase and decreases Abeta production in vitro and in vivo. <b>2005</b> , 280, 37516-25	104
1454	The development of anti-amyloid therapy for Alzheimer's disease : from secretase modulators to polymerisation inhibitors. <b>2005</b> , 19, 989-96	68
1453	Introduction. <b>2005</b> , 1-42	1
1452	Topology of the C-terminal fragment of human presenilin 1. <b>2005</b> , 44, 11821-8	40
1451	Amino-terminally truncated Abeta peptide species are the main component of cotton wool plaques. <b>2005</b> , 44, 10810-21	122
1450	Calpains and disease. <b>2005</b> , 352, 2413-23	189
1449	Seladin-1 as a target of estrogen receptor activation in the brain: a new gene for a rather old story?. <b>2005</b> , 28, 285-93	10
1448	Quantitative measurement of changes in amyloid-beta(40) in the rat brain and cerebrospinal fluid following treatment with the gamma-secretase inhibitor LY-411575 [N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L- <b>2005</b> , 313, 902-8	97
1447	Characterization of the reconstituted gamma-secretase complex from Sf9 cells co-expressing presenilin 1, nicastrin [correction of nacastrin], aph-1a, and pen-2. <b>2005</b> , 44, 4450-7	23
1446	Residual structure in the repeat domain of tau: echoes of microtubule binding and paired helical filament formation. <b>2005</b> , 44, 1026-36	94
1445	Multiple assembly pathways underlie amyloid-beta fibril polymorphisms. <b>2005</b> , 352, 282-98	260
1444	Proteomic identification of less oxidized brain proteins in aged senescence-accelerated mice following administration of antisense oligonucleotide directed at the Abeta region of amyloid precursor protein. <b>2005</b> , 138, 8-16	58
1443	ApoE isoform-specific effects on LTP: blockade by oligomeric amyloid-beta1-42. <b>2005</b> , 18, 75-82	74
1442	Bone-marrow-derived cells contribute to the recruitment of microglial cells in response to beta-amyloid deposition in APP/PS1 double transgenic Alzheimer mice. <b>2005</b> , 18, 134-42	246
1441	Pentapeptides derived from Abeta 1-42 protect neurons from the modulatory effect of Abeta fibrils--an in vitro and in vivo electrophysiological study. <b>2005</b> , 18, 499-508	24
1440	The ubiquitin-proteasome system in Creutzfeldt-Jakob and Alzheimer disease: intracellular redistribution of components correlates with neuronal vulnerability. <b>2005</b> , 19, 427-35	19

1439	Analysis of cholinergic markers, biogenic amines, and amino acids in the CNS of two APP overexpression mouse models. <b>2005</b> , 46, 409-22		38
1438	Oxidative stress induced by beta-amyloid peptide(1-42) is involved in the altered composition of cellular membrane lipids and the decreased expression of nicotinic receptors in human SH-SY5Y neuroblastoma cells. <b>2005</b> , 46, 613-21		39
1437	Candidate gene association study of solute carrier family 11a members 1 (SLC11A1) and 2 (SLC11A2) genes in Alzheimer's disease. <b>2005</b> , 374, 124-8		26
1436	Novel alpha-secretase cleavage of Alzheimer's amyloid beta precursor protein in the endoplasmic reticulum of COS7 cells. <b>2005</b> , 376, 14-9		20
1435	Overexpression of calsenilin enhances gamma-secretase activity. <b>2005</b> , 378, 59-64		38
1434	Amyloid beta peptide-induced cholinergic fibres loss in the cerebral cortex of the rat is modified by diet high in lipids and by age. <b>2005</b> , 29, 31-48		18
1433	Beta-amyloid (Abeta) causes detachment of N1E-115 neuroblastoma cells by acting as a scaffold for cell-associated plasminogen activation. <i>Molecular and Cellular Neurosciences</i> , <b>2005</b> , 28, 496-508	4.8	6
1432	GGA proteins regulate retrograde transport of BACE1 from endosomes to the trans-Golgi network. <i>Molecular and Cellular Neurosciences</i> , <b>2005</b> , 29, 453-61	4.8	104
1431	Tau phosphorylation: physiological and pathological consequences. <b>2005</b> , 1739, 280-97		289
1430	Can tau filaments be both physiologically beneficial and toxic?. <b>2005</b> , 1739, 260-7		11
1429	Cultured cell and transgenic mouse models for tau pathology linked to beta-amyloid. <b>2005</b> , 1739, 116-24		25
1428	Nanoparticle and other metal chelation therapeutics in Alzheimer disease. <b>2005</b> , 1741, 246-52		103
1427	Age-progressing cognitive impairments and neuropathology in transgenic CRND8 mice. <b>2005</b> , 160, 344-55		67
1426	Age-related impairments in operant DMTTP performance in the PS2APP mouse, a transgenic mouse model of Alzheimer's disease. <b>2005</b> , 161, 220-8		10
1425	Effects of memantine and donepezil on amyloid beta-induced memory impairment in a delayed-matching to position task in rats. <b>2005</b> , 162, 191-9		63
1424	Determination of hypoxic effect on neprilysin activity in human neuroblastoma SH-SY5Y cells using a novel HPLC method. <b>2005</b> , 334, 380-5		10
1423	Pin1 promotes production of Alzheimer's amyloid beta from beta-cleaved amyloid precursor protein. <b>2005</b> , 336, 521-9		52
1422	Interactions between Alzheimer's disease and cerebral ischemia--focus on inflammation. <b>2005</b> , 48, 240-50		115



1421	Are mitochondria critical in the pathogenesis of Alzheimer's disease?. <b>2005</b> , 49, 618-32	222
1420	High selective expression of alpha7 nicotinic receptors on astrocytes in the brains of patients with sporadic Alzheimer's disease and patients carrying Swedish APP 670/671 mutation: a possible association with neuritic plaques. <b>2005</b> , 192, 215-25	105
1419	Apoptotic signals within the basal forebrain cholinergic neurons in Alzheimer's disease. <b>2005</b> , 195, 484-96	68
1418	CoQ10 therapy attenuates amyloid beta-peptide toxicity in brain mitochondria isolated from aged diabetic rats. <b>2005</b> , 196, 112-9	62
1417	Amyloid-beta causes apoptosis of neuronal cells via caspase cascade, which can be prevented by amyloid-beta-derived short peptides. <b>2005</b> , 196, 282-9	76
1416	Regulation of the amyloid precursor protein ectodomain shedding by the 5-HT4 receptor and Epac. <b>2005</b> , 579, 1136-42	42
1415	Blocking the cleavage at midportion between gamma- and epsilon-sites remarkably suppresses the generation of amyloid beta-protein. <b>2005</b> , 579, 2907-12	23
1414	Ectoine and hydroxyectoine inhibit aggregation and neurotoxicity of Alzheimer's beta-amyloid. <b>2005</b> , 579, 4775-80	93
1413	Cerebral microvascular amyloid beta protein deposition induces vascular degeneration and neuroinflammation in transgenic mice expressing human vasculotropic mutant amyloid beta precursor protein. <b>2005</b> , 167, 505-15	150
1412	Cloning, expression, purification, and spectroscopic analysis of the fragment 57-102 of human alpha-synuclein. <b>2005</b> , 39, 90-6	8
1411	Production of recombinant amyloid-beta peptide 42 as an ubiquitin extension. <b>2005</b> , 40, 183-9	52
1410	The physiology and pathophysiology of nitric oxide in the brain. <b>2005</b> , 76, 126-52	550
1409	The insect homologue of the amyloid precursor protein interacts with the heterotrimeric G protein Go alpha in an identified population of migratory neurons. <b>2005</b> , 288, 160-78	29
1408	Dual role of interactions between membranous and soluble portions of helical membrane receptors for folding and signaling. <b>2005</b> , 26, 183-9	31
1407	Molecular misreading: the frequency of dinucleotide deletions in neuronal mRNAs for beta-amyloid precursor protein and ubiquitin B. <b>2005</b> , 26, 145-55	22
1406	Age- and region-dependent alterations in Abeta-degrading enzymes: implications for Abeta-induced disorders. <b>2005</b> , 26, 645-54	269
1405	Human-like rodent amyloid-beta-peptide determines Alzheimer pathology in aged wild-type Octodon degu. <b>2005</b> , 26, 1023-8	87
1404	Intraneuronal Abeta accumulation and origin of plaques in Alzheimer's disease. <b>2005</b> , 26, 1235-44	270

1403	Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. <b>2005</b> , 48, 913-22	882
1402	Non-steroidal anti-inflammatory drugs have anti-amyloidogenic effects for Alzheimer's beta-amyloid fibrils in vitro. <b>2005</b> , 49, 1088-99	111
1401	Lifelong immunization with human beta-amyloid (1-42) protects Alzheimer's transgenic mice against cognitive impairment throughout aging. <b>2005</b> , 130, 667-84	54
1400	Intraneuronal A $\beta$ , non-amyloid aggregates and neurodegeneration in a Drosophila model of Alzheimer's disease. <b>2005</b> , 132, 123-35	285
1399	The chick embryo appears as a natural model for research in beta-amyloid precursor protein processing. <b>2005</b> , 134, 1285-300	26
1398	Synthesis and biological evaluation of (E)-3-styrylpyridine derivatives as amyloid imaging agents for Alzheimer's disease. <b>2005</b> , 32, 329-35	25
1397	Cholesterol homeostasis in neurons and glial cells. <b>2005</b> , 16, 193-212	157
1396	A ketogenic diet reduces amyloid beta 40 and 42 in a mouse model of Alzheimer's disease. <b>2005</b> , 2, 28	191
1395	Structural variation in human apolipoprotein E3 and E4: secondary structure, tertiary structure, and size distribution. <b>2005</b> , 88, 455-66	47
1394	Design, synthesis, and biological evaluation of dual binding site acetylcholinesterase inhibitors: new disease-modifying agents for Alzheimer's disease. <b>2005</b> , 48, 7223-33	179
1393	Glyceraldehyde-3-phosphate dehydrogenase, apoptosis, and neurodegenerative diseases. <b>2005</b> , 45, 269-90	239
1392	Radioiodinated flavones for in vivo imaging of beta-amyloid plaques in the brain. <b>2005</b> , 48, 7253-60	65
1391	Yeast as a screening tool. <b>2005</b> , 2, 187-92	38
1390	Dementia of Alzheimer's disease and other neurodegenerative disorders--memantine, a new hope. <b>2005</b> , 51, 1-17	211
1389	Matrix metalloproteinase-9 in cerebral-amyloid-angiopathy-related hemorrhage. <b>2005</b> , 229-230, 249-54	46
1388	Chromosome 21 BACE2 haplotype associates with Alzheimer's disease: a two-stage study. <b>2005</b> , 236, 17-24	26
1387	Lymphocyte-specific protein tyrosine kinase is a novel risk gene for Alzheimer disease. <b>2005</b> , 238, 53-7	5
1386	Acetylcholinesterase interaction with Alzheimer amyloid beta. <b>2005</b> , 38, 299-317	59

1385	Developing novel immunogens for an effective, safe Alzheimer's disease vaccine. <b>2005</b> , 2, 267-72	24
1384	Mechanisms of Disease: astrocytes in neurodegenerative disease. <b>2006</b> , 2, 679-89	604
1383	Assigning the protonation states of the key aspartates in $\beta$ Secretase using QM/MM X-ray structure refinement. <b>2006</b> , 2, 1057-1069	86
1382	Neuroproteases in peptide neurotransmission and neurodegenerative diseases: applications to drug discovery research. <b>2006</b> , 20, 105-19	9
1381	The Serotonin Receptors. <b>2006</b> ,	21
1380	Structural study of metastable amyloidogenic protein oligomers by photo-induced cross-linking of unmodified proteins. <b>2006</b> , 413, 217-36	73
1379	Inhibition of gamma-secretase as a therapeutic intervention for Alzheimer's disease: prospects, limitations and strategies. <b>2006</b> , 20, 351-72	77
1378	Artefactual effects of lipid-based cell transfection reagents on AbetaPP processing and Abeta production. <b>2006</b> , 13, 86-92	1
1377	Protective effect of <i>Rosa laevigata</i> against amyloid beta peptide-induced oxidative stress. <b>2006</b> , 13, 6-12	28
1376	VEGF gene and phenotype relation with Alzheimer's disease and mild cognitive impairment. <b>2006</b> , 9, 485-93	74
1375	Gamma-secretase inhibitors for Alzheimer's disease: balancing efficacy and toxicity. <b>2006</b> , 7, 87-97	98
1374	Presenilin-dependent gamma-secretase on plasma membrane and endosomes is functionally distinct. <b>2006</b> , 45, 4907-14	57
1373	Amyloidogenic processing of beta-amyloid precursor protein in intracellular compartments. <b>2006</b> , 66, S69-73	188
1372	Inositol phosphates and phosphoinositides in health and disease. <b>2006</b> , 39, 265-92	35
1371	A high-throughput screen for compounds that inhibit aggregation of the Alzheimer's peptide. <b>2006</b> , 1, 461-9	143
1370	A dynamic relationship between intracellular and extracellular pools of Abeta. <b>2006</b> , 168, 184-94	189
1369	Ab initio discrete molecular dynamics approach to protein folding and aggregation. <b>2006</b> , 412, 314-38	50
1368	Trafficking of Alzheimer's disease-related membrane proteins and its participation in disease pathogenesis. <b>2006</b> , 139, 949-55	46

1367	Cognitive evaluation of disease-modifying efficacy of galantamine and memantine in the APP23 model. <b>2006</b> , 16, 59-69	63
1366	Mitochondria are a direct site of A beta accumulation in Alzheimer's disease neurons: implications for free radical generation and oxidative damage in disease progression. <b>2006</b> , 15, 1437-49	852
1365	Prévention de la maladie d'Alzheimer*. <b>2006</b> , 6, 12-22	
1364	Preparation of amyloid beta-protein for structural and functional studies. <b>2006</b> , 413, 20-33	149
1363	Boosting with intranasal dendrimeric Abeta1-15 but not Abeta1-15 peptide leads to an effective immune response following a single injection of Abeta1-40/42 in APP-tg mice. <b>2006</b> , 3, 14	18
1362	CD40 deficiency mitigates Alzheimer's disease pathology in transgenic mouse models. <b>2006</b> , 3, 3	20
1361	Unraveling in vivo functions of amyloid precursor protein: insights from knockout and knockdown studies. <b>2006</b> , 3, 134-47	36
1360	Abeta42 gene vaccination reduces brain amyloid plaque burden in transgenic mice. <b>2006</b> , 244, 151-8	63
1359	DAPT-induced intracellular accumulations of longer amyloid beta-proteins: further implications for the mechanism of intramembrane cleavage by gamma-secretase. <b>2006</b> , 45, 3952-60	55
1358	Secondary structure and interfacial aggregation of amyloid-beta(1-40) on sodium dodecyl sulfate micelles. <b>2006</b> , 45, 8639-48	67
1357	Signal peptide peptidase: biochemical properties and modulation by nonsteroidal antiinflammatory drugs. <b>2006</b> , 45, 8649-56	81
1356	Analysis of single Alzheimer solid plaque cores by laser capture microscopy and nanoelectrospray/tandem mass spectrometry. <b>2006</b> , 45, 9849-56	29
1355	The gamma-secretase complex: membrane-embedded proteolytic ensemble. <b>2006</b> , 45, 7931-9	180
1354	Design, synthesis and X-ray structure of protein-ligand complexes: important insight into selectivity of memapsin 2 (beta-secretase) inhibitors. <b>2006</b> , 128, 5310-1	57
1353	Novel benzofuran derivatives for PET imaging of beta-amyloid plaques in Alzheimer's disease brains. <b>2006</b> , 49, 2725-30	89
1352	Determination of beta-amyloid peptide signatures in cerebrospinal fluid using immunoprecipitation-mass spectrometry. <b>2006</b> , 5, 1010-6	161
1351	On the seeding and oligomerization of pGlu-amyloid peptides (in vitro). <b>2006</b> , 45, 12393-9	216
1350	Effects of lipids and aging on the neurotoxicity and neuronal loss caused by intracerebral injections of the amyloid-beta peptide in the rat. <b>2006</b> , 197, 41-55	20

1349	Kinetics of amyloid aggregation of mammal apomyoglobins and correlation with their amino acid sequences. <b>2006</b> , 580, 1681-4	13
1348	alphaB-crystallin competes with Alzheimer's disease beta-amyloid peptide for peptide-peptide interactions and induces oxidation of Abeta-Met35. <b>2006</b> , 580, 5941-6	45
1347	Anti-amyloidogenic effects of antioxidants: implications for the prevention and therapeutics of Alzheimer's disease. <b>2006</b> , 1762, 575-86	135
1346	Serum amyloid A (SAA)-induced remodeling of CSF-HDL. <b>2006</b> , 1761, 424-33	32
1345	Sphingolipids in apoptosis, survival and regeneration in the nervous system. <b>2006</b> , 1758, 1995-2015	52
1344	Differential effects of tumor necrosis factor-alpha co-administered with amyloid beta-peptide (25-35) on memory function and hippocampal damage in rat. <b>2006</b> , 175, 352-61	13
1343	Cytosolic amyloid-beta peptide 42 escaping from degradation induces cell death. <b>2006</b> , 344, 471-7	16
1342	Protease digestion indicates that endogenous presenilin 1 is present in at least two physical forms. <b>2006</b> , 346, 330-4	4
1341	Abeta 11-40/42 production without gamma-secretase epsilon-site cleavage. <b>2006</b> , 349, 1356-60	11
1340	The intracellular domain of the amyloid precursor protein (AICD) enhances the p53-mediated apoptosis. <b>2006</b> , 351, 57-63	66
1339	Allele-specific silencing of Alzheimer's disease genes: the amyloid precursor protein genes with Swedish or London mutations. <b>2006</b> , 371, 68-74	25
1338	Copper homeostasis and neurodegenerative disorders (Alzheimer's, prion, and Parkinson's diseases and amyotrophic lateral sclerosis). <b>2006</b> , 106, 1995-2044	1317
1337	Alzheimer's disease beta-amyloid peptides are released in association with exosomes. <b>2006</b> , 103, 11172-7	928
1336	A genome wide analysis of ubiquitin ligases in APP processing identifies a novel regulator of BACE1 mRNA levels. <i>Molecular and Cellular Neurosciences</i> , <b>2006</b> , 33, 227-35	4.8 22
1335	Abeta42 is more rigid than Abeta40 at the C terminus: implications for Abeta aggregation and toxicity. <b>2006</b> , 364, 853-62	214
1334	Increase in apoptosis with neural differentiation and shortening of the lifespan of P19 cells overexpressing tau. <b>2006</b> , 48, 243-54	6
1333	Anti-Parkinsonian agents have anti-amyloidogenic activity for Alzheimer's beta-amyloid fibrils in vitro. <b>2006</b> , 48, 275-85	39
1332	Clusterin in cerebrospinal fluid: analysis of carbohydrates and quantification of native and glycosylated forms. <b>2006</b> , 48, 718-28	71

1331	Influence of cholesterol and lovastatin on alpha-form of secreted amyloid precursor protein and expression of alpha7 nicotinic receptor on astrocytes. <b>2006</b> , 49, 459-65	25
1330	Identification of amyloid-beta 1-42 binding protein fragments by screening of a human brain cDNA library. <b>2006</b> , 397, 79-82	19
1329	Amyloid beta-peptide1-42 alters tight junction protein distribution and expression in brain microvessel endothelial cells. <b>2006</b> , 401, 219-24	119
1328	Chinese Presenilin-1 V97L mutation enhanced Abeta42 levels in SH-SY5Y neuroblastoma cells. <b>2006</b> , 406, 33-7	27
1327	Lower levels of cerebrospinal fluid amyloid beta (Abeta) in non-demented Indian controls. <b>2006</b> , 407, 121-3	6
1326	An Alzheimer's disease-specific beta-amyloid fragment signature in cerebrospinal fluid. <b>2006</b> , 409, 215-9	101
1325	Thioflavins released from nanoparticles target fibrillar amyloid beta in the hippocampus of APP/PS1 transgenic mice. <b>2006</b> , 24, 195-201	42
1324	Zinc uptake is mediated by M1 muscarinic acetylcholine receptors in differentiated SK-SH-SY5Y cells. <b>2006</b> , 24, 23-7	8
1323	Metal exposure and Alzheimer's pathogenesis. <b>2006</b> , 155, 45-51	106
1322	Mechanical manipulation of Alzheimer's amyloid beta1-42 fibrils. <b>2006</b> , 155, 316-26	55
1321	PEGylated phospholipid nanomicelles interact with beta-amyloid((1-42)) and mitigate its beta-sheet formation, aggregation and neurotoxicity in vitro. <b>2006</b> , 27, 2858-66	64
1320	Amyloid beta and neuromelanin--toxic or protective molecules? The cellular context makes the difference. <b>2006</b> , 78, 364-73	38
1319	"The seven sins" of the Hebbian synapse: can the hypothesis of synaptic plasticity explain long-term memory consolidation?. <b>2006</b> , 80, 99-113	47
1318	Amyloid peptides mediate hypoxic increase of L-type Ca <sup>2+</sup> channels in central neurones. <b>2006</b> , 27, 439-45	35
1317	Bosentan preserves endothelial function in mice overexpressing APP. <b>2006</b> , 27, 446-50	21
1316	Cellular distribution of insulin-like growth factor-II/mannose-6-phosphate receptor in normal human brain and its alteration in Alzheimer's disease pathology. <b>2006</b> , 27, 199-210	29
1315	Differences in regional brain atrophy in genetic forms of Alzheimer's disease. <b>2006</b> , 27, 387-93	30
1314	Mapping cellular transcriptosomes in autopsied Alzheimer's disease subjects and relevant animal models. <b>2006</b> , 27, 1060-77	59

1313	Activity changes and marked stereotypic behavior precede Abeta pathology in TgCRND8 Alzheimer mice. <b>2006</b> , 27, 955-64	74
1312	An array of genes implicated in Alzheimer's disease. <b>2006</b> , 27, 1078-80	2
1311	Deficient cerebral clearance of vasculotropic mutant Dutch/Iowa Double A beta in human A betaPP transgenic mice. <b>2006</b> , 27, 946-54	39
1310	siRNA targeted against amyloid precursor protein impairs synaptic activity in vivo. <b>2006</b> , 27, 1740-50	44
1309	M1 receptors play a central role in modulating AD-like pathology in transgenic mice. <b>2006</b> , 49, 671-82	348
1308	Estrogen-containing hormone therapy and Alzheimer's disease risk: understanding discrepant inferences from observational and experimental research. <b>2006</b> , 138, 1031-9	163
1307	In vivo protection by the xanthate tricyclodecan-9-yl-xanthogenate against amyloid beta-peptide (1-42)-induced oxidative stress. <b>2006</b> , 138, 1161-70	50
1306	High sensitivity analysis of amyloid-beta peptide composition in amyloid deposits from human and PS2APP mouse brain. <b>2006</b> , 143, 461-75	146
1305	Synthesis and evaluation of benzothiophene derivatives as ligands for imaging beta-amyloid plaques in Alzheimer's disease. <b>2006</b> , 33, 811-20	25
1304	The nucleation growth and reversibility of Amyloid-beta deposition in vivo. <b>2006</b> , 10, 291-301	11
1303	Heme binding to Amyloid-beta peptide: mechanistic role in Alzheimer's disease. <b>2006</b> , 10, 255-66	67
1302	Pathogenesis of Alzheimer's Dementia. <b>2006</b> , 49, 717	
1301	Lipid peroxidation and Alzheimer's disease: Key role of Amyloid- $\beta$ . <b>2006</b> , 13, 46-53	4
1300	An antibody to the beta-secretase cleavage site on amyloid-beta-protein precursor inhibits amyloid-beta production. <b>2006</b> , 10, 379-90	15
1299	Time window in cholinomimetic ability to rescue long-term potentiation in neurodegenerating anti-nerve growth factor mice. <b>2006</b> , 9, 59-68	17
1298	Deficiency in neuronal TGF-beta signaling promotes neurodegeneration and Alzheimer's pathology. <b>2006</b> , 116, 3060-9	246
1297	Mitochondrial oxidative damage in aging and Alzheimer's disease: implications for mitochondrially targeted antioxidant therapeutics. <b>2006</b> , 2006, 31372	102
1296	. <b>2006</b> ,	19

1295	References. <b>2006</b> , 453-566	
1294	Neurogenesis in Human Hippocampus: Implications for Alzheimer Disease Pathogenesis. <b>2006</b> , 4, 175-182	2
1293	Alzheimer's disease and frontotemporal dementia: prospects of a tailored therapy?. <b>2006</b> , 185, 381-4	23
1292	Atomic Force Microscopy. <b>2006</b> , 315-334	1
1291	Emerging biology of the cholinergic system across the spectrum of Alzheimer's disease. <b>2006</b> , 18, S3-S16	8
1290	Redox proteomics identification of oxidatively modified brain proteins in inherited Alzheimer's disease: an initial assessment. <b>2006</b> , 10, 391-7	103
1289	Switch on Amyloid [Peptide Self-Assembly by Enzyme-Triggered Acyl Migration. <b>2006</b> , 56-58	1
1288	La lunga attesa: towards a molecular approach to neuroimaging and therapeutics in Alzheimer's disease. <b>2006</b> , 19, 453-74	11
1287	LR11/SorLA expression is reduced in sporadic Alzheimer disease but not in familial Alzheimer disease. <b>2006</b> , 65, 866-72	107
1286	Amyloid-beta immunotherapies in mice and men. <b>2006</b> , 20, 118-23	14
1285	Chaperone Suppression of Aggregated Protein Toxicity. <b>2006</b> , 137-164	1
1284	Lipid Rafts in Trafficking and Processing of Prion Protein and Amyloid Precursor Protein. <b>2006</b> , 205-231	
1283	Glycogen Synthase Kinase 3: Role in Neurodegeneration and Neuroprotection. 173-187	
1282	Translocation and potential neurological effects of fine and ultrafine particles a critical update. <b>2006</b> , 3, 13	381
1281	Signal peptide peptidase (SPP) dimer formation as assessed by fluorescence lifetime imaging microscopy (FLIM) in intact cells. <b>2006</b> , 1, 16	15
1280	Beta-amyloid treatment of two complementary P301L tau-expressing Alzheimer's disease models reveals similar deregulated cellular processes. <b>2006</b> , 6, 6566-77	59
1279	'Click peptide': a novel 'O-acyl isopeptide method' for peptide synthesis and chemical biology-oriented synthesis of amyloid beta peptide analogues. <b>2006</b> , 12, 823-8	26
1278	Cholesterol Depletion Reduces the Internalization of [Amyloid Peptide in SH-SY5Y Cells*. <b>2006</b> , 11, 447-451	1



1277	Docosahexaenoic acid-induced protective effect against impaired learning in amyloid beta-infused rats is associated with increased synaptosomal membrane fluidity. <b>2006</b> , 33, 934-9	89
1276	NF-kappaB pathway: a target for preventing beta-amyloid (Abeta)-induced neuronal damage and Abeta42 production. <b>2006</b> , 23, 1711-20	108
1275	Interleukin-18 and transforming growth factor-beta 1 plasma levels in Alzheimer's disease and vascular dementia. <b>2006</b> , 26, 307-12	71
1274	Chaperone and anti-chaperone: two-faced synuclein as stimulator of synaptic evolution. <b>2006</b> , 26, 383-92	17
1273	Collagen XVIII: a novel heparan sulfate proteoglycan associated with vascular amyloid depositions and senile plaques in Alzheimer's disease brains. <b>2002</b> , 12, 456-62	54
1272	Apolipoprotein Abeta: black sheep in a good family. <b>2004</b> , 14, 433-47	13
1271	The Abeta hypothesis: leading us to rationally-designed therapeutic strategies for the treatment or prevention of Alzheimer disease. <b>2005</b> , 15, 84-7	82
1270	Mechanism of cerebral beta-amyloid angiopathy: murine and cellular models. <b>2006</b> , 16, 40-54	130
1269	Inhibition of endocytosis activates alternative degradation pathway of AβPP in cultured cells. <b>2006</b> , 6, 107-113	
1268	Neuronal protection by sirtuins in Alzheimer's disease. <b>2006</b> , 96, 305-13	128
1267	In vitro characterization of a gamma-secretase radiotracer in mammalian brain. <b>2006</b> , 96, 171-8	8
1266	A presenilin-independent aspartyl protease prefers the gamma-42 site cleavage. <b>2006</b> , 96, 118-25	22
1265	Amyloid precursor protein-mediated free radicals and oxidative damage: implications for the development and progression of Alzheimer's disease. <b>2006</b> , 96, 1-13	269
1264	The novel beta-secretase inhibitor KMI-429 reduces amyloid beta peptide production in amyloid precursor protein transgenic and wild-type mice. <b>2006</b> , 96, 533-40	132
1263	Sialylation enhances the secretion of neurotoxic amyloid-beta peptides. <b>2006</b> , 96, 924-33	59
1262	Homocysteine-induced endoplasmic reticulum protein (Herp) is up-regulated in sporadic inclusion-body myositis and in endoplasmic reticulum stress-induced cultured human muscle fibers. <b>2006</b> , 96, 1491-9	52
1261	Amyloid precursor protein cross-linking stimulates beta amyloid production and pro-inflammatory cytokine release in monocytic lineage cells. <b>2006</b> , 97, 449-61	28
1260	Tomoregulin-2 is found extensively in plaques in Alzheimer's disease brain. <b>2006</b> , 98, 34-44	15

1259	Nephrilysin activity and expression are controlled by nicastrin. <b>2006</b> , 97, 1052-6	31
1258	Do axonal defects in tau and amyloid precursor protein transgenic animals model axonopathy in Alzheimer's disease?. <b>2006</b> , 98, 993-1006	104
1257	Bis(7)-tacrine attenuates beta amyloid-induced neuronal apoptosis by regulating L-type calcium channels. <b>2006</b> , 98, 1400-10	95
1256	Molecular mechanisms for Alzheimer's disease: implications for neuroimaging and therapeutics. <b>2006</b> , 97, 1700-25	190
1255	The chemical biology of clinically tolerated NMDA receptor antagonists. <b>2006</b> , 97, 1611-26	361
1254	Tauroursodeoxycholic acid modulates p53-mediated apoptosis in Alzheimer's disease mutant neuroblastoma cells. <b>2006</b> , 98, 1610-8	55
1253	Toxicity mediated by soluble oligomers of beta-amyloid(1-42) on cholinergic SN56.B5.G4 cells. <b>2006</b> , 98, 1930-45	43
1252	Potential implications of endogenous aldehydes in beta-amyloid misfolding, oligomerization and fibrillogenesis. <b>2006</b> , 99, 1413-24	98
1251	Disease modifying therapy for AD?. <b>2006</b> , 99, 689-707	105
1250	Overexpression of Aβeta is associated with acceleration of onset of motor impairment and superoxide dismutase 1 aggregation in an amyotrophic lateral sclerosis mouse model. <b>2006</b> , 5, 153-65	32
1249	The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease. <b>2003</b> , 9, 275-308	256
1248	Altered membrane fluidity and lipid raft composition in presenilin-deficient cells. <b>2006</b> , 185, 27-32	31
1247	Mutagenesis of the central hydrophobic cluster in Aβeta42 Alzheimer's peptide. Side-chain properties correlate with aggregation propensities. <b>2006</b> , 273, 658-68	137
1246	Physicochemical characterization of the Alzheimer's disease-related peptides A beta 1-42Arctic and A beta 1-42wt. <b>2006</b> , 273, 2618-30	77
1245	Construction of a small peptide library related to inhibitor OM99-2 and its structure-activity relationship to beta-secretase. <b>2006</b> , 27, 1586-93	6
1244	Inhibition of APP trafficking by tau protein does not increase the generation of amyloid-beta peptides. <b>2006</b> , 7, 873-88	66
1243	Regression stage senile plaques in the natural course of Alzheimer's disease. <b>2006</b> , 32, 539-56	28
1242	Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo. <b>2006</b> , 12, 856-61	441

1241	Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond. <b>2006</b> , 5, 160-70	657
1240	ER stress and neurodegenerative diseases. <b>2006</b> , 13, 385-92	663
1239	Regulated intramembrane proteolysis of amyloid precursor protein and regulation of expression of putative target genes. <b>2006</b> , 7, 739-45	163
1238	Hyperforin prevents beta-amyloid neurotoxicity and spatial memory impairments by disaggregation of Alzheimer's amyloid-beta-deposits. <b>2006</b> , 11, 1032-48	84
1237	Macrocyclic peptidomimetic inhibitors of beta-secretase (BACE): first X-ray structure of a macrocyclic peptidomimetic-BACE complex. <b>2006</b> , 16, 191-5	31
1236	Novel gamma-secretase inhibitors discovered by library screening of in-house synthetic natural product intermediates. <b>2006</b> , 16, 3813-6	18
1235	Kinetic analysis of beta-amyloid peptide aggregation induced by metal ions based on surface plasmon resonance biosensing. <b>2006</b> , 154, 190-7	52
1234	Noncovalent interaction between amyloid-beta-peptide (1-40) and oleuropein studied by electrospray ionization mass spectrometry. <b>2006</b> , 17, 568-75	64
1233	LRP in amyloid-beta production and metabolism. <b>2006</b> , 1086, 35-53	89
1232	Age-related inflammatory diseases: role of genetics and gender in the pathophysiology of Alzheimer's disease. <b>2006</b> , 1089, 472-86	37
1231	Genetic selection for protein solubility enabled by the folding quality control feature of the twin-arginine translocation pathway. <b>2006</b> , 15, 449-58	107
1230	Simulation of molecular crowding effects on an Alzheimer's beta-amyloid peptide. <b>2006</b> , 46, 123-41	9
1229	beta-Amyloid and endoplasmic reticulum stress responses in primary neurons: effects of drugs that interact with the cytoskeleton. <b>2006</b> , 28, 111-23	40
1228	Calpain and synaptic function. <b>2006</b> , 33, 215-36	117
1227	Protease pathways in peptide neurotransmission and neurodegenerative diseases. <b>2006</b> , 26, 449-69	18
1226	On the molecular basis linking Nerve Growth Factor (NGF) to Alzheimer's disease. <b>2006</b> , 26, 619-33	76
1225	Studies of the effects of central administration of beta-amyloid peptide (25-35): pathomorphological changes in the Hippocampus and impairment of spatial memory. <b>2006</b> , 36, 101-6	37
1224	Alzheimer's disease, brain immune privilege and memory: a hypothesis. <b>2006</b> , 113, 1697-707	19

1223	Relative paucity of tau accumulation in the small areas with abundant Abeta42-positive capillary amyloid angiopathy within a given cortical region in the brain of patients with Alzheimer pathology. <b>2006</b> , 111, 510-8	15
1222	Structural and thermodynamical properties of Cull amyloid-beta16/28 complexes associated with Alzheimer's disease. <b>2006</b> , 11, 1024-38	118
1221	Metal binding in amyloid beta-peptides shows intra- and inter-peptide coordination modes. <b>2006</b> , 35, 340-51	100
1220	Linear interaction energy models for beta-secretase (BACE) inhibitors: Role of van der Waals, electrostatic, and continuum-solvation terms. <b>2006</b> , 24, 475-84	22
1219	Neuronal differentiation of human mesenchymal stem cells: changes in the expression of the Alzheimer's disease-related gene seladin-1. <b>2006</b> , 312, 2592-604	57
1218	Differential regulation of c-jun and CREB by acrolein and 4-hydroxynonenal. <b>2006</b> , 40, 21-34	55
1217	The various aggregation states of beta-amyloid 1-42 mediate different effects on oxidative stress, neurodegeneration, and BACE-1 expression. <b>2006</b> , 41, 202-12	95
1216	Interaction of the amyloid precursor like protein 1 with the alpha2A-adrenergic receptor increases agonist-mediated inhibition of adenylate cyclase. <b>2006</b> , 18, 1748-57	12
1215	Decreased plasma cholesterol levels during aging in transgenic mouse models of Alzheimer's disease. <b>2006</b> , 41, 220-4	16
1214	Alzheimer's disease and post-operative cognitive dysfunction. <b>2006</b> , 41, 346-59	132
1213	Low molecular weight thiol amides attenuate MAPK activity and protect primary neurons from Abeta(1-42) toxicity. <b>2006</b> , 1069, 198-206	36
1212	Chronic hypoxia in the human neuroblastoma SH-SY5Y causes reduced expression of the putative alpha-secretases, ADAM10 and TACE, without altering their mRNA levels. <b>2006</b> , 1099, 18-24	29
1211	A novel membrane protein, encoded by the gene covering KIAA0233, is transcriptionally induced in senile plaque-associated astrocytes. <b>2006</b> , 1108, 19-27	35
1210	Resveratrol--a boon for treating Alzheimer's disease?. <b>2006</b> , 52, 316-26	262
1209	Isoprenoids and Alzheimer's disease: a complex relationship. <b>2006</b> , 22, 209-22	68
1208	BACE inhibitor reduces APP-beta-C-terminal fragment accumulation in axonal swellings of okadaic acid-induced neurodegeneration. <b>2006</b> , 22, 435-44	33
1207	Selective effects of the APOE epsilon4 allele on presynaptic cholinergic markers in the neocortex of Alzheimer's disease. <b>2006</b> , 22, 555-61	23
1206	"Click peptides"--chemical biology-oriented synthesis of Alzheimer's disease-related amyloid beta peptide (abeta) analogues based on the "O-acyl isopeptide method". <b>2006</b> , 7, 1549-57	62

1205	(Make) stick and cut loose--disintegrin metalloproteases in development and disease. <b>2006</b> , 78, 24-46	45
1204	Reductive modification of a methionine residue in the amyloid-beta peptide. <b>2006</b> , 45, 2595-8	32
1203	Modulation of neurosteroid production in human neuroblastoma cells by Alzheimer's disease key proteins. <b>2006</b> , 66, 868-81	36
1202	Norstatins From Aldehydes by Sequential Organocatalytic $\alpha$ -Amination and Passerini Reaction. <b>2006</b> , 2006, 4585-4595	28
1201	Minocycline affects microglia activation, Abeta deposition, and behavior in APP-tg mice. <b>2006</b> , 53, 776-82	171
1200	Elevated levels of amyloid precursor protein in muscle of patients with amyotrophic lateral sclerosis and a mouse model of the disease. <b>2006</b> , 34, 444-50	27
1199	Acetyl-L-carnitine-induced up-regulation of heat shock proteins protects cortical neurons against amyloid-beta peptide 1-42-mediated oxidative stress and neurotoxicity: implications for Alzheimer's disease. <b>2006</b> , 84, 398-408	118
1198	Intravenous immunoglobulin enhances the clearance of fibrillar amyloid-beta peptide. <b>2006</b> , 84, 434-43	64
1197	Effect of valine on the efficiency and precision at S4 cleavage of the Notch-1 transmembrane domain. <b>2006</b> , 84, 918-25	5
1196	Reductive Modification of a Methionine Residue in the Amyloid- $\beta$ Peptide. <b>2006</b> , 118, 2657-2660	5
1195	Significance of molecular signaling for protein translation control in neurodegenerative diseases. <b>2006</b> , 15, 249-58	21
1194	Control of amyloid-beta-peptide generation by subcellular trafficking of the beta-amyloid precursor protein and beta-secretase. <b>2006</b> , 3, 247-54	12
1193	Gamma-secretase modulation with Abeta42-lowering nonsteroidal anti-inflammatory drugs and derived compounds. <b>2006</b> , 3, 298-304	24
1192	Functional modulation of nuclear steroid receptors by tauroursodeoxycholic acid reduces amyloid beta-peptide-induced apoptosis. <b>2006</b> , 20, 2292-303	37
1191	Create and assess protein networks through molecular characteristics of individual proteins. <b>2006</b> , 22, e402-7	6
1190	Three-dimensional structural changes in living hippocampal neurons imaged using magnetic AC mode atomic force microscopy. <b>2006</b> , 55, 165-72	15
1189	Early diagnostics and therapeutics for Alzheimer's disease--how early can we get there?. <b>2006</b> , 6, 1293-306	19
1188	Phosphorylation of amyloid precursor protein (APP) at Thr668 regulates the nuclear translocation of the APP intracellular domain and induces neurodegeneration. <b>2006</b> , 26, 4327-38	127

1187	Inclusion-body myositis: a myodegenerative conformational disorder associated with Abeta, protein misfolding, and proteasome inhibition. <b>2006</b> , 66, S39-48	127
1186	Inclusion-body myositis and Alzheimer disease: two sides of the same coin, or different currencies altogether?. <b>2006</b> , 66, S65-8	14
1185	Tau-dependent microtubule disassembly initiated by prefibrillar beta-amyloid. <b>2006</b> , 175, 541-6	180
1184	Selective modulation of Abeta42 production in Alzheimer's disease: non-steroidal anti-inflammatory drugs and beyond. <b>2006</b> , 12, 4337-55	36
1183	Vaccine development for Alzheimer's disease. <b>2006</b> , 12, 4283-93	13
1182	Anti-inflammatory drugs in the treatment of neurodegenerative diseases: current state. <b>2006</b> , 12, 3509-19	37
1181	Filling the gaps in the abeta cascade hypothesis of Alzheimer's disease. <b>2006</b> , 3, 421-30	111
1180	Molecular insights into mechanisms of the cell death program: role in the progression of neurodegenerative disorders. <b>2006</b> , 3, 269-83	131
1179	Genetically modified mice models for Alzheimer's disease. <b>2006</b> , 6, 609-27	13
1178	Antioxidants as a potential therapy against age-related neurodegenerative diseases: amyloid Beta toxicity and Alzheimer's disease. <b>2006</b> , 12, 699-704	32
1177	The role of MRI and PET/SPECT in Alzheimer's disease. <b>2006</b> , 6, 629-47	30
1176	Inhibition of GSK3 dependent tau phosphorylation by metals. <b>2006</b> , 3, 123-7	21
1175	Pathways by which Abeta facilitates tau pathology. <b>2006</b> , 3, 437-48	148
1174	Cell Life versus cell longevity: the mysteries surrounding the NAD <sup>+</sup> precursor nicotinamide. <b>2006</b> , 13, 883-95	101
1173	Gamma-secretase as a pharmacological target in Alzheimer disease research: when, why and how?. <b>2006</b> , 12, 4313-35	13
1172	Amyloid beta peptide, 4-hydroxynonenal and apoptosis. <b>2006</b> , 3, 359-64	32
1171	Combinatorial approaches to probe the sequence determinants of protein aggregation and amyloidogenicity. <b>2006</b> , 13, 279-86	13
1170	Approaches to palliative therapies for Alzheimer's disease. <b>2006</b> , 6, 553-68	25

1169	Frameshift proteins in autosomal dominant forms of Alzheimer disease and other tauopathies. <b>2006</b> , 66, S86-92	34
1168	Alzheimer's disease and anaesthesia: implications for the central cholinergic system. <b>2006</b> , 97, 445-52	83
1167	Effect of gamma-secretase inhibitors on muscarinic receptor-mediated calcium signaling in human salivary epithelial cells. <b>2006</b> , 291, C76-82	20
1166	The ASK1-MAP kinase signaling in ER stress and neurodegenerative diseases. <b>2006</b> , 6, 87-97	123
1165	Reduction of soluble Abeta and tau, but not soluble Abeta alone, ameliorates cognitive decline in transgenic mice with plaques and tangles. <b>2006</b> , 281, 39413-23	227
1164	Encyclopedic Reference of Genomics and Proteomics in Molecular Medicine. <b>2006</b> , 15-15	
1163	In vivo characterization of Abeta(40) changes in brain and cerebrospinal fluid using the novel gamma-secretase inhibitor N-[cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]-1,1,1-trifluoromethanesulfonamide (MRK-560) in the rat. <b>2006</b> , 317, 786-90	53
1162	Neuritic deposits of amyloid-beta peptide in a subpopulation of central nervous system-derived neuronal cells. <b>2006</b> , 26, 4982-97	31
1161	A high-throughput drug screen targeted to the 5'untranslated region of Alzheimer amyloid precursor protein mRNA. <b>2006</b> , 11, 469-80	35
1160	Interaction of the cytosolic domains of sorLA/LR11 with the amyloid precursor protein (APP) and beta-secretase beta-site APP-cleaving enzyme. <b>2006</b> , 26, 418-28	145
1159	A review of genome mutation and Alzheimer's disease. <b>2007</b> , 22, 15-33	41
1158	beta-Amyloid infusion results in delayed and age-dependent learning deficits without role of inflammation or beta-amyloid deposits. <b>2006</b> , 103, 8852-7	40
1157	Calpain inhibitor MDL28170 modulates Abeta formation by inhibiting the formation of intermediate Abeta46 and protecting Abeta from degradation. <b>2006</b> , 20, 331-3	22
1156	PKCepsilon increases endothelin converting enzyme activity and reduces amyloid plaque pathology in transgenic mice. <b>2006</b> , 103, 8215-20	107
1155	Unique neuronal functions of cathepsin L and cathepsin B in secretory vesicles: biosynthesis of peptides in neurotransmission and neurodegenerative disease. <b>2006</b> , 387, 1429-39	17
1154	Expression of a familial Alzheimer's disease-linked presenilin-1 variant enhances perforant pathway lesion-induced neuronal loss in the entorhinal cortex. <b>2006</b> , 26, 429-34	24
1153	A secreted type of beta1,6 N-acetylglucosaminyltransferase V (GnT-V), a novel angiogenesis inducer, is regulated by gamma-secretase. <b>2006</b> , 20, 2451-9	25
1152	Increased BACE1 maturation contributes to the pathogenesis of Alzheimer's disease in Down syndrome. <b>2006</b> , 20, 1361-8	52

1151	Abeta-induced meningoencephalitis is IFN-gamma-dependent and is associated with T cell-dependent clearance of Abeta in a mouse model of Alzheimer's disease. <b>2006</b> , 103, 5048-53	123
1150	Microtubule-associated protein MAP1A, MAP1B, and MAP2 proteolysis during soluble amyloid beta-peptide-induced neuronal apoptosis. Synergistic involvement of calpain and caspase-3. <b>2006</b> , 281, 229-40	88
1149	The cytosolic loop of the gamma-secretase component presenilin enhancer 2 protects zebrafish embryos from apoptosis. <b>2006</b> , 281, 11933-9	20
1148	Coated-platelets retain amyloid precursor protein on their surface. <b>2006</b> , 17, 56-60	38
1147	Focally elevated creatine detected in amyloid precursor protein (APP) transgenic mice and Alzheimer disease brain tissue. <b>2006</b> , 281, 5-8	56
1146	Notice of Concern. <b>2006</b> , 58, 135-135	
1145	Screening of upregulated genes in suckling mouse central nervous system during the disease stage of rabies virus infection. <b>2006</b> , 50, 951-9	7
1144	Encyclopedic Reference of Genomics and Proteomics in Molecular Medicine. <b>2006</b> , 36-36	
1143	Encyclopedic Reference of Genomics and Proteomics in Molecular Medicine. <b>2006</b> , 1-1	
1142	Encyclopedic Reference of Genomics and Proteomics in Molecular Medicine. <b>2006</b> , 1-1	
1141	Metal homeostasis in Alzheimer's disease. <b>2006</b> , 6, 711-22	36
1140	Down-regulation of endogenous amyloid precursor protein processing due to cellular aging. <b>2006</b> , 281, 2405-13	54
1139	Secretion of the Notch-1 Abeta-like peptide during Notch signaling. <b>2006</b> , 281, 7890-8	87
1138	GGA1 acts as a spatial switch altering amyloid precursor protein trafficking and processing. <b>2006</b> , 26, 9913-22	55
1137	GGA1 is expressed in the human brain and affects the generation of amyloid beta-peptide. <b>2006</b> , 26, 12838-46	68
1136	Interaction between presenilin 1 and ubiquilin 1 as detected by fluorescence lifetime imaging microscopy and a high-throughput fluorescent plate reader. <b>2006</b> , 281, 26400-7	20
1135	The lipoprotein receptor LR11 regulates amyloid beta production and amyloid precursor protein traffic in endosomal compartments. <b>2006</b> , 26, 1596-603	224
1134	Enhanced amyloidogenic metabolism of the amyloid beta-protein precursor in the X11L-deficient mouse brain. <b>2006</b> , 281, 37853-60	43



1133	Calcium-mediated transient phosphorylation of tau and amyloid precursor protein followed by intraneuronal amyloid-beta accumulation. <b>2006</b> , 281, 39907-14	85
1132	Biology of Inositols and Phosphoinositides. <b>2006</b> ,	20
1131	Reactivity of apolipoprotein E4 and amyloid beta peptide: lysosomal stability and neurodegeneration. <b>2006</b> , 281, 2683-92	102
1130	Transgenic expression of beta-APP in fast-twitch skeletal muscle leads to calcium dyshomeostasis and IBM-like pathology. <b>2006</b> , 20, 2165-7	33
1129	Broad-spectrum effects of 4-aminopyridine to modulate amyloid beta1-42-induced cell signaling and functional responses in human microglia. <b>2006</b> , 26, 11652-64	54
1128	Immunization therapy in Alzheimer's disease. <b>2006</b> , 6, 653-9	6
1127	Amyloid-beta immunotherapy for the prevention and treatment of Alzheimer disease: lessons from mice, monkeys, and humans. <b>2006</b> , 9, 77-84	55
1126	ADAM10 activation is required for green tea (-)-epigallocatechin-3-gallate-induced alpha-secretase cleavage of amyloid precursor protein. <b>2006</b> , 281, 16419-27	145
1125	Temporal profile of amyloid-beta (Abeta) oligomerization in an in vivo model of Alzheimer disease. A link between Abeta and tau pathology. <b>2006</b> , 281, 1599-604	303
1124	Endomorphin-2, an endogenous tetrapeptide, protects against Abeta1-42 in vitro and in vivo. <b>2006</b> , 20, 1191-3	23
1123	Equimolar production of amyloid beta-protein and amyloid precursor protein intracellular domain from beta-carboxyl-terminal fragment by gamma-secretase. <b>2006</b> , 281, 14776-86	125
1122	Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. <b>2006</b> , 26, 10129-40	1834
1121	Minocycline reduces microglial activation and improves behavioral deficits in a transgenic model of cerebral microvascular amyloid. <b>2007</b> , 27, 3057-63	157
1120	Mitoenergetic failure in Alzheimer disease. <b>2007</b> , 292, C8-23	103
1119	Conformation-sensitive antibodies against alzheimer amyloid-beta by immunization with a thioredoxin-constrained B-cell epitope peptide. <b>2007</b> , 282, 11436-45	54
1118	Wnt-7a induces presynaptic colocalization of alpha 7-nicotinic acetylcholine receptors and adenomatous polyposis coli in hippocampal neurons. <b>2007</b> , 27, 5313-25	95
1117	Lipocalin-type prostaglandin D synthase/beta-trace is a major amyloid beta-chaperone in human cerebrospinal fluid. <b>2007</b> , 104, 6412-7	118
1116	Partial reduction of BACE1 has dramatic effects on Alzheimer plaque and synaptic pathology in APP Transgenic Mice. <b>2007</b> , 282, 26326-34	238

1115	Inhibition of familial cerebral amyloid angiopathy mutant amyloid beta-protein fibril assembly by myelin basic protein. <b>2007</b> , 282, 9952-9961	21
1114	{gamma}-Secretase Substrate Concentration Modulates the Abeta42/Abeta40 Ratio: IMPLICATIONS FOR ALZHEIMER DISEASE. <b>2007</b> , 282, 23639-44	85
1113	A structural switch of presenilin 1 by glycogen synthase kinase 3beta-mediated phosphorylation regulates the interaction with beta-catenin and its nuclear signaling. <b>2007</b> , 282, 14083-93	23
1112	HtrA2 regulates beta-amyloid precursor protein (APP) metabolism through endoplasmic reticulum-associated degradation. <b>2007</b> , 282, 28285-95	48
1111	Cathepsin L expression is directed to secretory vesicles for enkephalin neuropeptide biosynthesis and secretion. <b>2007</b> , 282, 9556-9563	42
1110	Traumatic brain injury and Alzheimer's disease: a review. <b>2007</b> , 161, 303-16	147
1109	Immunotherapy as treatment for Alzheimer's disease. <b>2007</b> , 7, 1535-48	25
1108	Pushing the Complexity of Model Bilayers: Novel Prospects for Membrane Biophysics. <b>2007</b> , 339-359	1
1107	Novel Abeta immunogens: is shorter better?. <b>2007</b> , 4, 427-36	28
1106	Memapsin 2 (beta-secretase) inhibitor drug, between fantasy and reality. <b>2007</b> , 4, 418-22	30
1105	Minocycline attenuates neuronal cell death and improves cognitive impairment in Alzheimer's disease models. <b>2007</b> , 32, 2393-404	219
1104	Advances on the understanding of the origins of synaptic pathology in AD. <b>2007</b> , 8, 486-508	28
1103	Specific mechanism for blood inflow stimulation in brain area prone to Alzheimer's disease lesions. <b>2007</b> , 117, 1425-42	4
1102	JNK signalling: a possible target to prevent neurodegeneration. <b>2007</b> , 13, 1875-86	208
1101	A role for presenilin in post-stress regulation: effects of presenilin mutations on Ca2+ currents in Drosophila. <b>2007</b> , 21, 2368-78	11
1100	RAGE: a potential target for Abeta-mediated cellular perturbation in Alzheimer's disease. <b>2007</b> , 7, 735-42	123
1099	TNF-alpha inhibition as a treatment strategy for neurodegenerative disorders: new drug candidates and targets. <b>2007</b> , 4, 378-85	152
1098	Two isoforms of PSAP/MTCH1 share two proapoptotic domains and multiple internal signals for import into the mitochondrial outer membrane. <b>2007</b> , 293, C1347-61	16

1097	Development of a protease production platform for structure-based drug design. <b>2007</b> , 8, 439-45	3
1096	gamma-Secretase modulators. <b>2007</b> , 4, 571-3	18
1095	Stimulation of endogenous neurogenesis by anti-EFRH immunization in a transgenic mouse model of Alzheimer's disease. <b>2007</b> , 104, 1691-6	39
1094	Effect of flavonoids on human health: old subjects but new challenges. <b>2007</b> , 1, 139-50	58
1093	Pathologically-activated therapeutics for neuroprotection: mechanism of NMDA receptor block by memantine and S-nitrosylation. <b>2007</b> , 8, 621-32	151
1092	Humanin: a potential peptide for neuroprotective therapy against Alzheimer's disease. <b>2007</b> , 2, 1273-82	4
1091	Anesthesia leads to tau hyperphosphorylation through inhibition of phosphatase activity by hypothermia. <b>2007</b> , 27, 3090-7	295
1090	Apolipoprotein receptor 2 and X11 alpha/beta mediate apolipoprotein E-induced endocytosis of amyloid-beta precursor protein and beta-secretase, leading to amyloid-beta production. <b>2007</b> , 27, 4052-60	87
1089	Inflammation in the Pathogenesis of Chronic Diseases. <b>2007</b> ,	4
1088	Cellular prion protein regulates beta-secretase cleavage of the Alzheimer's amyloid precursor protein. <b>2007</b> , 104, 11062-7	217
1087	Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. <b>2007</b> , 27, 2866-75	1232
1086	Magnetoencephalogram blind source separation and component selection procedure to improve the diagnosis of Alzheimer's disease patients. <b>2007</b> , 2007, 5437-40	1
1085	Clinical immunologic approaches for the treatment of Alzheimer's disease. <b>2007</b> , 16, 819-28	16
1084	Cysteine protease inhibitors reduce brain beta-amyloid and beta-secretase activity in vivo and are potential Alzheimer's disease therapeutics. <b>2007</b> , 388, 979-83	28
1083	Toxic human islet amyloid polypeptide (h-IAPP) oligomers are intracellular, and vaccination to induce anti-toxic oligomer antibodies does not prevent h-IAPP-induced beta-cell apoptosis in h-IAPP transgenic mice. <b>2007</b> , 56, 1324-32	152
1082	Activation of microglia acidifies lysosomes and leads to degradation of Alzheimer amyloid fibrils. <b>2007</b> , 18, 1490-6	169
1081	Critical role for sphingosine kinase-1 in regulating survival of neuroblastoma cells exposed to amyloid-beta peptide. <b>2007</b> , 72, 341-9	50
1080	Transcutaneous beta-amyloid immunization reduces cerebral beta-amyloid deposits without T cell infiltration and microhemorrhage. <b>2007</b> , 104, 2507-12	60

1079	Identification of amyloid fibril-forming segments based on structure and residue-based statistical potential. <b>2007</b> , 23, 2218-25	86
1078	Gleevec increases levels of the amyloid precursor protein intracellular domain and of the amyloid-beta degrading enzyme neprilysin. <b>2007</b> , 18, 3591-600	46
1077	Ex vivo occupancy of gamma-secretase inhibitors correlates with brain beta-amyloid peptide reduction in Tg2576 mice. <b>2007</b> , 323, 102-8	10
1076	Valsartan lowers brain beta-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease. <b>2007</b> , 117, 3393-402	235
1075	Amyloid beta1-40 quantification in CSF: comparison between chromatographic and immunochemical methods. <b>2007</b> , 23, 246-50	23
1074	Pediatric respiratory and systemic effects of chronic air pollution exposure: nose, lung, heart, and brain pathology. <b>2007</b> , 35, 154-62	126
1073	Amyloid beta-protein precursor juxtamembrane domain regulates specificity of gamma-secretase-dependent cleavages. <b>2007</b> , 282, 35350-60	42
1072	Signal peptide peptidase and gamma-secretase share equivalent inhibitor binding pharmacology. <b>2007</b> , 282, 36829-36	21
1071	The amyloid-beta precursor protein is phosphorylated via distinct pathways during differentiation, mitosis, stress, and degeneration. <b>2007</b> , 18, 3835-44	40
1070	[Molecular mechanism of learning and memory based on the research for Ca <sup>2+</sup> /calmodulin-dependent protein kinase II]. <b>2007</b> , 127, 1173-97	4
1069	Nitric oxide and nitroxidative stress in Alzheimer's disease. <b>2007</b> , 11, 207-18	164
1068	Environmental enrichment delays the onset of memory deficits and reduces neuropathological hallmarks in a mouse model of Alzheimer-like neurodegeneration. <b>2007</b> , 11, 359-70	91
1067	Chapter 1 Amyloid and Amyloid-Like Protein Aggregates in Neurodegenerative Disease. <b>2007</b> , 30, 1-32	
1066	Increase of locomotor activity underlying the behavioral disinhibition in tg2576 mice. <b>2007</b> , 121, 340-4	52
1065	Nanoparticles: a step forward for iron chelation in the brain. <b>2007</b> , 2, 265-269	7
1064	Oxidative stress and transcriptional regulation in Alzheimer disease. <b>2007</b> , 21, 276-91	115
1063	Reduction of mint-1, mint-2, and APP overexpression in okadaic acid-treated neurons. <b>2007</b> , 18, 1879-83	5
1062	Mulberry leaf extract prevents amyloid beta-peptide fibril formation and neurotoxicity. <b>2007</b> , 18, 813-6	46

1061	Inclusion-body myositis, a multifactorial muscle disease associated with aging: current concepts of pathogenesis. <b>2007</b> , 19, 550-9	70
1060	Hematopoietic prostaglandin D synthase and DP1 receptor are selectively upregulated in microglia and astrocytes within senile plaques from human patients and in a mouse model of Alzheimer disease. <b>2007</b> , 66, 469-80	57
1059	Protective substances against zinc-induced neuronal death after ischemia: carnosine as a target for drug of vascular type of dementia. <b>2007</b> , 2, 145-9	20
1058	Amyloid angiogenic activity in vitro and in vivo. <b>2007</b> ,	4
1057	NSAIDs: small molecules for prevention of Alzheimer's disease or precursors for future drug development?. <b>2007</b> , 28, 536-43	96
1056	Effects of peptides derived from BACE1 catalytic domain on APP processing. <b>2007</b> , 28, 838-44	9
1055	The Alzheimer's disease-associated gamma-secretase complex: functional domains in the presenilin 1 protein. <b>2007</b> , 92, 115-20	17
1054	Presenilin-mediated signal transduction. <b>2007</b> , 92, 93-7	26
1053	Expression of mDab1 promotes the stability and processing of amyloid precursor protein and this effect is counteracted by X11alpha. <b>2007</b> , 28, 377-88	38
1052	CSF Abeta42, Tau and phosphorylated Tau, APOE epsilon4 allele and MCI type in progressive MCI. <b>2007</b> , 28, 507-14	90
1051	Targeting soluble Abeta peptide with Tramiprosate for the treatment of brain amyloidosis. <b>2007</b> , 28, 537-47	221
1050	Plasma beta amyloid and impaired CO2-induced cerebral vasomotor reactivity. <b>2007</b> , 28, 707-12	12
1049	Dendrimeric Abeta1-15 is an effective immunogen in wildtype and APP-tg mice. <b>2007</b> , 28, 813-23	52
1048	Alzheimer's disease, oxidative stress and gamma-hydroxybutyrate. <b>2007</b> , 28, 1340-60	86
1047	An apolipoprotein E-based therapeutic improves outcome and reduces Alzheimer's disease pathology following closed head injury: evidence of pharmacogenomic interaction. <b>2007</b> , 144, 1324-33	56
1046	Early-onset subicular microvascular amyloid and neuroinflammation correlate with behavioral deficits in vasculotropic mutant amyloid beta-protein precursor transgenic mice. <b>2007</b> , 146, 98-107	70
1045	Characterization of amyloid beta peptides in cerebrospinal fluid by an automated immunoprecipitation procedure followed by mass spectrometry. <b>2007</b> , 6, 4433-9	113
1044	G protein-coupled receptor systems and their lipid environment in health disorders during aging. <b>2007</b> , 1768, 964-75	62

1043	Physicochemical interactions of amyloid beta-peptide with lipid bilayers. <b>2007</b> , 1768, 1935-42	166
1042	Amyloid beta-protein and lipid metabolism. <b>2007</b> , 1768, 1991-2001	33
1041	Berberine alters the processing of Alzheimer's amyloid precursor protein to decrease Abeta secretion. <b>2007</b> , 352, 498-502	144
1040	Proteins that bind to the RERMS region of beta amyloid precursor protein. <b>2007</b> , 355, 907-12	10
1039	Monomeric A beta and metals reduce their cytotoxicities to each other. <b>2007</b> , 358, 540-4	2
1038	A transgenic rat expressing human APP with the Swedish Alzheimer's disease mutation. <b>2007</b> , 358, 777-82	31
1037	Estrogen has anti-amyloidogenic effects on Alzheimer's beta-amyloid fibrils in vitro. <b>2007</b> , 359, 697-702	35
1036	Aurones serve as probes of beta-amyloid plaques in Alzheimer's disease. <b>2007</b> , 361, 116-21	54
1035	Conversion of non-fibrillar beta-sheet oligomers into amyloid fibrils in Alzheimer's disease amyloid peptide aggregation. <b>2007</b> , 361, 916-21	98
1034	Reduced serum level of antibodies against amyloid beta peptide is associated with aging in Tg2576 mice. <b>2007</b> , 361, 800-4	10
1033	Visualization of beta-secretase cleavage in living cells using a genetically encoded surface-displayed [corrected] FRET probe. <b>2007</b> , 362, 25-30	14
1032	Methyl dynamics of the amyloid-beta peptides Abeta40 and Abeta42. <b>2007</b> , 362, 410-4	29
1031	Air pollution alters brain and pituitary endothelin-1 and inducible nitric oxide synthase gene expression. <b>2007</b> , 105, 224-33	56
1030	Activation of 5-HT4 receptors inhibits secretion of beta-amyloid peptides and increases neuronal survival. <b>2007</b> , 203, 274-8	78
1029	5-HT4 receptor and Alzheimer's disease: the amyloid connection. <b>2007</b> , 205, 325-9	51
1028	Paroxetine administration decreases AD-like pathology and reverses memory impairments in a transgenic model of Alzheimer disease. <b>2007</b> , 207, 1-3	1
1027	Multiple proteins implicated in neurodegenerative diseases accumulate in axons after brain trauma in humans. <b>2007</b> , 208, 185-92	271
1026	Gamma-secretase: a complex target for Alzheimer's disease. <b>2007</b> , 7, 112-8	47

1025	Destabilization of non-pathological variants of ataxin-3 by metal ions results in aggregation/fibrillogenesis. <b>2007</b> , 39, 966-77	18
1024	Plants traditionally used in age related brain disorders--a survey of ethnobotanical literature. <b>2007</b> , 113, 363-81	214
1023	Abeta40 protects non-toxic Abeta42 monomer from aggregation. <b>2007</b> , 369, 909-16	73
1022	Soybean-derived phosphatidylinositol inhibits in vivo low concentrations of amyloid beta protein-induced degeneration of hippocampal neurons in V337M human tau-expressing mice. <b>2007</b> , 80, 1971-6	11
1021	C1q binding and complement activation by prions and amyloids. <b>2007</b> , 212, 355-62	42
1020	Immunotherapy for Alzheimer's disease: attacking amyloid-beta from the inside. <b>2007</b> , 28, 511-3	13
1019	Role of complement in neurodegeneration and neuroinflammation. <b>2007</b> , 44, 999-1010	245
1018	Mitogen activated protein kinase and protein kinase C activation mediate promotion of sAPPalpha secretion by deprenyl. <b>2007</b> , 50, 74-82	23
1017	Glutamate-glutamine cycling in Alzheimer's disease. <b>2007</b> , 50, 1052-66	110
1016	Effects of statins on alpha7 nicotinic receptor, cholinesterase and alpha-form of secreted amyloid precursor peptide in SH-SY5Y cells. <b>2007</b> , 50, 800-6	21
1015	The mitochondrial permeability transition in neurologic disease. <b>2007</b> , 50, 983-97	126
1014	Toxicity of beta-amyloid in HEK293 cells expressing NR1/NR2A or NR1/NR2B N-methyl-D-aspartate receptor subunits. <b>2007</b> , 50, 872-80	44
1013	Calpastatin levels affect calpain activation and calpain proteolytic activity in APP transgenic mouse model of Alzheimer's disease. <b>2007</b> , 51, 391-7	31
1012	3,4-dihydroxybenzoic acid from Smilacis chinae rhizome protects amyloid beta protein (25-35)-induced neurotoxicity in cultured rat cortical neurons. <b>2007</b> , 420, 184-8	41
1011	The Abeta1-42M35C mutated amyloid peptide Abeta1-42 and the 25-35 fragment fail to mimic the subtype-specificity of actions on recombinant human nicotinic acetylcholine receptors (alpha7, alpha4beta2, alpha3beta4). <b>2007</b> , 427, 28-33	6
1010	The influence of diagnosis, intra- and inter-person variability on serum and plasma Abeta levels. <b>2007</b> , 428, 53-8	32
1009	Decreased Abeta secretion by cells expressing familial Alzheimer's disease-linked mutant presenilin 1. <b>2007</b> , 57, 446-53	22
1008	Attenuated cytotoxicity but enhanced betafibril of a mutant amyloid beta-peptide with a methionine to cysteine substitution. <b>2007</b> , 581, 1269-74	12

1007	Stable insertion of Alzheimer Abeta peptide into the ER membrane strongly correlates with its length. <b>2007</b> , 581, 3809-13	4
1006	A chapter in the development of Alzheimer's disease research: a case study of public policies on the development and funding of research programs. <b>2007</b> , 3, 243-58	10
1005	Selection and characterization of Affibody ligands binding to Alzheimer amyloid beta peptides. <b>2007</b> , 128, 162-83	98
1004	Interferon-gamma and tumor necrosis factor-alpha regulate amyloid-beta plaque deposition and beta-secretase expression in Swedish mutant APP transgenic mice. <b>2007</b> , 170, 680-92	283
1003	Evidence of a role for lactadherin in Alzheimer's disease. <b>2007</b> , 170, 921-9	74
1002	Lithium reduces tau phosphorylation but not A beta or working memory deficits in a transgenic model with both plaques and tangles. <b>2007</b> , 170, 1669-75	163
1001	Intraneuronal amyloid-beta plays a role in mediating the synergistic pathological effects of apoE4 and environmental stimulation. <b>2007</b> , 103, 1031-40	18
1000	The molecular mechanisms of the anti-amyloid effects of phenols. <b>2007</b> , 14, 73-87	57
999	Abeta Peptide and Alzheimer's Disease. <b>2007</b> ,	1
998	Pharmacological Mechanisms in Alzheimer's Therapeutics. <b>2007</b> ,	1
997	Apolipoprotein E epsilon4 genotype and gender: effects on memory. <b>2007</b> , 15, 869-78	20
996	Mitochondrial dysfunction in aging and Alzheimer's disease: strategies to protect neurons. <b>2007</b> , 9, 1647-58	150
995	Alzheimer's disease and genetics of inflammation: a pharmacogenomic vision. <b>2007</b> , 8, 1735-45	40
994	Amyloid-beta(1-42) rapidly forms protofibrils and oligomers by distinct pathways in low concentrations of sodium dodecylsulfate. <b>2007</b> , 46, 12451-62	126
993	Synthesis, characterization, and metal coordinating ability of multifunctional carbohydrate-containing compounds for Alzheimer's therapy. <b>2007</b> , 129, 7453-63	122
992	Neuronal apoptosis in neurodegeneration. <b>2007</b> , 9, 1059-96	157
991	NSAIDs for the chemoprevention of Alzheimer's disease. <b>2007</b> , 42, 229-48	37
990	Sirtuin functions in health and disease. <b>2007</b> , 21, 1745-55	343



989	Effect of gender on mitochondrial toxicity of Alzheimer's Abeta peptide. <b>2007</b> , 9, 1677-90	29
988	SPECT imaging in dementia. <b>2007</b> , 80 Spec No 2, S153-9	27
987	New diphenylacetylenes as probes for positron emission tomographic imaging of amyloid plaques. <b>2007</b> , 50, 2415-23	28
986	Three histidine residues of amyloid-beta peptide control the redox activity of copper and iron. <b>2007</b> , 46, 12737-43	146
985	Zinc binding to amyloid-beta: isothermal titration calorimetry and Zn competition experiments with Zn sensors. <b>2007</b> , 46, 13658-66	94
984	Cysteine protease inhibitors effectively reduce in vivo levels of brain beta-amyloid related to Alzheimer's disease. <b>2007</b> , 388, 247-52	37
983	The oxidative stress metabolite 4-hydroxynonenal promotes Alzheimer protofibril formation. <b>2007</b> , 46, 1503-10	129
982	Immunotherapy against APP beta-secretase cleavage site improves cognitive function and reduces neuroinflammation in Tg2576 mice without a significant effect on brain abeta levels. <b>2007</b> , 4, 392-402	35
981	Coumarin derivatives protection against ROS production in cellular models of Abeta toxicities. <b>2007</b> , 41, 1168-80	29
980	Abeta42 gene vaccine prevents Abeta42 deposition in brain of double transgenic mice. <b>2007</b> , 260, 204-13	47
979	Cleavage of E-cadherin: a mechanism for disruption of the intestinal epithelial barrier by <i>Candida albicans</i> . <b>2007</b> , 149, 211-22	63
978	Osteopetrotic (op/op) mice have reduced microglia, no Abeta deposition, and no changes in dopaminergic neurons. <b>2007</b> , 4, 31	26
977	Metal ions differentially influence the aggregation and deposition of Alzheimer's beta-amyloid on a solid template. <b>2007</b> , 46, 6118-25	184
976	TgCRND8 amyloid precursor protein transgenic mice exhibit an altered gamma-secretase processing and an aggressive, additive amyloid pathology subject to immunotherapeutic modulation. <b>2007</b> , 46, 10317-27	22
975	Synthesis and structure-affinity relationships of new 4-(6-iodo-H-imidazo[1,2-a]pyridin-2-yl)-N-dimethylbenzeneamine derivatives as ligands for human beta-amyloid plaques. <b>2007</b> , 50, 4746-58	37
974	Distribution of amyloid precursor protein and amyloid-beta immunoreactivity in DBA/2J glaucomatous mouse retinas. <b>2007</b> , 48, 5085-90	53
973	Alzheimer's Disease. <b>2007</b> , 779-789	1
972	Beyond in vitro data: a review of in vivo evidence regarding the allosteric potentiating effect of galantamine on nicotinic acetylcholine receptors in Alzheimer's neuropathology. <b>2007</b> , 11, 491-507	26

971	Protein Aggregation Disorders. <b>2007</b> , 111-123	2
970	The role of Metals in Amyloid Aggregation: A Test Case for ab initio Simulations. <b>2007</b> ,	
969	Invertebrates as Powerful Genetic Models for Human Neurodegenerative Diseases. <b>2007</b> ,	
968	Development of O-acyl isopeptide method. <b>2007</b> , 88, 253-62	68
967	Conformational solution studies of the SDS micelle-bound 11-28 fragment of two Alzheimer's beta-amyloid variants (E22K and A21G) using CD, NMR, and MD techniques. <b>2007</b> , 87, 23-39	15
966	Dense-core and diffuse A $\beta$ plaques in TgCRND8 mice studied with synchrotron FTIR microspectroscopy. <b>2007</b> , 87, 207-17	71
965	Cleavage agents for soluble oligomers of amyloid beta peptides. <b>2007</b> , 46, 7064-7	92
964	Cleavage Agents for Soluble Oligomers of Amyloid $\beta$ Peptides. <b>2007</b> , 119, 7194-7197	19
963	Interaction between the ADAM12 and SH3MD1 genes may confer susceptibility to late-onset Alzheimer's disease. <b>2007</b> , 144B, 448-52	18
962	Mechanism-Based Development of Memantine as a Therapeutic Agent in Treating Alzheimer's Disease and Other Neurologic Disorders: Low-Affinity, Uncompetitive Antagonism with Fast Off-Rate. 439-464	
961	Presynaptic plasticity and associative learning are impaired in a Drosophila presenilin null mutant. <b>2007</b> , 67, 1598-613	23
960	Estradiol enhances long term potentiation in hippocampal slices from aged apoE4-TR mice. <b>2007</b> , 17, 1153-7	20
959	Ensemble-docking approach on BACE-1: pharmacophore perception and guidelines for drug design. <b>2007</b> , 2, 667-78	39
958	Chronic but not acute intracerebroventricular administration of amyloid beta-peptide(25-35) decreases somatostatin content, adenylate cyclase activity, somatostatin-induced inhibition of adenylate cyclase activity, and adenylate cyclase I levels in the rat hippocampus. <b>2007</b> , 85, 433-42	14
957	Structure, function, property, and role in neurologic diseases and other diseases of the sHsp22. <b>2007</b> , 85, 2071-9	19
956	Differential binding and activation of caspase-3 in cultured hippocampal neurons by assembly forms of A $\beta$ 1-42. <b>2007</b> , 85, 1205-14	5
955	Swedish amyloid precursor protein mutation increases phosphorylation of eIF2 $\alpha$ in vitro and in vivo. <b>2007</b> , 85, 1528-37	35
954	The use of conformation-specific ligands and assays to dissect the molecular mechanisms of neurodegenerative diseases. <b>2007</b> , 85, 2285-97	16

953	Aspartic protease inhibitors via C1-homologation of peptidic aldehydes and studies on reduced amide isosteres. <b>2007</b> , 48, 7990-7993	7
952	Comparative IR and X-ray studies of natural and model amyloid peptides at the air/water interface. <b>2007</b> , 303, 73-78	16
951	Electronic structure calculations toward new potentially AChE inhibitors. <b>2007</b> , 446, 304-308	11
950	Structure-activity relationship of chalcones and related derivatives as ligands for detecting of beta-amyloid plaques in the brain. <b>2007</b> , 15, 6388-96	40
949	Novel chalcones as probes for in vivo imaging of beta-amyloid plaques in Alzheimer's brains. <b>2007</b> , 15, 6802-9	64
948	Discovery of (S)-2-((S)-2-(3,5-difluorophenyl)-2-hydroxyacetamido)-N-((S,Z)-3-methyl-4-oxo-4,5-dihydro-3H-benzo[d][1,2]diazepin-5-yl)propanamide (BMS-433796): a gamma-secretase inhibitor with Abeta lowering activity in a transgenic mouse model of Alzheimer's disease. <b>2007</b> , 17, 1006-11	39
947	A multigram chemical synthesis of the gamma-secretase inhibitor LY411575 and its diastereoisomers. <b>2007</b> , 17, 6392-5	54
946	Thiophene substituted acylguanidines as BACE1 inhibitors. <b>2007</b> , 17, 5353-6	55
945	Synthesis and evaluation of a (99m)Tc-BAT-phenylbenzothiazole conjugate as a potential in vivo tracer for visualization of amyloid beta. <b>2007</b> , 17, 6086-90	47
944	The inflammation-sensitive protein alpha 1-anti-chymotrypsin neutralizes fibrillar aggregation and cytotoxicity of the beta-amyloid peptide more effectively than alpha 1-antitrypsin. <b>2007</b> , 40, 887-92	12
943	Development and specific induction of apoptosis of cultured cell models overexpressing human tau during neural differentiation: Implication in Alzheimer's disease. <b>2007</b> , 360, 114-22	13
942	Modeling behavioral and neuronal symptoms of Alzheimer's disease in mice: a role for intraneuronal amyloid. <b>2007</b> , 31, 125-47	175
941	A novel monoclonal antibody specific for the amino-truncated beta-amyloid Abeta5-40/42 produced from caspase-cleaved amyloid precursor protein. <b>2007</b> , 161, 244-9	12
940	Role of the ubiquitin proteasome system in Alzheimer's disease. <b>2007</b> , 8 Suppl 1, S12	77
939	ApoER2 expression increases Abeta production while decreasing Amyloid Precursor Protein (APP) endocytosis: Possible role in the partitioning of APP into lipid rafts and in the regulation of gamma-secretase activity. <b>2007</b> , 2, 14	56
938	The Alzheimer's disease beta-secretase enzyme, BACE1. <b>2007</b> , 2, 22	301
937	Structural variation manipulates the differential oxidative susceptibility and conformational stability of apolipoprotein E isoforms. <b>2007</b> , 68, 363-74	3
936	Intracellular domains of amyloid precursor-like protein 2 interact with CP2 transcription factor in the nucleus and induce glycogen synthase kinase-3beta expression. <b>2007</b> , 14, 79-91	30

935	DNA damage-inducing agent-elicited gamma-secretase activity is dependent on Bax/Bcl-2 pathway but not on caspase cascades. <b>2007</b> , 14, 189-92	12
934	Abrogation of signal-dependent activation of the cdk9/cyclin T2a complex in human RD rhabdomyosarcoma cells. <b>2007</b> , 14, 192-5	22
933	Calreticulin exposure is required for the immunogenicity of gamma-irradiation and UVC light-induced apoptosis. <b>2007</b> , 14, 1848-50	356
932	The TAT-JNK inhibitor peptide interferes with beta amyloid protein stability. <b>2007</b> , 14, 1845-8	37
931	Receptor tyrosine kinases positively regulate BACE activity and Amyloid-beta production through enhancing BACE internalization. <b>2007</b> , 17, 389-401	29
930	Perivascular drainage of amyloid-beta peptides from the brain and its failure in cerebral amyloid angiopathy and Alzheimer's disease. <b>2008</b> , 18, 253-66	439
929	New protein kinase C activator regulates amyloid precursor protein processing in vitro by increasing alpha-secretase activity. <b>2007</b> , 26, 381-91	32
928	Impairment of hippocampal gamma-frequency oscillations in vitro in mice overexpressing human amyloid precursor protein (APP). <b>2007</b> , 26, 1280-8	59
927	The same gamma-secretase accounts for the multiple intramembrane cleavages of APP. <b>2007</b> , 100, 1234-46	35
926	Calnuc binds to Alzheimer's beta-amyloid precursor protein and affects its biogenesis. <b>2007</b> , 100, 1505-14	29
925	The Arctic Alzheimer mutation favors intracellular amyloid-beta production by making amyloid precursor protein less available to alpha-secretase. <b>2007</b> , 101, 854-62	46
924	Genetically augmenting tau levels does not modulate the onset or progression of Abeta pathology in transgenic mice. <b>2007</b> , 102, 1053-63	67
923	Amyloid precursor protein knockdown by siRNA impairs spontaneous alternation in adult mice. <b>2007</b> , 102, 1928-1940	35
922	Enhancement of alpha-secretase cleavage of amyloid precursor protein by a metalloendopeptidase nardilysin. <b>2007</b> , 102, 1595-1605	40
921	Alzheimer's disease: the lipid connection. <b>2007</b> , 103 Suppl 1, 159-70	159
920	A role for 12/15 lipoxygenase in the amyloid beta precursor protein metabolism. <b>2007</b> , 103, 380-7	29
919	Toll-like receptors 2 and 4 mediate Abeta(1-42) activation of the innate immune response in a human monocytic cell line. <b>2008</b> , 104, 524-33	128
918	Oxidative stress activates a positive feedback between the gamma- and beta-secretase cleavages of the beta-amyloid precursor protein. <b>2008</b> , 104, 683-95	230

917	Docosahexaenoic acid stabilizes soluble amyloid-beta protofibrils and sustains amyloid-beta-induced neurotoxicity in vitro. <b>2007</b> , 274, 990-1000	32
916	Conformational stability of Abeta-(25-35) in the presence of thiazolidine derivatives. <b>2007</b> , 69, 111-8	11
915	Protective effects of vitamin E against oxidative damage induced by Abeta1-40Cu(II) complexes. <b>2007</b> , 39, 123-30	19
914	Advancing translational research with the Semantic Web. <b>2007</b> , 8 Suppl 3, S2	165
913	Requirement of aggregation propensity of Alzheimer amyloid peptides for neuronal cell surface binding. <b>2007</b> , 8, 29	29
912	The amyloid precursor protein potentiates CHOP induction and cell death in response to ER Ca <sup>2+</sup> depletion. <b>2007</b> , 1773, 157-65	34
911	The c-jun kinase/stress-activated pathway: regulation, function and role in human disease. <b>2007</b> , 1773, 1341-8	322
910	Regulation of alpha2AR trafficking and signaling by interacting proteins. <b>2007</b> , 73, 1135-45	27
909	Macromolecules involved in production and metabolism of beta-amyloid at the brain barriers. <b>2007</b> , 1138, 187-95	31
908	Susceptibility of hippocampal neurons to Abeta peptide toxicity is associated with perturbation of Ca <sup>2+</sup> homeostasis. <b>2007</b> , 1143, 11-21	79
907	Neprilysin protects neurons against Abeta peptide toxicity. <b>2007</b> , 1152, 191-200	45
906	Characterizing the neuroprotective effects of alkaline extract of Lycium barbarum on beta-amyloid peptide neurotoxicity. <b>2007</b> , 1158, 123-34	89
905	Common pathological processes in Alzheimer disease and type 2 diabetes: a review. <b>2007</b> , 56, 384-402	277
904	Roles of amyloid beta-peptide-associated oxidative stress and brain protein modifications in the pathogenesis of Alzheimer's disease and mild cognitive impairment. <b>2007</b> , 43, 658-77	430
903	Immunity and neuronal repair in the progression of Alzheimer's disease: a brief overview. <b>2007</b> , 42, 64-9	12
902	Beta-amyloid(1-42) induces a reduction in the parallel fiber responses of Purkinje cells: possible involvement of pro-inflammatory processes. <b>2007</b> , 42, 951-62	4
901	Alzheimer's disease: cholesterol, membrane rafts, isoprenoids and statins. <b>2007</b> , 11, 383-92	95
900	The role of amyloid beta peptide 42 in Alzheimer's disease. <b>2007</b> , 116, 266-86	233

899	Polymorphisms of pro-inflammatory genes and Alzheimer's disease risk: a pharmacogenomic approach. <b>2007</b> , 128, 67-75	35
898	Structural principles of intramembrane proteases. <b>2007</b> , 17, 405-11	15
897	Age-dependent sexual dimorphism in cognition and stress response in the 3xTg-AD mice. <b>2007</b> , 28, 76-82	208
896	Cholinergic forebrain degeneration in the APP <sup>swe</sup> /PS1 <sup>DeltaE9</sup> transgenic mouse. <b>2007</b> , 28, 3-15	78
895	Aβ(1-40)-induced secretion of matrix metalloproteinase-9 results in sAPP <sub>α</sub> release by association with cell surface APP. <b>2007</b> , 28, 304-15	38
894	The anti-amyloidogenic effect is exerted against Alzheimer's beta-amyloid fibrils in vitro by preferential and reversible binding of flavonoids to the amyloid fibril structure. <b>2007</b> , 46, 1888-99	129
893	Potassium-dependent oriented growth of amyloid Aβ <sub>25-35</sub> fibrils on mica. <b>2007</b> , 18, 345102	34
892	Defects of immune regulation in the presenilin-1 mutant knockin mouse. <b>2007</b> , 9, 35-45	5
891	Inflammation--a lifelong companion. Attempt at a non-analytical holistic view. <b>2007</b> , 52, 159-73	14
890	Glial cell dysregulation: a new perspective on Alzheimer disease. <b>2007</b> , 12, 215-32	106
889	Mitochondrial respiratory inhibition and oxidative stress elevate beta-secretase (BACE1) proteins and activity in vivo in the rat retina. <b>2007</b> , 181, 435-46	65
888	Amyloid-beta-peptide reduces the expression level of mitochondrial cytochrome oxidase subunits. <b>2007</b> , 32, 1483-8	29
887	Insulysin cleaves the APP cytoplasmic fragment at multiple sites. <b>2007</b> , 32, 2225-34	18
886	Mitochondria and neurodegeneration. <b>2007</b> , 27, 87-104	105
885	Effect of aldehydes derived from oxidative deamination and oxidative stress on beta-amyloid aggregation; pathological implications to Alzheimer's disease. <b>2007</b> , 114, 835-9	58
884	Amyloid precursor protein cytoplasmic domain with phospho-Thr668 accumulates in Alzheimer's disease and its transgenic models: a role to mediate interaction of Aβ and tau. <b>2007</b> , 113, 627-36	44
883	Neurodegeneration and Alzheimer's disease: the lesson from tauopathies. <b>2007</b> , 28, 63-71	49
882	Metal-amyloid-β-peptide interactions: a preliminary investigation of molecular mechanisms for Alzheimer's disease. <b>2007</b> , 50, 453-467	1

881	Molecular modeling of the ion channel-like nanotube structure of amyloid $\beta$ peptide. <b>2007</b> , 52, 1576-1580	4
880	Application of Surface-Enhanced Raman Spectroscopy for Detection of Beta Amyloid Using Nanoshells. <b>2007</b> , 2, 55-64	60
879	Characterization of an antibody scFv that recognizes fibrillar insulin and beta-amyloid using atomic force microscopy. <b>2008</b> , 4, 1-7	13
878	Lead-induced increase in antioxidant enzymes and lipid peroxidation products in developing rat brain. <b>2008</b> , 21, 9-16	89
877	Development of a smart nano-vehicle to target cerebrovascular amyloid deposits and brain parenchymal plaques observed in Alzheimer's disease and cerebral amyloid angiopathy. <b>2008</b> , 25, 2674-84	65
876	Regularities of homo- and heteroassociation of the pinacyanol cation in aqueous solution. <b>2008</b> , 57, 1405-1415	10
875	Inhibitory effects of short-term administration of DL-alpha-lipoic acid on oxidative vulnerability induced by A $\beta$ amyloid fibrils (25-35) in mice. <b>2008</b> , 311, 145-56	12
874	Effects of beta-amyloid (25-35) on learning in the common snail. <b>2008</b> , 38, 377-82	
873	Effects of vitamin C on fibroblasts from sporadic Alzheimer's disease patients. <b>2008</b> , 33, 2510-5	3
872	Translocation of amyloid precursor protein C-terminal fragment(s) to the nucleus precedes neuronal death due to thiamine deficiency-induced mild impairment of oxidative metabolism. <b>2008</b> , 33, 1365-72	15
871	Determination of primary structure and microheterogeneity of a beta-amyloid plaque-specific antibody using high-performance LC-tandem mass spectrometry. <b>2008</b> , 391, 325-36	10
870	Oriented epitaxial growth of amyloid fibrils of the N27C mutant beta 25-35 peptide. <b>2008</b> , 37, 1133-7	19
869	Acetylcholine receptors in dementia and mild cognitive impairment. <b>2008</b> , 35 Suppl 1, S30-45	97
868	[Alzheimer's disease. Molecular pathology, animal models, and current treatment]. <b>2008</b> , 79 Suppl 3, 117-25; quiz 126-7	1
867	Beta-secretase (BACE1) inhibitors from <i>Perilla frutescens</i> var. <i>acuta</i> . <b>2008</b> , 31, 183-7	46
866	Neurological benefits of omega-3 fatty acids. <b>2008</b> , 10, 219-35	194
865	Mitochondrial medicine for aging and neurodegenerative diseases. <b>2008</b> , 10, 291-315	161
864	The environment, epigenetics and amyloidogenesis. <b>2008</b> , 34, 1-7	83

863	Regulated proteolysis of APP and ApoE receptors. <b>2008</b> , 37, 64-72	18
862	Therapeutic strategies for Alzheimer's disease. <b>2008</b> , 37, 171-86	102
861	Inclusion body myositis: a view from the <i>Caenorhabditis elegans</i> muscle. <b>2008</b> , 38, 178-98	14
860	Selective loss of P2Y2 nucleotide receptor immunoreactivity is associated with Alzheimer's disease neuropathology. <b>2008</b> , 115, 1165-72	44
859	Intracranial administration of vaccinia virus complement control protein in Mo/Hu APP <sup>swe</sup> PS1 <sup>dE9</sup> transgenic mice at an early age shows enhanced performance at a later age using a cheese board maze test. <b>2008</b> , 9, 405-20	15
858	Cortical alpha-synuclein load is associated with amyloid-beta plaque burden in a subset of Parkinson's disease patients. <b>2008</b> , 115, 417-25	121
857	Inclusion-body myositis: muscle-fiber molecular pathology and possible pathogenic significance of its similarity to Alzheimer's and Parkinson's disease brains. <b>2008</b> , 116, 583-95	90
856	Mercury-induced crystallization and SAD phasing of the human Fe65-PTB1 domain. <b>2008</b> , 64, 382-5	2
855	Overproduction, purification, crystallization and preliminary X-ray analysis of human Fe65-PTB2 in complex with the amyloid precursor protein intracellular domain. <b>2008</b> , 64, 409-12	6
854	Effects of chronic hypoxia on Ca(2+) stores and capacitative Ca(2+) entry in human neuroblastoma (SH-SY5Y) cells. <b>2001</b> , 79, 877-84	19
853	The N-domain of angiotensin-converting enzyme specifically hydrolyzes the Arg-5-His-6 bond of Alzheimer's Aβ(1-16) peptide and its isoAsp-7 analogue with different efficiency as evidenced by quantitative matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. <b>2008</b> , 22, 231-9	44
852	Redox proteomics studies of in vivo amyloid beta-peptide animal models of Alzheimer's disease: Insight into the role of oxidative stress. <b>2008</b> , 2, 685-96	14
851	Decreased nicotinic receptors and cognitive deficit in rats intracerebroventricularly injected with beta-amyloid peptide(1-42) and fed a high-cholesterol diet. <b>2008</b> , 86, 183-93	28
850	Swedish amyloid precursor protein mutation increases cell cycle-related proteins in vitro and in vivo. <b>2008</b> , 86, 2476-87	23
849	Okadaic acid increases autophagosomes in rat neurons: implications for Alzheimer's disease. <b>2008</b> , 86, 3230-9	35
848	Transplanted astrocytes internalize deposited beta-amyloid peptides in a transgenic mouse model of Alzheimer's disease. <b>2008</b> , 56, 154-63	125
847	Mutational screening analysis of DHCR24/seladin-1 gene in Italian familial Alzheimer's disease. <b>2008</b> , 147B, 117-9	9
846	Inhibition and modulation of gamma-secretase for Alzheimer's disease. <b>2008</b> , 5, 391-8	119



845	Abeta(1-42) reduces synapse number and inhibits neurite outgrowth in primary cortical and hippocampal neurons: a quantitative analysis. <b>2008</b> , 175, 96-103	46
844	A synthetic amyloid lawn system for high-throughput analysis of amyloid toxicity and drug screening. <b>2008</b> , 29, 2813-9	11
843	Cathepsin D--many functions of one aspartic protease. <b>2008</b> , 68, 12-28	428
842	Examining the levels of ganglioside and cholesterol in cell membrane on attenuation the cytotoxicity of beta-amyloid peptide. <b>2008</b> , 65, 172-7	31
841	Development of novel beta-amyloid probes based on 3,5-diphenyl-1,2,4-oxadiazole. <b>2008</b> , 16, 6867-72	42
840	BACE1 inhibitory effects of lavandulyl flavanones from <i>Sophora flavescens</i> . <b>2008</b> , 16, 6669-74	44
839	Design, synthesis, and acetylcholinesterase inhibitory activity of novel coumarin analogues. <b>2008</b> , 16, 8011-21	104
838	Acylguanidine inhibitors of beta-secretase: optimization of the pyrrole ring substituents extending into the S1' substrate binding pocket. <b>2008</b> , 18, 767-71	34
837	Carbamate-appended N-alkylsulfonamides as inhibitors of gamma-secretase. <b>2008</b> , 18, 464-8	7
836	Acylguanidine inhibitors of beta-secretase: optimization of the pyrrole ring substituents extending into the S1 and S3 substrate binding pockets. <b>2008</b> , 18, 1063-6	60
835	Potent memapsin 2 (beta-secretase) inhibitors: design, synthesis, protein-ligand X-ray structure, and in vivo evaluation. <b>2008</b> , 18, 1031-6	81
834	Synthesis and biological evaluation of <sup>99m</sup> Tc, Re-monoamine-monoamide conjugated to 2-(4-aminophenyl)benzothiazole as potential probes for beta-amyloid plaques in the brain. <b>2008</b> , 18, 1442-5	42
833	Synthesis, SAR, and X-ray structure of human BACE-1 inhibitors with cyclic urea derivatives. <b>2008</b> , 18, 2900-4	21
832	Influence of fluorinated and hydrogenated nanoparticles on the structure and fibrillogenesis of amyloid beta-peptide. <b>2008</b> , 137, 35-42	94
831	Metal complexes as artificial proteases: toward catalytic drugs. <b>2008</b> , 12, 207-13	61
830	Nitrogen-appended N-alkylsulfonamides as inhibitors of gamma-secretase. <b>2008</b> , 18, 175-8	8
829	Integrated analysis of the cerebrospinal fluid peptidome and proteome. <b>2008</b> , 7, 386-99	148
828	Yeast as a model for studying human neurodegenerative disorders. <b>2008</b> , 3, 325-38	59

827	Targeted proteomics in Alzheimer's disease: focus on amyloid-beta. <b>2008</b> , 5, 225-37	43
826	Neurotrophic factors in Alzheimer's disease: role of axonal transport. <b>2008</b> , 7 Suppl 1, 43-56	249
825	Amyloid-cholinesterase interactions. Implications for Alzheimer's disease. <b>2008</b> , 275, 625-32	179
824	Active gamma-secretase is localized to detergent-resistant membranes in human brain. <b>2008</b> , 275, 1174-87	72
823	Formation of highly toxic soluble amyloid beta oligomers by the molecular chaperone prefoldin. <b>2008</b> , 275, 5982-93	51
822	A TAG1-APP signalling pathway through Fe65 negatively modulates neurogenesis. <b>2008</b> , 10, 283-94	155
821	Blocking TGF-beta-Smad2/3 innate immune signaling mitigates Alzheimer-like pathology. <b>2008</b> , 14, 681-7	353
820	Abeta-degrading enzymes in Alzheimer's disease. <b>2008</b> , 18, 240-52	279
819	Heparan sulfate accumulation with Abeta deposits in Alzheimer's disease and Tg2576 mice is contributed by glial cells. <b>2008</b> , 18, 548-61	62
818	Macrophage colony stimulating factor is associated with excretion of amyloid- $\beta$ peptides from cerebrospinal fluid to peripheral blood. <b>2008</b> , 8, 188-195	3
817	Antibody-based approaches in Alzheimer's research: safety, pharmacokinetics, metabolism, and analytical tools. <b>2008</b> , 104, 859-74	55
816	Interleukin-1 beta up-regulates TACE to enhance alpha-cleavage of APP in neurons: resulting decrease in Abeta production. <b>2008</b> , 104, 1387-93	78
815	Increased intraneuronal resting $[Ca^{2+}]$ in adult Alzheimer's disease mice. <b>2008</b> , 105, 262-71	122
814	Inhibition of glutamyl cyclase prevents pGlu-Abeta formation after intracortical/hippocampal microinjection in vivo/in situ. <b>2008</b> , 106, 1225-36	58
813	Role of methionine 35 in the intracellular $Ca^{2+}$ homeostasis dysregulation and $Ca^{2+}$ -dependent apoptosis induced by amyloid beta-peptide in human neuroblastoma IMR32 cells. <b>2008</b> , 107, 1070-82	25
812	Down-regulation of insulin-degrading enzyme by presenilin 1 V97L mutant potentially underlies increased levels of amyloid beta 42. <b>2008</b> , 27, 2425-32	9
811	Dimerization of the transmembrane domain of amyloid precursor proteins and familial Alzheimer's disease mutants. <b>2008</b> , 9, 17	61
810	Amyloid-beta peptide degradation in cell cultures by mycoplasma contaminants. <b>2008</b> , 1, 38	24

809	Assessment of classification improvement in patients with Alzheimer's disease based on magnetoencephalogram blind source separation. <b>2008</b> , 43, 75-85	18
808	High content analysis of gamma-secretase activity reveals variable dominance of presenilin mutations linked to familial Alzheimer's disease. <b>2008</b> , 1783, 1551-60	16
807	Nuclear bodies in neurodegenerative disease. <b>2008</b> , 1783, 2195-206	39
806	Phosphorylation of beta-amyloid precursor protein (APP) cytoplasmic tail facilitates amyloidogenic processing during apoptosis. <b>2008</b> , 1198, 204-12	16
805	Amyloid peptides in different assembly states and related effects on isolated and cellular proteasomes. <b>2008</b> , 1209, 8-18	34
804	Induction of ketosis may improve mitochondrial function and decrease steady-state amyloid-beta precursor protein (APP) levels in the aged dog. <b>2008</b> , 1226, 209-17	59
803	CD40 ligation mediates plaque-associated tau phosphorylation in beta-amyloid overproducing mice. <b>2008</b> , 1231, 132-42	10
802	Increased exploratory activity of APP23 mice in a novel environment is reversed by siRNA. <b>2008</b> , 1243, 124-33	13
801	Inflammation, genes and zinc in Alzheimer's disease. <b>2008</b> , 58, 96-105	88
800	Release of acetylcholinesterase (AChE) from beta-amyloid plaques assemblies improves the spatial memory impairments in APP-transgenic mice. <b>2008</b> , 175, 142-9	30
799	Modulatory effect of acetyl-L-carnitine on amyloid precursor protein metabolism in hippocampal neurons. <b>2008</b> , 597, 51-6	15
798	Targeted library design for the generation of actives against biological targets: Peptidomimetic inhibitors of myeloid differentiation factor 88. <b>2008</b> , 13, 827-828	
797	Seladin-1/DHCR24 protects neuroblastoma cells against Abeta toxicity by increasing membrane cholesterol content. <b>2008</b> , 12, 1990-2002	52
796	Neuroprotective and neurotoxic properties of glial cells in the pathogenesis of Alzheimer's disease. <b>2008</b> , 12, 762-80	164
795	Neuronal cell death in neurodegenerative diseases: recurring themes around protein handling. <b>2008</b> , 12, 2263-80	191
794	Muscarinic acetylcholine receptors as CNS drug targets. <b>2008</b> , 117, 232-43	320
793	Homer2 and Homer3 interact with amyloid precursor protein and inhibit Abeta production. <b>2008</b> , 30, 353-364	26
792	A transgenic rat that develops Alzheimer's disease-like amyloid pathology, deficits in synaptic plasticity and cognitive impairment. <b>2008</b> , 31, 46-57	84

791	Increased expression of the oligopeptidase THOP1 is a neuroprotective response to Abeta toxicity. <b>2008</b> , 31, 145-58	25
790	Caspase inhibition attenuates accumulation of beta-amyloid by reducing beta-secretase production and activity in rat brains after stroke. <b>2008</b> , 32, 433-41	30
789	Abeta deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease. <b>2008</b> , 46, 1688-97	239
788	Endoplasmic reticulum stress in disease pathogenesis. <b>2008</b> , 3, 399-425	487
787	Protein folding and misfolding on surfaces. <b>2008</b> , 9, 2515-42	57
786	Nanofluidic biosensing for beta-amyloid detection using surface enhanced Raman spectroscopy. <b>2008</b> , 8, 1729-35	166
785	Clinically Tolerated Strategies for NMDA Receptor Antagonism. <b>2008</b> , 327-361	
784	Interactions between APP secretases and inflammatory mediators. <b>2008</b> , 5, 25	127
783	All-or-nothing type biphasic cytokine production of human lymphocytes after exposure to Alzheimer's beta-amyloid peptide. <b>2008</b> , 64, 891-5	19
782	Somatostatin and Alzheimer's disease. <b>2008</b> , 286, 104-11	65
781	Kinetic properties of cathepsin D and BACE 1 indicate the need to search for additional beta-secretase candidate(s). <b>2008</b> , 389, 313-20	25
780	Colloids for Nano- and Biotechnology. <b>2008</b> ,	5
779	Early diagnosis and treatment of Alzheimer's disease. <b>2008</b> , 8, 769-80	20
778	Association between deposition of beta-amyloid and pathological prion protein in sporadic Creutzfeldt-Jakob disease. <b>2008</b> , 5, 347-54	42
777	Presenilin 1 polymorphism associated with Alzheimer's disease in apolipoprotein E4 carriers. <b>2008</b> , 26, 440-4	8
776	Mitochondrial Medicine. <b>2008</b> , 103-113	1
775	Adaptor protein sorting nexin 17 regulates amyloid precursor protein trafficking and processing in the early endosomes. <b>2008</b> , 283, 11501-8	113
774	Central Nervous System Diseases and Inflammation. <b>2008</b> ,	5

773	Nuclear factor erythroid 2-related factor 2 protects against beta amyloid. <i>Molecular and Cellular Neurosciences</i> , <b>2008</b> , 39, 302-13	4.8	186
772	The Arctic mutation alters helix length and type in the 11-28 beta-amyloid peptide monomer-CD, NMR and MD studies in an SDS micelle. <b>2008</b> , 164, 199-209		6
771	Mutations enhance the aggregation propensity of the Alzheimer's A beta peptide. <b>2008</b> , 377, 565-74		45
770	Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer's disease. <b>2008</b> , 14, 45-53		644
769	Amyloid-beta (25-35) increases activity of neuronal NO-synthase in rat brain. <b>2008</b> , 52, 1114-24		42
768	Dose-dependent and sequence-sensitive effects of amyloid-beta peptide on neurosteroidogenesis in human neuroblastoma cells. <b>2008</b> , 52, 948-55		36
767	Sodium selenite inhibits gamma-secretase activity through activation of ERK. <b>2008</b> , 440, 38-43		31
766	Loading Amlodipine on Diamond Nanoparticles: A Novel Drug Delivery System. <b>2019</b> , 12, 47-53		6
765	Hippocampal Growth Factor and Myokine Cathepsin B Expression following Aerobic and Resistance Training in 3xTg-AD Mice. <b>2020</b> , 2020, 5919501		8
764	Computer simulations of protein-membrane systems. <b>2020</b> , 170, 273-403		15
763	Activation of Mitochondrial Unfolded Protein Response in SHSY5Y Expressing APP Cells and APP/PS1 Mice. <b>2019</b> , 13, 568		14
762	Pine Bark Polyphenolic Extract Attenuates Amyloid- $\beta$ and Tau Misfolding in a Model System of Alzheimer's Disease Neuropathology. <b>2020</b> , 73, 1597-1606		4
761	Autophagy in Astrocytes and its Implications in Neurodegeneration. <b>2020</b> , 432, 2605-2621		24
760	"Amyloid-beta accumulation cycle" as a prevention and/or therapy target for Alzheimer's disease. <b>2020</b> , 19, e13109		21
759	Characterization of a G-Quadruplex Structure in Pre-miRNA-1229 and in Its Alzheimer's Disease-Associated Variant rs2291418: Implications for miRNA-1229 Maturation. <b>2020</b> , 21,		15
758	IL-1R alleviates cognitive deficits through microglial M2 polarization in AD mice. <b>2020</b> , 157, 10-17		5
757	Alzheimer's disease: review of current nanotechnological therapeutic strategies. <b>2020</b> , 20, 271-279		12
756	Substrate interaction inhibits $\beta$ secretase production of amyloid- $\beta$ peptides. <b>2020</b> , 56, 2578-2581		2

755	Dimension-Tunable Circularly Polarized Luminescent Nanoassemblies with Emerging Selective Chirality and Energy Transfer. <b>2020</b> , 14, 2373-2384	26
754	Self-assembled gold nanoparticles and amphiphile peptides: a colorimetric probe for copper(II) ion detection. <b>2020</b> , 49, 16226-16237	2
753	Biological and Computational Studies for Dual Cholinesterases Inhibitory Effect of Zerumbone. <b>2020</b> , 12,	7
752	Cornel iridoid glycoside ameliorates cognitive deficits in APP/PS1/tau triple transgenic mice by attenuating amyloid-beta, tau hyperphosphorylation and neurotrophic dysfunction. <b>2020</b> , 8, 328	5
751	Advances in protein misfolding, amyloidosis and its correlation with human diseases. <b>2020</b> , 10, 193	3
750	The GSM BPN-15606 as a Potential Candidate for Preventative Therapy in Alzheimer's Disease. <b>2020</b> , 73, 1541-1554	3
749	Targeting endoplasmic reticulum stress and autophagy as therapeutic approaches for neurological diseases. <b>2020</b> , 350, 285-325	14
748	Molecular insights into the inhibitory mechanisms of gallate moiety on the A $\beta$ amyloid aggregation: A molecular dynamics simulation study. <b>2020</b> , 156, 40-50	6
747	Mossy cell synaptic dysfunction causes memory imprecision via miR-128 inhibition of STIM2 in Alzheimer's disease mouse model. <b>2020</b> , 19, e13144	11
746	Small heat shock proteins in neurodegenerative diseases. <b>2020</b> , 25, 679-699	18
745	Genome Editing in a Wide Area of the Brain Using Dendrimer-Based Ternary Polyplexes of Cas9 Ribonucleoprotein. <b>2020</b> , 12, 21386-21397	12
744	Therapeutic potential of stem cells for treatment of neurodegenerative diseases. <b>2020</b> , 42, 1073-1101	12
743	Shenqi Yizhi granules protect hippocampus of AD transgenic mice by modulating on multiple pathological processes. <b>2020</b> , 263, 112869	5
742	Impact of Ecklonia radiata extracts on the neuroprotective activities against amyloid beta (A $\beta$ -42) toxicity and aggregation. <b>2020</b> , 68, 103893	11
741	Identification of Methylated Gene Biomarkers in Patients with Alzheimer's Disease Based on Machine Learning. <b>2020</b> , 2020, 8348147	5
740	Key role of MIF-related neuroinflammation in neurodegeneration and cognitive impairment in Alzheimer's disease. <b>2020</b> , 26, 34	10
739	Regulatory function of praja ring finger ubiquitin ligase 2 mediated by the axis in mouse hippocampal neuronal cells. <b>2020</b> , 318, C1123-C1135	5
738	Deterioration of cognitive function after transient cerebral ischemia with amyloid- $\beta$ infusion-possible amelioration of cognitive function by AT receptor activation. <b>2020</b> , 17, 106	6

737	Nicotine Promotes Aβ Nonamyloidogenic Processing via RACK1-Dependent Activation of PKC in SH-SY5Y-AβP695 Cells. <b>2020</b> , 75, 451-460	2
736	Acute Pannexin 1 Blockade Mitigates Early Synaptic Plasticity Defects in a Mouse Model of Alzheimer's Disease. <b>2020</b> , 14, 46	9
735	Bioactive Polyphenols and Neuromodulation: Molecular Mechanisms in Neurodegeneration. <b>2020</b> , 21,	18
734	Glial Connexins and Pannexins in the Healthy and Diseased Brain. <i>Physiological Reviews</i> , <b>2021</b> , 101, 93-145.9	35
733	Alkaloid profile and cholinesterase inhibition activity of five species of Amaryllidaceae family collected from Mérida state-Venezuela. <b>2021</b> , 136, 126-136	7
732	Synaptic basis of Alzheimer's disease: Focus on synaptic amyloid beta, P-tau and mitochondria. <b>2021</b> , 65, 101208	42
731	Ruthenium(III) complexes with imidazole ligands that modulate the aggregation of the amyloid-β peptide via hydrophobic interactions. <b>2021</b> , 214, 111303	3
730	Lavender and coriander essential oils and their main component linalool exert a protective effect against amyloid-β neurotoxicity. <b>2021</b> , 35, 486-493	9
729	Novel nicotinonitrile-coumarin hybrids as potential acetylcholinesterase inhibitors: design, synthesis, in vitro and in silico studies. <b>2021</b> , 18, 213-224	15
728	Alzheimer's protection effect of A673T mutation may be driven by lower Aβ oligomer binding affinity. <b>2021</b> , 157, 1316-1330	9
727	Effect of an Intracerebroventricular Injection of Aggregated Beta-amyloid (1-42) on Daily Rhythms of Oxidative Stress Parameters in the Prefrontal Cortex. <b>2021</b> , 458, 99-107	7
726	The association between toxic pesticide environmental exposure and Alzheimer's disease: A scientometric and visualization analysis. <b>2021</b> , 263, 128238	18
725	Fluorescent peptide nanoparticles to detect amyloid-beta aggregation in cerebrospinal fluid and serum for Alzheimer's disease diagnosis and progression monitoring. <b>2021</b> , 405, 126733	7
724	Electrochemiluminescence detection for β amyloid1-42 oligomers using silver nanoparticle decorated CuS@CoS2 double shelled nanoboxes as dual-quencher. <b>2021</b> , 329, 129155	2
723	Early detection and personalized medicine: Future strategies against Alzheimer's disease. <b>2021</b> , 177, 157-173	1
722	Binding of Cu to Aβ-29 causes aggregation and toxicity in SH-SY5Y cells. <b>2021</b> , 534, 617-623	0
721	Tardive neurotoxicity of anticholinergic drugs: A review. <b>2021</b> , 158, 1334-1344	3
720	Association between chronic stress and Alzheimer's disease: Therapeutic effects of Saffron. <b>2021</b> , 133, 110995	13

719	Brain targeted Polysorbate-80 coated PLGA thymoquinone nanoparticles for the treatment of Alzheimer's disease, with biomechanistic insights. <b>2021</b> , 61, 102214	9
718	The Interplay of ABC Transporters in A $\beta$ Translocation and Cholesterol Metabolism: Implicating Their Roles in Alzheimer's Disease. <b>2021</b> , 58, 1564-1582	14
717	Resveratrol confers neuroprotection against high-fat diet in a mouse model of Alzheimer's disease via modulation of proteolytic mechanisms. <b>2021</b> , 89, 108569	10
716	The bile acid TUDCA improves glucose metabolism in streptozotocin-induced Alzheimer's disease mice model. <b>2021</b> , 521, 111116	10
715	Decreased Proteasomal Function Induces Neuronal Loss and Memory Impairment. <b>2021</b> , 191, 144-156	4
714	A potential defense mechanism against amyloid deposition in cerebellum. <b>2021</b> , 535, 25-32	1
713	The role of hypoxia on Alzheimer's disease-related APP and Tau mRNA formation. <b>2021</b> , 766, 145146	4
712	Identification of truncated C-terminal fragments of the Alzheimer's disease amyloid protein precursor derived from sequential proteolytic pathways. <b>2021</b> , 156, 943-956	
711	Plasma Amyloid Beta Concentrations in Aged and Cognitively Impaired Pet Dogs. <b>2021</b> , 58, 483-489	2
710	Thioredoxin-80 protects against amyloid-beta pathology through autophagic-lysosomal pathway regulation. <b>2021</b> , 26, 1410-1423	5
709	The Highlighted Roles of Metabolic and Cellular Response to Stress Pathways Engaged in Circulating hsa-miR-494-3p and hsa-miR-661 in Alzheimer's Disease. <b>2021</b> , 25, 62-7	1
708	Class I HDAC Inhibitor Improves Synaptic Proteins and Repairs Cytoskeleton Through Regulating Synapse-Related Genes and. <b>2020</b> , 12, 619866	2
707	Identification of hub ubiquitin ligase genes affecting Alzheimer's disease by analyzing transcriptome data from multiple brain regions. <b>2021</b> , 104, 368504211001146	3
706	Anti-Parallel $\beta$ Hairpin Structure in Soluble A $\beta$ Oligomers of A $\beta$ 0-Dutch and A $\beta$ 0-Iowa. <b>2021</b> , 22,	1
705	Stem cell-based therapy as a promising approach in Alzheimer's disease: current perspectives on novel treatment. <b>2021</b> , 22, 339-353	5
704	Liraglutide Has Anti-Inflammatory and Anti-Amyloid Properties in Streptozotocin-Induced and 5xFAD Mouse Models of Alzheimer's Disease. <b>2021</b> , 22,	7
703	The Prion-like Properties of Amyloid-beta Peptide and Tau: Is there Any Risk of Transmitting Alzheimer's Disease During Neurosurgical Interventions?. <b>2020</b> , 17, 781-789	
702	Kynurenic Acid Electrochemical Immunosensor: Blood-Based Diagnosis of Alzheimer's Disease. <b>2021</b> , 11,	4



701	The F19W mutation reduces the binding affinity of the transmembrane A $\beta$ trimer to the membrane bilayer.. <b>2021</b> , 11, 2664-2676	1
700	Neuroprotective effects of oleocanthal in neurological disorders. <b>2021</b> , 671-679	
699	Decreased Orexin Receptor 1 mRNA Expression in the Locus Coeruleus in Both Tau Transgenic rTg4510 and Tau Knockout Mice and Accompanying Ascending Arousal System Tau Invasion in rTg4510. <b>2021</b> , 79, 693-708	3
698	[Amyloid $\beta$ hypothesis in Alzheimer's disease and Cl-ATPase-Neuronal cell death via PI4KII $\beta$ inhibition and recovery agents]. <b>2021</b> , 156, 166-170	
697	Biophysical characteristics of lipid-induced A $\beta$ oligomers correlate to distinctive phenotypes in transgenic mice. <b>2021</b> , 35, e21318	3
696	Neurodegenerative Diseases and Flavonoids: Special Reference to Kaempferol. <b>2021</b> , 20, 327-342	5
695	Late-onset epilepsy and subsequent increased risk of dementia. <b>2021</b> , 13, 3573-3587	5
694	Advances in Hollow Inorganic Nanomedicines for Photothermal-Based Therapies. <b>2021</b> , 16, 493-513	4
693	Genetic Aspects of Early-Onset Alzheimer's Disease. <b>2021</b> , 29-39	
692	Addition of A $\beta$ to Total Cerebral Small Vessel Disease Score Improves the Prediction for Cognitive Impairment in Cerebral Small Vessel Disease Patients. <b>2021</b> , 17, 195-201	0
691	Directed Network Defects in Alzheimer's Disease Using Granger Causality and Graph Theory. <b>2020</b> , 17, 939-947	0
690	Comprehensive review of Alzheimer's disease drugs (conventional, newer, and plant-derived) with focus on Bacopa monnieri. <b>2021</b> , 227-248	
689	On estimation in the nested case-control design under nonproportional hazards.	
688	Combining bioscaffolds and iPSCs in the treatment of neural trauma and Alzheimer's disease. <b>2021</b> , 123-162	
687	Peptide Hydrolysis by Metal (Oxa)cyclen Complexes: Revisiting the Mechanism and Assessing Ligand Effects. <b>2021</b> , 60, 807-815	1
686	Infrared nanospectroscopy reveals the molecular interaction fingerprint of an aggregation inhibitor with single A $\beta$ 2 oligomers. <b>2021</b> , 12, 688	11
685	Flavonoid-Based Nanomedicines in Alzheimer's Disease Therapeutics: Promises Made, a Long Way To Go. <b>2021</b> , 4, 74-95	4
684	Tau phosphorylation and cochlear apoptosis cause hearing loss in 3 $\mu$ g-AD Mouse Model of Alzheimer's Disease. <b>2021</b> , 64, 61-71	1

683	Effects of the fermented in the amyloid Induced Alzheimer's disease mouse model. <b>2021</b> , 15, 173-186	2
682	The molecular tweezer CLR01 improves behavioral deficits and reduces tau pathology in P301S-tau transgenic mice. <b>2021</b> , 13, 6	7
681	Treadmill Exercise Alleviates Brain Iron Dyshomeostasis Accelerating Neuronal Amyloid- $\beta$ Production, Neuronal Cell Death, and Cognitive Impairment in Transgenic Mice Model of Alzheimer's Disease. <b>2021</b> , 58, 3208-3223	9
680	Cathepsin D Variants Associated With Neurodegenerative Diseases Show Dysregulated Functionality and Modified $\beta$ Synuclein Degradation Properties. <b>2021</b> , 9, 581805	7
679	Implication of Nicotinamide Adenine Dinucleotide Phosphate (NADPH) Oxidase and Its Inhibitors in Alzheimer's Disease Murine Models. <b>2021</b> , 10,	6
678	Phytosterols: Targeting Neuroinflammation in Neurodegeneration. <b>2021</b> , 27, 383-401	15
677	Cerebrovascular phenotypes in mouse models of Alzheimer's disease. <b>2021</b> , 41, 1821-1841	7
676	Moxibustion for the treatment of Alzheimer's disease: A protocol for a systematic reviews and meta-analysis. <b>2021</b> , 100, e24657	0
675	Protective effects of antidepressant citalopram against abnormal APP processing and amyloid beta-induced mitochondrial dynamics, biogenesis, mitophagy and synaptic toxicities in Alzheimer's disease. <b>2021</b> , 30, 847-864	7
674	Intranasal drug delivery for treatment of Alzheimer's disease. <b>2021</b> , 11, 411-425	6
673	Complex Inclusion Bodies and Defective Proteome Hubs in Neurodegenerative Disease: New Clues, New Challenges. <b>2021</b> , 1073858421989582	2
672	Essential Oils as a Potential Neuroprotective Remedy for Age-Related Neurodegenerative Diseases: A Review. <b>2021</b> , 26,	10
671	SSAO/VAP-1 in Cerebrovascular Disorders: A Potential Therapeutic Target for Stroke and Alzheimer's Disease. <b>2021</b> , 22,	5
670	Brain Lipid Dynamics in Amyloid Precursor Protein/Presenilin 1 Mouse Model of Early Alzheimer's Disease by Desorption Electrospray Ionization and Matrix Assisted Laser Desorption Ionization-Mass Spectrometry Imaging Techniques. <b>2021</b> , 20, 2643-2650	5
669	Angiotensin (1-7) Expressing Probiotic as a Potential Treatment for Dementia.. <b>2021</b> , 2,	0
668	Exposure of Mesenchymal Stem Cells to an Alzheimer's Disease Environment Enhances Therapeutic Effects. <b>2021</b> , 2021, 6660186	1
667	A cross-sectional examination of a family history of Alzheimer's disease and ApoE epsilon 4 on physical fitness, molecular biomarkers, and neurocognitive performance. <b>2021</b> , 230, 113268	2
666	Extracellular CIRP Activates the IL-6R $\alpha$ /STAT3/Cdk5 Pathway in Neurons. <b>2021</b> , 58, 3628-3640	0

665	In-situ side-chain peptide cyclization as a breaker strategy against the amyloid aggregating peptide. <b>2021</b> , 33, 116017	1
664	Effect of policosanol from insect wax on amyloid $\beta$ peptide-induced toxicity in a transgenic <i>Caenorhabditis elegans</i> model of Alzheimer's disease. <b>2021</b> , 21, 103	5
663	GLP-1 Receptor Agonist Inhibited the Activation of RIPK1 for Alleviation the Neuronal Death and Neuroinflammation in APP/PS1 Mice. <b>2021</b> , 27, 1699-1707	
662	Biological relevance and therapeutic potential of G-quadruplex structures in the human noncoding transcriptome. <b>2021</b> , 49, 3617-3633	10
661	Sleep disorders and late-onset epilepsy of unknown origin: Understanding new trajectories to brain amyloidopathy. <b>2021</b> , 194, 111434	5
660	Sex differences in behaviour and molecular pathology in the 5XFAD model.	
659	Plasma amyloid $\beta$ levels in Alzheimer's disease and cognitively normal controls in Syrian population. <b>2021</b> , 35, 19	1
658	Tooth Loss Induces Memory Impairment and Gliosis in App Knock-In Mouse Models of Alzheimer's Disease. <b>2021</b> , 80, 1687-1704	2
657	Recent advances in pre-clinical diagnosis of Alzheimer's disease. <b>2021</b> , 1	
656	A $\beta$ -16 controls synaptic vesicle pools at excitatory synapses via cholinergic modulation of synapsin phosphorylation. <b>2021</b> , 78, 4973-4992	2
655	Overview of the Neuroprotective Effects of the MAO-Inhibiting Antidepressant Phenelzine. <b>2021</b> , 1	4
654	Remote monitoring technologies in Alzheimer's disease: design of the RADAR-AD study. <b>2021</b> , 13, 89	10
653	Alternative Targets to Fight Alzheimer's Disease: Focus on Astrocytes. <b>2021</b> , 11,	7
652	Alzheimer's Disease: New Concepts on the Role of Autoimmunity and NLRP3 Inflammasome in the Pathogenesis of the Disease. <b>2021</b> , 19, 498-512	7
651	APP/PS1 Gene-Environment Noise Interaction Aggravates AD-like Neuropathology in Hippocampus Via Activation of the VDAC1 Positive Feedback Loop. <b>2021</b> ,	0
650	P2X7 receptors in the central nervous system. <b>2021</b> , 187, 114472	1
649	The role of Bcl-2 proteins in modulating neuronal Ca signaling in health and in Alzheimer's disease. <b>2021</b> , 1868, 118997	4
648	Interacting Models of Amyloid- $\beta$ and Tau Proteins: An Approach to Identify Drug Targets in Alzheimer's Disease. <b>2021</b> , 5, 405-411	0

647	Multi-Target-Directed Ligands as an Effective Strategy for the Treatment of Alzheimer's Disease. <b>2021,</b>	1
646	Thioredoxin-1 Is a Target to Attenuate Alzheimer-Like Pathology in Diabetic Encephalopathy by Alleviating Endoplasmic Reticulum Stress and Oxidative Stress. <b>2021, 12, 651105</b>	8
645	Characterization of monomeric and soluble aggregated A $\beta$ in Down's syndrome and Alzheimer's disease brains. <b>2021, 754, 135894</b>	5
644	Emerging Brain-Pathophysiology-Mimetic Platforms for Studying Neurodegenerative Diseases: Brain Organoids and Brains-on-a-Chip. <b>2021, 10, e2002119</b>	7
643	The bile acid TUDCA and neurodegenerative disorders: An overview. <b>2021, 272, 119252</b>	17
642	Melatonin Improves Short-Term Spatial Memory in a Mouse Model of Alzheimer's Disease. <b>2021, 11, 15-27</b>	4
641	Cerebral Blood Flow Predicts Conversion of Mild Cognitive Impairment into Alzheimer's Disease and Cognitive Decline: An Arterial Spin Labeling Follow-up Study. <b>2021, 82, 293-305</b>	2
640	Recent Progress in the Drug Development for the Treatment of Alzheimer's Disease Especially on Inhibition of Amyloid-peptide Aggregation. <b>2021, 21, 969-990</b>	1
639	Contribution of astrocytes to neuropathology of neurodegenerative diseases. <b>2021, 1758, 147291</b>	16
638	Electrochemical biosensors for biometal-protein interactions in neurodegenerative diseases. <b>2021, 179, 113035</b>	5
637	Tau Exon 10 Inclusion by PrP through Downregulating GSK3 $\beta$ Activity. <b>2021, 22,</b>	
636	Oxidase Reactivity of Cu Bound to $\beta$ -Truncated A $\beta$ Peptides Promoted by Dopamine. <b>2021, 22,</b>	0
635	NOX4 promotes ferroptosis of astrocytes by oxidative stress-induced lipid peroxidation via the impairment of mitochondrial metabolism in Alzheimer's diseases. <b>2021, 41, 101947</b>	23
634	The role of amyloid oligomers in neurodegenerative pathologies. <b>2021, 181, 582-604</b>	2
633	Memantine ameliorates cognitive deficit in AD mice via enhancement of entorhinal-CA1 projection. <b>2021, 22, 41</b>	3
632	Neurotrophic signaling deficiency exacerbates environmental risks for Alzheimer's disease pathogenesis. <b>2021, 118,</b>	3
631	Emerging two-dimensional materials-enabled diagnosis and treatments of Alzheimer's disease: Status and future challenges. <b>2021, 23, 101028</b>	1
630	Transcranial Magnetic Stimulation as a Diagnostic and Therapeutic Tool in Various Types of Dementia. <b>2021, 10,</b>	1

629	Association between open-angle glaucoma and Alzheimer's disease in Sweden: a long-term population-based follow-up study. <b>2021</b> , 126,	1
628	Destabilization of the Alzheimer's amyloid- $\beta$ protofibrils by THC: A molecular dynamics simulation study. <b>2021</b> , 105, 107889	1
627	The Antioxidant Activity of Limonene Counteracts Neurotoxicity Triggered by A $\beta$ Oligomers in Primary Cortical Neurons. <b>2021</b> , 10,	7
626	Neuroprotective mechanisms of chronic physical exercise via reduction of $\beta$ amyloid protein in experimental models of Alzheimer's disease: A systematic review. <b>2021</b> , 275, 119372	3
625	The Effect of a Traditional Preparation Containing L. and (Boiss.) B.Fedtsch. on Immobility Stress-Induced Memory Loss in Mice. <b>2021</b> , 2021, 5577594	1
624	Dose-effect relationships for PBM in the treatment of Alzheimer's disease. <b>2021</b> , 54, 353001	2
623	Enhancing the binding of the sheet breaker peptide LPFFD to the amyloid- $\beta$ fibrils by aromatic modifications: A molecular dynamics simulation study. <b>2021</b> , 92, 107471	3
622	Mild magnetic nanoparticle hyperthermia promotes the disaggregation and microglia-mediated clearance of beta-amyloid plaques. <b>2021</b> , 34, 102397	5
621	Leveraging hallmark Alzheimer's molecular targets using phytoconstituents: Current perspective and emerging trends. <b>2021</b> , 139, 111634	0
620	Mechanistic roles for altered O-GlcNAcylation in neurodegenerative disorders. <b>2021</b> , 478, 2733-2758	2
619	Stressed mitochondria: A target to intrude alzheimer's disease. <b>2021</b> , 59, 48-57	13
618	A $\beta$ Influx into the Blood Evoked by Different Blood A $\beta$ Removal Systems: A Potential Therapy for Alzheimer's Disease. <b>2021</b> , 17, 2291-2308	0
617	Estrogen Deficiency Induces Mitochondrial Damage Prior to Emergence of Cognitive Deficits in a Postmenopausal Mouse Model. <b>2021</b> , 13, 713819	4
616	The complexity of Alzheimer's disease: an evolving puzzle. <i>Physiological Reviews</i> , <b>2021</b> , 101, 1047-1081 47.9	7
615	The Emerging Role of Long Non-Coding RNAs and MicroRNAs in Neurodegenerative Diseases: A Perspective of Machine Learning. <b>2021</b> , 11,	5
614	Can a Micronutrient Mixture Delay the Onset and Progression of Symptoms of Single-Point Mutation Diseases?. <b>2021</b> , 1-10	
613	Integrated Analysis of Weighted Gene Coexpression Network Analysis Identifying Six Genes as Novel Biomarkers for Alzheimer's Disease. <b>2021</b> , 2021, 9918498	3
612	Protective effects of a small molecule inhibitor, DDQ against amyloid beta in Alzheimer's disease. <b>2021</b> , 59, 17-29	6

611	Optical Imaging of Beta-Amyloid Plaques in Alzheimer's Disease. <b>2021</b> , 11,	0
610	Thiophene- $\beta$ -Cyanoacetamides Show Intense and Tau-selective Turn-on Fluorescence in the Near-Infrared Region. <b>2021</b> , 42, 1285	0
609	Quantifying scaling exponents for neurite morphology of in vitro-cultured human iPSC-derived neurons using discrete Loewner evolution: A statistical-physical approach to the neuropathology in Alzheimer's disease. <b>2021</b> , 31, 073140	3
608	N-Truncated A $\beta$ Starting at Position Four-Biochemical Features, Preclinical Models, and Potential as Drug Target in Alzheimer's Disease. <b>2021</b> , 13, 710579	4
607	Flavan-3-ol Microbial Metabolites Modulate Proteolysis in Neuronal Cells Reducing Amyloid-beta (1-42) Levels. <b>2021</b> , 65, e2100380	7
606	High-fat diet-induced atherosclerosis promotes neurodegeneration in the triple transgenic (3 Tg) mouse model of Alzheimer's disease associated with chronic platelet activation. <b>2021</b> , 13, 144	2
605	Tunable inhibition of $\beta$ amyloid peptides by fast green molecules*. <b>2021</b> , 30, 088701	0
604	New thiazole and thiazole-chromene hybrids possessing morpholine units: Piperazine-mediated one-pot synthesis of potential acetylcholinesterase inhibitors. 1-13	8
603	Alteration of gene expression in reactive astrocytes induced by A $\beta$ -42 using low dose of methamphetamine. <b>2021</b> , 48, 6103-6112	
602	The molecular and cellular basis of copper dysregulation and its relationship with human pathologies. <b>2021</b> , 35, e21810	6
601	Protein misfolding, ER Stress and Chaperones: An approach to develop chaperone-based therapeutics for Alzheimer's Disease. <b>2021</b> , 1-32	2
600	Innate Immunity Protein IFITM3 in Alzheimer's Disease. <b>2021</b> , 40, 1351-1355	0
599	Dexmedetomidine Alleviates Lipopolysaccharide-Induced Hippocampal Neuronal Apoptosis via Inhibiting the p38 MAPK/c-Myc/CLIC4 Signaling Pathway in Rats. <b>2021</b> , 58, 5533-5547	2
598	Sulfonylureas target the neurovascular response to decrease Alzheimer's pathology.	
597	The Role of Age on Beta-Amyloid Plasma Levels in Healthy Subjects. <b>2021</b> , 13, 698571	1
596	Anxiety and Alzheimer's disease: Behavioral analysis and neural basis in rodent models of Alzheimer's-related neuropathology. <b>2021</b> , 127, 647-658	5
595	Long-Term Treatment of Cuban Policosanol Attenuates Abnormal Oxidative Stress and Inflammatory Response via Amyloid Plaques Reduction in 5xFAD Mice. <b>2021</b> , 10,	4
594	Anti-inflammatory Activity of a Polypeptide Fraction From in Amyloid $\beta$ Oligomers Induced Model of Alzheimer's Disease. <b>2021</b> , 12, 716177	2

593	DSCR1 upregulation enhances dural meningeal lymphatic drainage to attenuate amyloid pathology of Alzheimer's disease. <b>2021</b> , 255, 296-310	2
592	Differential expression of long non-coding RNAs in the hippocampus of mice exposed to PM in Dalian, China. <b>2021</b> , 1	0
591	Metallobiology and therapeutic chelation of biometals (copper, zinc and iron) in Alzheimer's disease: Limitations, and current and future perspectives. <b>2021</b> , 67, 126779	14
590	Association Between Adenosine A Receptors and Connexin 43 Regulates Hemichannels Activity and ATP Release in Astrocytes Exposed to Amyloid- $\beta$ Peptides. <b>2021</b> , 58, 6232-6248	3
589	L. (Saffron) in Alzheimer's Disease Treatment: Bioactive Effects on Cognitive Impairment. <b>2021</b> , 19, 1606-1616	2
588	Early Spatial Memory Impairment in a Double Transgenic Model of Alzheimer's Disease TgF-344 AD. <b>2021</b> , 11,	1
587	Potent therapeutic targets for treatment of Alzheimer's disease: Amyloid degrading enzymes.	0
586	Exploring ER stress response in cellular aging and neuroinflammation in Alzheimer's disease. <b>2021</b> , 70, 101417	5
585	Brain Exosomes: Friend or Foe in Alzheimer's Disease?. <b>2021</b> , 58, 6610-6624	2
584	Delta- and beta- secretases crosstalk amplifies the amyloidogenic pathway in Alzheimer's disease. <b>2021</b> , 204, 102113	1
583	Phosphodiesterase-4D Knockdown in the Prefrontal Cortex Alleviates Memory Deficits and Synaptic Failure in Mouse Model of Alzheimer's Disease. <b>2021</b> , 13, 722580	3
582	A sticky situation: regulation and function of protein palmitoylation with a spotlight on the axon and axon initial segment. <b>2021</b> , 5, NS20210005	0
581	Protective effects of mitophagy enhancers against amyloid beta-induced mitochondrial and synaptic toxicities in Alzheimer disease. <b>2021</b> ,	12
580	Inflammatory Chemokines Expression Variations and Their Receptors in APP/PS1 Mice. <b>2021</b> , 83, 1051-1060	1
579	Mitophagy enhancers against phosphorylated Tau-induced mitochondrial and synaptic toxicities in Alzheimer disease.	
578	Targeting Brain-Derived Neurotrophic Factor (BDNF) - An Important Strategy to Alzheimer's Disease. <b>2021</b> , 6, 121-127	
577	Breaker peptides against amyloid- $\beta$ aggregation: a potential therapeutic strategy for Alzheimer's disease. <b>2021</b> , 13, 1767-1794	3
576	Amyloid beta peptides electrochemistry: A review. <b>2021</b> , 31, 100837	0

575	Design, synthesis and biological evaluation of harmine derivatives as potent GSK-3 $\beta$ /DYRK1A dual inhibitors for the treatment of Alzheimer's disease. <b>2021</b> , 222, 113554	14
574	Qingyangshen mitigates amyloid- $\beta$ and Tau aggregate defects involving PPAR $\beta$ /FEB activation in transgenic mice of Alzheimer's disease. <b>2021</b> , 91, 153648	7
573	Female specific risk factors for the development of Alzheimer's disease neuropathology and cognitive impairment: Call for a precision medicine approach. <b>2021</b> , 71, 101459	4
572	Can platelet activation result in increased plasma A $\beta$ levels and contribute to the pathogenesis of Alzheimer's disease?. <b>2021</b> , 71, 101420	6
571	The calcium-iron connection in ferroptosis-mediated neuronal death. <b>2021</b> , 175, 28-41	9
570	Untangling huge literature to disinter genetic underpinnings of Alzheimer's Disease: A systematic review and meta-analysis. <b>2021</b> , 71, 101421	
569	Label-free detection of $\beta$ Amyloid (1-42) in plasma using electrospun SnO <sub>2</sub> nanofiber based electro-analytical sensor. <b>2021</b> , 346, 130522	5
568	Auto-weighted centralised multi-task learning via integrating functional and structural connectivity for subjective cognitive decline diagnosis. <b>2021</b> , 74, 102248	0
567	Potential neuroprotection by nobiletin alkaloid in Alzheimer's disease models. <b>2022</b> , 17, 972-977	1
566	The Impact of Apolipoprotein E Allelic Variants on Alzheimer's Disease. <b>2021</b> , 397-418	1
565	Blood-Brain Barrier Disruption Increases Amyloid-Related Pathology in TgSwDI Mice. <b>2021</b> , 22,	4
564	Defective Autophagy and Mitophagy in Aging and Alzheimer's Disease. <b>2020</b> , 14, 612757	37
563	Interaction between A $\beta$ and Tau in the Pathogenesis of Alzheimer's Disease. <b>2021</b> , 17, 2181-2192	10
562	Retinal Thickness Changes Over Time in a Murine AD Model APP. <b>2020</b> , 12, 625642	3
561	Nobiletin. <b>2021</b> , 185-196	
560	Dual Effect of Prussian Blue Nanoparticles on A $\beta$ 0 Aggregation: $\beta$ Sheet Fibril Reduction and Copper Dyshomeostasis Regulation. <b>2021</b> , 22, 430-440	3
559	Platycodin D Inhibits $\beta$ Amyloid-Induced Inflammation and Oxidative Stress in BV-2 Cells Via Suppressing TLR4/NF- $\kappa$ B Signaling Pathway and Activating Nrf2/HO-1 Signaling Pathway. <b>2021</b> , 46, 638-647	6
558	Transgenic Animal Models of Proteinopathies. 26-36	1



557	Cell Cycle and Chromosome Segregation Defects in Alzheimer's Disease. <b>2005</b> , 55-78	2
556	Modulation of Proteolytic Processing by Glycosphingolipids Generates Amyloid $\beta$ Peptide. <b>2006</b> , 319-328	1
555	Role of A $\beta$ Transport and Clearance in the Pathogenesis and Treatment of Alzheimer's Disease. <b>2007</b> , 179-198	5
554	Nonsteroidal Anti-inflammatory Drugs (NSAIDs) and Derived A $\beta$ 2-Lowering Molecules for Treatment and Prevention of Alzheimer's Disease (AD). <b>2007</b> , 167-193	1
553	Alzheimer's Disease and Reelin. <b>2008</b> , 401-409	1
552	The Genetics of Innate Immunity and Inflammation in Ageing, Age-Related Diseases and Longevity. <b>2007</b> , 154-173	1
551	Alternative Agonists and Modulators: Evidence that the Calcium-Sensing Receptor is a Multi-Modal Sensor. <b>2003</b> , 203-226	3
550	Single-Molecule Studies of Amyloidogenic Proteins. <b>2012</b> , 169-210	1
549	Neuroprotective strategies in Alzheimer's disease. <b>2002</b> , 513, 475-96	6
548	Plasminogen Activators in CNS Physiology and Disease. <b>2003</b> , 251-267	1
547	The APP Proteolytic System and Its Interactions with Dynamic Networks in Alzheimer's Disease. <b>2016</b> , 1303, 71-99	6
546	5-HT <sub>3</sub> and 5-HT <sub>4</sub> Receptors as Targets for Drug Discovery for Dementia. <b>2006</b> , 459-479	1
545	Analysis of A $\beta$ interactions using ProteinChip technology. <b>2008</b> , 494, 71-86	2
544	Pathobiology of Diabetic Encephalopathy in Animal Models. <b>2009</b> , 409-431	2
543	A $\beta$ Infusion and Related Models of Alzheimer Dementia. <b>2011</b> , 347-370	5
542	Detecting amyloid- $\beta$ plaques in Alzheimer's disease. <b>2011</b> , 711, 511-33	15
541	Role of the proteasome in fly models of neurodegeneration. <b>2011</b> , 793, 149-65	2
540	Establishing the links between A $\beta$ aggregation and cytotoxicity in vitro using biophysical approaches. <b>2012</b> , 849, 227-43	1

539	Brain Oxidative Stress in the Pathogenesis and Progression of Alzheimer's Disease. <b>2013</b> , 99-118	1
538	The A $\beta$ entric Pathway of Alzheimer's Disease. <b>2007</b> , 5-36	1
537	The Role of Astrocytes in Parkinson's Disease. <b>2014</b> , 127-144	3
536	The Aged Dog as a Natural Model of Alzheimer's Disease Progression. <b>2017</b> , 69-92	2
535	Grapevine Stilbenes and Their Biological Effects. <b>2008</b> , 25-54	8
534	Integrating Data for Modeling Biological Complexity. <b>2014</b> , 921-949	1
533	Neuroprotective effects of estrogens in the central nervous system: mechanisms of action. <b>2002</b> , 263-270	3
532	Current drugs and future hopes in the treatment of Alzheimer's disease. <b>2002</b> , 149-64	8
531	Dementia and End-of-Life Decisions: Ethical Issues [A Perspective from The Netherlands. <b>2010</b> , 401-420	1
530	Alzheimer's Disease, Schizophrenia and Depression. <b>2011</b> , 377-415	1
529	The $\beta$ Secretase Protease Complexes in Neurodegeneration, Cancer and Immunity. <b>2017</b> , 47-87	2
528	Removal of Blood Amyloid As a Therapeutic Strategy for Alzheimer's Disease: The Influence of Smoking and Nicotine. <b>2018</b> , 173-191	1
527	Astroglia in Alzheimer's Disease. <b>2019</b> , 1175, 273-324	25
526	Chemical Constituents and their Antioxidant, Anti-Inflammatory and Anti-Acetylcholinesterase Activities from <i>Pholidota cantonensis</i> . <b>2021</b> , 76, 105-110	2
525	The Role of Mitochondria in Neurodegenerative Diseases: the Lesson from Alzheimer's Disease and Parkinson's Disease. <b>2020</b> , 57, 2959-2980	60
524	Biometals and Alzheimer's Disease. <b>2017</b> , 1-17	3
523	Graphene oxide enhances $\beta$ amyloid clearance by inducing autophagy of microglia and neurons. <b>2020</b> , 325, 109126	15
522	Development and comprehensive comparison of two on-line capillary electrophoretic methods for $\beta$ Secretase inhibitor screening. <b>2017</b> , 1518, 89-96	12

521	Neuregulin 1 regulates amyloid precursor protein cell surface expression and non-amyloidogenic processing. <b>2018</b> , 137, 146-153	6
520	Stress and Alzheimer's disease: A senescence link?. <b>2020</b> , 115, 285-298	13
519	Recognition memory impairments and amyloid-beta deposition of the retrosplenial cortex at the early stage of 5XFAD mice. <b>2020</b> , 222, 112891	6
518	Prion-like transmission of protein aggregates in neurodegenerative diseases.	1
517	Amyloid $\beta$ peptide and Alzheimer's disease. <b>2014</b> , 56, 99-110	18
516	Nitrous oxide plus isoflurane induces apoptosis and increases beta-amyloid protein levels. <b>2009</b> , 111, 741-52	75
515	Anesthetic sevoflurane causes neurotoxicity differently in neonatal naïve and Alzheimer disease transgenic mice. <b>2010</b> , 112, 1404-16	154
514	Human Tau Isoform Aggregation and Selective Detection of Misfolded Tau from Post-Mortem Alzheimer's Disease Brains.	3
513	Alzheimer's disease-relevant tau modifications selectively impact neurodegeneration and mitophagy in a novel <i>C. elegans</i> single-copy transgenic model.	1
512	A game theoretic approach to deciphering the dynamics of amyloid- $\beta$ aggregation along competing pathways.	1
511	A single-nuclei RNA sequencing study of Mendelian and sporadic AD in the human brain.	1
510	Amyloid beta(1-42) peptide alters the gating of human and mouse alpha-bungarotoxin-sensitive nicotinic receptors. <b>2003</b> , 547, 147-57	74
509	WRN's tenth anniversary. <b>2006</b> , 2006, pe18	6
508	Physiologic and Pathologic Events Mediated by Intramembranous and Juxtamembranous Proteolysis. <b>2003</b> , 2003, re4-re4	2
507	Cholesterol, lipid rafts, and disease. <b>2002</b> , 110, 597-603	715
506	Deciphering the genesis and fate of amyloid $\beta$ protein yields novel therapies for Alzheimer disease. <b>2002</b> , 110, 1375-1381	133
505	Spotlight on BACE: the secretases as targets for treatment in Alzheimer disease. <b>2001</b> , 108, 1243-6	25
504	Cholesterol, lipid rafts, and disease. <b>2002</b> , 110, 597-603	321

503	Increased T cell reactivity to amyloid beta protein in older humans and patients with Alzheimer disease. <b>2003</b> , 112, 415-22	122
502	Alzheimer disease therapy: Can the amyloid cascade be halted?. <b>2003</b> , 111, 11-18	116
501	Anti-Abeta antibody treatment promotes the rapid recovery of amyloid-associated neuritic dystrophy in PDAPP transgenic mice. <b>2005</b> , 115, 428-33	140
500	The potential role of amyloid beta in the pathogenesis of age-related macular degeneration. <b>2005</b> , 115, 2793-800	151
499	Cholinergic dysfunction in a mouse model of Alzheimer disease is reversed by an anti-A beta antibody. <b>2006</b> , 116, 825-32	92
498	Endocytosis of synaptic ADAM10 in neuronal plasticity and Alzheimer's disease. <b>2013</b> , 123, 2523-38	74
497	Thinking laterally about neurodegenerative proteinopathies. <b>2013</b> , 123, 1847-55	80
496	Amyloid precursor protein-mediated endocytic pathway disruption induces axonal dysfunction and neurodegeneration. <b>2016</b> , 126, 1815-33	109
495	Reducing expression of synapse-restricting protein Ephexin5 ameliorates Alzheimer's-like impairment in mice. <b>2017</b> , 127, 1646-1650	10
494	Protective effect of the aerial parts of <i>Silybum marianum</i> against amyloid $\beta$ protein (25-35)-induced neuronal death in cultured neurons. <b>2016</b> , 17, 109-114	1
493	Reducing amyloid plaque burden via ex vivo gene delivery of an A $\beta$ -degrading protease: a novel therapeutic approach to Alzheimer disease. <b>2007</b> , 4, e262	95
492	Identification of beta-secretase (BACE1) substrates using quantitative proteomics. <b>2009</b> , 4, e8477	140
491	S100a9 knockdown decreases the memory impairment and the neuropathology in Tg2576 mice, AD animal model. <b>2010</b> , 5, e8840	63
490	APP processing induced by herpes simplex virus type 1 (HSV-1) yields several APP fragments in human and rat neuronal cells. <b>2010</b> , 5, e13989	93
489	Alzheimer's A $\beta$ peptides with disease-associated N-terminal modifications: influence of isomerisation, truncation and mutation on Cu <sup>2+</sup> coordination. <b>2010</b> , 5, e15875	35
488	Calcium ions promote formation of amyloid $\beta$ peptide (1-40) oligomers causally implicated in neuronal toxicity of Alzheimer's disease. <b>2011</b> , 6, e18250	84
487	The collagen chaperone HSP47 is a new interactor of APP that affects the levels of extracellular beta-amyloid peptides. <b>2011</b> , 6, e22370	9
486	A $\beta$ peptide fibrillar architectures controlled by conformational constraints of the monomer. <b>2011</b> , 6, e25157	14

485	Distinct temporal and anatomical distributions of amyloid- $\beta$ and tau abnormalities following controlled cortical impact in transgenic mice. <b>2011</b> , 6, e25475	71
484	Defects in mitochondrial dynamics and metabolomic signatures of evolving energetic stress in mouse models of familial Alzheimer's disease. <b>2012</b> , 7, e32737	176
483	Interactions between amyloid- $\beta$ and hemoglobin: implications for amyloid plaque formation in Alzheimer's disease. <b>2012</b> , 7, e33120	58
482	Amyloid- $\beta$ acts as a regulator of neurotransmitter release disrupting the interaction between synaptophysin and VAMP2. <b>2012</b> , 7, e43201	69
481	The preventive and therapeutic effects of intravenous human adipose-derived stem cells in Alzheimer's disease mice. <b>2012</b> , 7, e45757	107
480	Alzheimer's disease related markers, cellular toxicity and behavioral deficits induced six weeks after oligomeric amyloid- $\beta$ peptide injection in rats. <b>2013</b> , 8, e53117	80
479	Ferulic acid is a nutraceutical $\beta$ -secretase modulator that improves behavioral impairment and alzheimer-like pathology in transgenic mice. <b>2013</b> , 8, e55774	118
478	PKC $\beta$ promotes HuD-mediated neprilysin mRNA stability and enhances neprilysin-induced A $\beta$ degradation in brain neurons. <b>2014</b> , 9, e97756	18
477	Involvement of Intracellular and Mitochondrial A $\beta$ in the Ameliorative Effects of Huperzine A against Oligomeric A $\beta$ 2-Induced Injury in Primary Rat Neurons. <b>2015</b> , 10, e0128366	18
476	Enhanced Phospholipase A2 Group 3 Expression by Oxidative Stress Decreases the Insulin-Degrading Enzyme. <b>2015</b> , 10, e0143518	13
475	Functional Impact of Corticotropin-Releasing Factor Exposure on Tau Phosphorylation and Axon Transport. <b>2016</b> , 11, e0147250	15
474	Total Lignans of Schisandra chinensis Ameliorates A $\beta$ 1-42-Induced Neurodegeneration with Cognitive Impairment in Mice and Primary Mouse Neuronal Cells. <b>2016</b> , 11, e0152772	26
473	Optimization of the All-D Peptide D3 for A $\beta$ Oligomer Elimination. <b>2016</b> , 11, e0153035	14
472	Amelioration of cognitive impairments in APPswe/PS1dE9 mice is associated with metabolites alteration induced by total salvianolic acid. <b>2017</b> , 12, e0174763	12
471	AlzhCPI: A knowledge base for predicting chemical-protein interactions towards Alzheimer's disease. <b>2017</b> , 12, e0178347	9
470	The Critical Role of Nurr1 as a Mediator and Therapeutic Target in Alzheimer's Disease-related Pathogenesis. <b>2020</b> , 11, 705-724	18
469	Rodent Models of Amyloid-Beta Feature of Alzheimer's Disease: Development and Potential Treatment Implications. <b>2020</b> , 11, 1235-1259	10
468	Transcranial Magnetic Stimulation in Alzheimer's Disease: Are We Ready?. <b>2020</b> , 7,	21

467	Physical therapy in patients with Alzheimer's disease: a systematic review of randomized controlled clinical trials. <b>2019</b> , 26, 311-321	5
466	[Development of preclinical diagnosis and preventive treatment of neurodegenerative diseases]. <b>2015</b> , 115, 4-14	5
465	Molecular signatures in exosomes as diagnostic markers for neurodegenerative disorders. <b>2020</b> , 4, 012-017	1
464	Phosphorylation of amyloid beta (A $\beta$ ) peptides - a trigger for formation of toxic aggregates in Alzheimer's disease. <b>2011</b> , 3, 803-12	108
463	A novel rhamnoside derivative PL402 up-regulates matrix metalloproteinase 3/9 to promote A $\beta$ degradation and alleviates Alzheimer's-like pathology. <b>2020</b> , 12, 481-501	4
462	Neuroprotective effects of CD4+CD25+Foxp3+ regulatory T cells in a 3xTg-AD Alzheimer's disease model. <b>2016</b> , 7, 69347-69357	71
461	Friend or foe: the dichotomous impact of T cells on neuro-de/re-generation during aging. <b>2017</b> , 8, 7116-7137	24
460	Synthetic A $\beta$ peptides acquire prion-like properties in the brain. <b>2015</b> , 6, 642-50	2
459	Diabetes and Alzheimer's disease - is there a connection?. <b>2006</b> , 3, 161-8	13
458	Porous Inorganic and Hybrid Systems for Drug Delivery: Future Promise in Combatting Drug Resistance and Translation to Botanical Applications. <b>2019</b> , 26, 6107-6131	18
457	Potential Enzymatic Targets in Alzheimer's: A Comprehensive Review. <b>2019</b> , 20, 316-339	17
456	Antioxidant therapy in Alzheimer's disease: theory and practice. <b>2008</b> , 8, 1395-406	95
455	Involvement of the Apoer2 and Lrp1 receptors in mediating the pathological effects of ApoE4 in vivo. <b>2014</b> , 11, 549-57	23
454	Reduced Alzheimer's disease pathology by St. John's Wort treatment is independent of hyperforin and facilitated by ABCC1 and microglia activation in mice. <b>2013</b> , 10, 1057-69	65
453	Commonalities in Biological Pathways, Genetics, and Cellular Mechanism between Alzheimer Disease and Other Neurodegenerative Diseases: An In Silico-Updated Overview. <b>2017</b> , 14, 1190-1197	26
452	Neuroprotective Effect of $\beta$ -secretase Inhibitory Peptide from Pacific Hake ( <i>Merluccius productus</i> ) Fish Protein Hydrolysate. <b>2019</b> , 16, 1028-1038	7
451	Pyroglutamate-Modified Amyloid Beta Peptides: Emerging Targets for Alzheimer's Disease Immunotherapy. <b>2013</b> , 11, 491-8	41
450	The Long Run: Neuroprotective Effects of Physical Exercise on Adult Neurogenesis from Youth to Old Age. <b>2017</b> , 15, 519-533	45

449	YKL-40 as a Potential Biomarker and a Possible Target in Therapeutic Strategies of Alzheimer's Disease. <b>2017</b> , 15, 906-917	37
448	Molecular interaction study of N1-p-fluorobenzyl-cymserine with TNF- $\alpha$ p38 kinase and JNK kinase. <b>2013</b> , 12, 129-35	6
447	Targeting TNF- $\alpha$ to elucidate and ameliorate neuroinflammation in neurodegenerative diseases. <b>2011</b> , 10, 391-403	150
446	Perspective Design of Chalcones for the Management of CNS Disorders: A Mini-Review. <b>2019</b> , 18, 432-445	18
445	The MMP-2/TIMP-2 System in Alzheimer Disease. <b>2020</b> , 19, 402-416	4
444	Cardiovascular dementia - a different perspective. <b>2010</b> , 4, 29-52	21
443	The effects of aerobic training before and after the induction of Alzheimer's disease on ABCA1 and APOE mRNA expression and the level of soluble A $\beta$ -42 in the hippocampus of male Wistar rats. <b>2019</b> , 22, 399-406	2
442	Long-Term Culture of Organotypic Hippocampal Slice from Old 3xTg-AD Mouse: An Model of Alzheimer's Disease. <b>2018</b> , 15, 205-213	14
441	Neurodegenerative processes in Alzheimer's disease. <b>2004</b> , 363-368	2
440	Biochemical aspects of dementias. <b>2003</b> , 5, 27-33	4
439	Genetic studies in Alzheimer's disease. <b>2003</b> , 5, 17-26	22
438	Differences in Synaptic Dysfunction Between rTg4510 and APP/PS1 Mouse Models of Alzheimer's Disease. <b>2018</b> , 61, 195-208	19
437	Outline of therapeutic interventions with muscarinic receptor-mediated transmission. <b>2014</b> , 63, S177-89	5
436	Elevated age-related cortical iron, ferritin and amyloid plaques in APP(swe)/PS1(deltaE9) transgenic mouse model of Alzheimer's disease. <b>2019</b> , 68, S445-S451	9
435	Differences in Protein Profiles in Schizophrenia Prefrontal Cortex Compared to Other Major Brain Disorders. <b>2007</b> , 1, 73-91	7
434	Resveratrol and Neuroprotection: Impact and Its Therapeutic Potential in Alzheimer's Disease. <b>2020</b> , 11, 619024	43
433	Zn Interaction with Amyloid- $\beta$ Affinity and Speciation. <b>2019</b> , 24,	6
432	[Effects of Naoerkang on expressions of beta-amyloid peptide 1-42 and neprilysin in hippocampus in a rat model of Alzheimer's disease]. <b>2010</b> , 8, 152-7	4

431	[Chinese herbal medicine for patients with mild to moderate Alzheimer disease based on syndrome differentiation: a randomized controlled trial]. <b>2012</b> , 10, 766-76	13
430	Cytoprotective Effects of Phaeophyta Extracts from the Coast of Jeju Island in HT-22 Mouse Neuronal Cells. <b>2014</b> , 43, 224-230	7
429	Neuroprotective effect of CPCGI on Alzheimer's disease and its mechanism. <b>2020</b> , 21, 115-122	2
428	Neuroprotective effect of emodin against Alzheimer's disease via Nrf2 signaling in U251 'cells and APP/PS1 mice. <b>2021</b> , 23,	6
427	Neuroprotective action of lithium in disorders of the central nervous system. <b>2011</b> , 36, 461-76	25
426	Brain-derived neurotrophic factor prevents beta- amyloid-induced apoptosis of pheochromocytoma cells by regulating Bax/Bcl-2 expression. <b>2012</b> , 7, 347-51	8
425	Zinc and Neurodegenerative Disorders. <b>2019</b> , 176-193	4
424	ER Stress Signaling in Alzheimer's Disease. <b>2020</b> , 180-211	1
423	A review of butyrylcholinesterase as a therapeutic target in the treatment of Alzheimer's disease. <b>2013</b> , 15,	174
422	rAAV/ABAD-DP-6His attenuates oxidative stress-induced injury of PC12 cells. <b>2014</b> , 9, 481-8	1
421	Connexin: a potential novel target for protecting the central nervous system?. <b>2015</b> , 10, 659-66	18
420	Optogenetics and its application in neural degeneration and regeneration. <b>2017</b> , 12, 1197-1209	30
419	Utilizing zebrafish and okadaic acid to study Alzheimer's disease. <b>2018</b> , 13, 1538-1541	18
418	Can mouse models mimic sporadic Alzheimer's disease?. <b>2020</b> , 15, 401-406	20
417	Neuroprotective effects of Rosa damascena extract on learning and memory in a rat model of amyloid-β-induced Alzheimer's disease. <b>2015</b> , 4, 131	22
416	Absence of Nitric Oxide Synthase 3 Increases Amyloid β-Protein Pathology in Tg-5xFAD Mice. <b>2013</b> , 4, 84-91	6
415	Chronic ramelteon treatment in a mouse model of Alzheimer's disease. <b>2012</b> , 150, 5-14	13
414	β-Secretase (BACE1) Purification by Refolding Method and Complex with Hispidin. <b>2014</b> , 58, 553-559	1



413	Platelets and Alzheimer's disease: Potential of APP as a biomarker. <b>2012</b> , 2, 102-13	36
412	Neuroprotective effects of treadmill exercise on BDNF and PI3-K/Akt signaling pathway in the cortex of transgenic mice model of Alzheimer's disease. <b>2013</b> , 17, 151-60	35
411	Effects of treadmill exercise on brain insulin signaling and $\beta$ amyloid in intracerebroventricular streptozotocin induced-memory impairment in rats. <b>2014</b> , 18, 89-96	23
410	Alzheimer's disease and HIV associated dementia related genes: I. location and function. <b>2008</b> , 2, 348-57	6
409	Somatostatin binds to the human amyloid $\beta$ peptide and favors the formation of distinct oligomers. <b>2017</b> , 6,	21
408	Suppression Effect of the Inflammatory Response in Macrophages by Paeoniae Radix Rubra Extracts. <b>2011</b> , 19, 373-379	8
407	[Advances in enrichment of phosphorylated peptides and glycopeptides by smart polymer-based materials]. <b>2021</b> , 39, 15-25	0
406	Periodontitis and Dementia: A Bidirectional Relationship?. <b>2021</b> , 220345211043461	0
405	A partial reduction of Drp1 enhances mitophagy, autophagy, mitochondrial biogenesis, dendritic spines and synaptic activity in a transgenic Tau mouse model of Alzheimer disease.	
404	KYNA/Ahr Signaling Suppresses Neural Stem Cell Plasticity and Neurogenesis in Adult Zebrafish Model of Alzheimer's Disease. <b>2021</b> , 10,	2
403	Serum aberrant expression of miR-24-3p and its diagnostic value in Alzheimer's disease. <b>2021</b> , 15, 1499-1507	0
402	Interactions of the A $\beta$ (1-42) Peptide with Boron Nitride Nanoparticles of Varying Curvature in an Aqueous Medium: Different Pathways to Inhibit $\beta$ Sheet Formation. <b>2021</b> , 125, 11159-11178	3
401	Nanomaterials for neurodegenerative diseases: Molecular mechanisms guided design and applications. 1	1
400	Activation of Microbiota Sensing - Free Fatty Acid Receptor 2 Signaling Ameliorates Amyloid- $\beta$ Induced Neurotoxicity by Modulating Proteolysis-Senescence Axis. <b>2021</b> , 13, 735933	4
399	Structure-activity relationship study of hydroxyethylamine isostere and P1' site structure of peptide mimetic BACE1 inhibitors. <b>2021</b> , 50, 116459	1
398	Calsenilin-Presenilin Interaction in Alzheimer's Disease. <b>2002</b> , 105-110	
397	G-Protein Mediated Metabotropic Receptors Offer Novel Avenues in Neuronal and Vascular Cells for Cytoprotective Strategies. <b>2003</b> , 257-298	
396	Amyloid peptide-mediated hypoxic regulation of Ca <sup>2+</sup> channels in PC12 cells. <b>2003</b> , 536, 187-92	

- 395 Intranasal A $\beta$  Vaccination as an Approach to Treating  $\beta$  Amyloidosis. **2003**, 45-57
- 394 Mitochondria, Aging, and Disease. **2003**,
- 393 Genetic and molecular aspects of Alzheimer's disease shed light on new mechanisms of transcriptional regulation. **2005**, 051213091414049
- 392 Alzheimer Disease (AD, FAD).
- 391 The Conformation of Amyloid  $\beta$  Peptide in the Presence of Fluorinated and Alkylated Nanoparticles. **2004**, 30-32
- 390 The Conformation of Amyloid  $\beta$  Peptide in the Presence of Fluorinated and Alkylated Nanoparticles. **2004**, 30-32
- 389 Studying Amyloid  $\beta$ -Protein Assembly. **2004**,
- 388 Intracellular Accumulation of Amyloid  $\beta$  and Mitochondrial Dysfunction in Down's Syndrome. **2004**,
- 387 Fractal Analysis of Binding and Dissociation Interactions of Prions on Biosensor Surfaces. **2005**, 71-87
- 386 Functional genomics and pharmacogenetics in Alzheimer's disease. **2005**, 111-124
- 385 Cysteine Proteases as beta-Secretases for A $\beta$  Production in the Major Regulated Secretory Pathway of Neurons. **2005**, 327-342
- 384 Ginkgo biloba Extract EGb 761 Extends Life Span and Attenuates H<sub>2</sub>O<sub>2</sub> Levels in a Caenorhabditis elegans Model of Alzheimer's Disease. **2005**, 301-326
- 383 Apple Phenolics and Alzheimer's Disease. **2005**, 247-263
- 382 Molecular Mechanism of Memantine in Treatment of Alzheimer's Disease and Other Neurologic Insults. **2005**, 351-372
- 381 Z. **2005**, 505-507
- 380 Pathophysiology of sialyltransferases cleavage by Alzheimer's  $\beta$ -secretase. **2006**, 17, 78-82
- 379  $\beta$  Secretase as a Target for Alzheimer's Disease. **2007**, 125-140
- 378 Neuroimaging (MRI, PET). **2007**, 251-260

- 377 Aβ Variants and Their Impact on Amyloid Formation and Alzheimer's Disease Progression. **2007**, 102-124
- 376 3. ??????????????. **2007**, 38, 189-195
- 375 Secretases as Pharmacological Targets in Alzheimer's Disease. **2007**, 113-124
- 374 Protein Misfolding, a Common Mechanism in the Pathogenesis of Neurodegenerative Diseases. **2008**, 285-304
- 373 ANTI-AMYLOID-β IMMUNOTHERAPY AS A TREATMENT FOR ALZHEIMER'S DISEASE. **2008**, 295-318 1
- 372 Protein Aggregates in Neurodegenerative Disorders. 355
- 371 Alternative pathways for production of β amyloid peptides of Alzheimer's disease. **2008**, 080808070126964-37 1
- 370 Glutaminyl cyclases from animals and plants: a case of functionally convergent protein evolution. **2008**, 080808064837827-24
- 369 Status and Potential Therapeutic Importance of n-3 Fatty Acids in Neurodegenerative Disease. **2009**, 217-260
- 368 References. **2009**, 279-323
- 367 Potential Therapeutic Strategies for Neurodegenerative Diseases. **2010**, 325-382 1
- 366 Neurochemical Aspects of Neurodegenerative Diseases. **2010**, 249-324
- 365 Raman Detection in Microchips and Microchannels. **2010**, 17-1-17-25
- 364 Synapses and Alzheimer's Disease: Effect of Immunotherapy?. **2011**, 269-287
- 363 APP-Based Transgenic Models: The APP23 Model. **2011**, 399-413
- 362 Drosophila Melanogaster as a Model Organism for Dementia. **2011**, 223-240
- 361 The Genetics of Alzheimer's Disease and Parkinson's Disease. **2011**, 695-755 0
- 360 Cognitive Deficits in Neurodegenerative Disorders: Parkinson's Disease and Alzheimer's Disease. **2011**, 243-292

359 Genetics of Alzheimer's Disease. **2010**, 238-251

358 The Molecular Neuropathology of Alzheimer's Disease. **2010**, 287-294

357 Chapter 6:Discovery of the Cysteine Protease Cathepsin B as a Drug Target for Alzheimer's Disease. **2011**, 145-168

356 Histone Deacetylase Inhibitors: A Novel Therapeutic Approach for Cognitive Disorders. **2011**, 245-266

355 DHEA and Alzheimer's Disease. **2011**, 433-445

354 Impact of Aging on Brain Structure and Function in Rodents and Canines. 125-138

353 Gene Expression Analysis of the Human Astrocytoma Cell after A $\beta$ 5-35 Stimulation Followed by Ibuprofen Administration. **2011**, 15, 144-161

352 Target Selection in Drug Discovery. 1

351 Understanding Mechanism of Action of Herbal Drugs in Age Related Degenerative Brain Disorders. **2012**, 159-176

350 Pathological Materiomics. **2012**, 357-398

349 Mitochondrial Dysfunction in Sporadic Alzheimer's Disease: Mechanisms, Consequences and Interventions. **2012**, 49-65

348 S18-2. Perspectives on the Future Therapeutics of Alzheimer Disease. **2012**, 43, 123-124

347 New Small Molecule Drug Discovery for Alzheimer's Disease. **2012**, 163-210

346 Effect of Lifestyle, Aging, and Phytochemicals on the Onset of Neurological Disorders. **2013**, 1-29

1

345 Genetics of Alzheimer's disease. **2012**, 4-11

344 Near-Field Detection of A $\beta$  Proteins Using Micro Beads. **2012**, 21, 319-323

343 Conformation Transformation of A $\beta$ 2 Protein under Different Temperature by Molecular Dynamics Simulations. **2013**, 03, 1-6

0

342 Clinicopathological Stratification of Idiopathic Autism and Autism with 15q11.2q13 Duplications. **2013**, 347-359

- 341 Effect of Green Tea Catechins on Cognitive Learning Ability and Dementia. **2013**, 1363-1371
- 340 Apolipoproteína E e Doença de Alzheimer. **2013**, 21, 118-125 1
- 339 Hiperfagia e Doença de Alzheimer. **2013**, 21, 141-147
- 338 Effects Amyloid Beta Peptide on the Inflammatory Response in Neuronal Cells. **2013**, 28, 230-237
- 337 Large-Scale Proteome and Phosphoproteome Quantification by Using Dimethylation Isotope Labeling. **2014**, 67-94
- 336 p75NTR: A Molecule with Multiple Functions in Amyloid-Beta Metabolism and Neurotoxicity. **2014**, 1925-1944
- 335 Neurodegenerative Disorders: Dementia and Parkinsonism, Lumping Together or Splitting Apart?. **2014**, 1-16
- 334 Role of MFG-E8 in the Brain. **2014**, 173-187
- 333 Protein Crystals: Molecular to Continuum Level Models Based on Crystal Plasticity Theory. **2015**, 13-25
- 332 Alzheimer's Disease and Other Neurodegenerative Disorders. **2015**, 329-351
- 331 Immunotherapeutic Approaches Against Amyloid- $\beta$  In Drug Discovery for Alzheimer's Disease. **2015**, 395-415
- 330 Metal Oxides and Related Nanostructures. **2015**, 115-130 0
- 329 Different Gene Products with a Similar Role in Neuronal Defense Against Oxidative Stress [Heme Oxygenase System. **2015**, 1-17
- 328 Alzheimer's Disease. **2016**, 3893-3913
- 327 A modification-specific peptide-based immunization approach using CRM197 carrier protein: Development of a selective vaccine against pyroglutamate A $\beta$  peptides.
- 326 Sedation in Neurocritical Units. **2017**, 259-274
- 325 Out-of-Register A $\beta$ 2 Assemblies as Models for Neurotoxic Oligomers and Fibrils.
- 324 Neuroprotection: Pharmacological Approaches. **2018**,

- 323 The Beneficial Effect of Enriched Environment on Pathogenesis of Alzheimer's Disease. **2018**, 02, 225-243 0
- 322 Genetic variants associated with Alzheimer's disease confer different cerebral cortex cell-type population structure. 1
- 321 SEMI-SYNTHESIS AND EVALUATION OF HESPERETIN DERIVATIVES AS ACETYLCHOLINESTERASE INHIBITORS. **2018**, 8, 7-12
- 320 Oxidative Stress and Neurodegeneration. **2019**, 24-47 1
- 319 Strengthen Alzheimer's Awareness Through Biomusic. **2019**, 117-128
- 318 Stem Cell Therapy: A Great Leap Forward in Alzheimer's Treatment. **2019**, 167-182
- 317 Stability of Aβ Fibril fragments in the presence of fatty acids.
- 316 Time-Resolved Integrative Optical Imaging of Diffusion during Spreading Depression.
- 315 Spontaneous Self-assembly of Amyloid Aβ(1-40) into Dimers.
- 314 Alteration in the Expression of Alzheimer's-Related Genes in Rat Hippocampus by Exercise and Morphine Treatments. **2019**, 7, 23-29
- 313 Screening of Beta-Secretase Inhibitors by Capillary Electrophoresis-Mass Spectrometry. **2020**, 2089, 147-157
- 312 Cobalt(III) Schiff Base complexes stabilize non-fibrillar amyloid-β aggregates with reduced toxicity.
- 311 Infrared Nanospectroscopy Reveals the Molecular Interaction Fingerprint of an Aggregation Inhibitor with Single Aβ2 Oligomers. 1
- 310 A Novel Concept is Needed for Combating Alzheimer's Disease and NeuroHIV. **2020**, 4, 85-91
- 309 Disentangling Mitochondria in Alzheimer's Disease. **2021**, 22, 2
- 308 Transcriptional activation with Cas9 activator nanocomplexes rescues Alzheimer's disease pathology. **2021**, 279, 121229 0
- 307 Semimechanistic Population Pharmacokinetic Modeling to Investigate Amyloid Beta Trafficking and Accumulation at the BBB Endothelium. **2021**, 18, 4148-4161 0
- 306 Insights into T-cell dysfunction in Alzheimer's disease. **2021**, 20, e13511 4

- 305 Removal of blood amyloid- $\beta$ s an effective and safe therapeutic strategy for Alzheimer's disease. **2020**, 647-662
- 304 A novel paradigm for assessing olfactory working memory capacity in mice. **2020**, 10, 431 0
- 303 Molecular Dynamics Simulations of Acetylcholinesterase  $\beta$ -Amyloid Peptide Complex. **2020**, 20, 140-154
- 302 Blume (Tianma): Hope for Brain Aging and Dementia. **2020**, 2020, 8870148 5
- 301 Neoechinulins: Molecular, cellular, and functional attributes as promising therapeutics against cancer and other human diseases. **2021**, 145, 112378 4
- 300 Modelling Complex Phenomena in Physiology. **2020**, 189-237
- 299 Traditional Plant Compounds for the Treatment of Neuropsychiatric Disorders. **2020**, 435-459
- 298 Bacopa monnieri: The Neuroprotective Elixir from the East  $\beta$ Phytochemistry, Pharmacology, and Biotechnological Improvement. **2020**, 97-126
- 297 CHAPTER 5: Peptide Self-assembly Applied to Catalytic Asymmetric Aldol Reactions. **2020**, 126-173 0
- 296 Characterization of amyloid  $\beta$  fibril formation under microgravity conditions.
- 295 The Implication of Androgens in the Presence of Protein Kinase C to Repair Alzheimer's Disease-Induced Cognitive Dysfunction. **2020**, 24, 64-80 3
- 294 Mitophagy enhancers against phosphorylated Tau-induced mitochondrial and synaptic toxicities in Alzheimer disease. **2021**, 174, 105973 3
- 293 Switched A $\beta$ 3 generation in familial Alzheimer's disease with presenilin 1 mutation. **2021**, 11, 558 1
- 292 The Potential Utility of Prebiotics to Modulate Alzheimer's Disease: A Review of the Evidence. **2021**, 9, 1 1
- 291 Sulphonate functionalized AIEgens: Strategic approach beyond water-solubility for sensing and imaging applications. 0
- 290 Nanoparticle-Guided Brain Drug Delivery: Expanding the Therapeutic Approach to Neurodegenerative Diseases. **2021**, 13, 4 4
- 289 A novel hybrid protein promotes A $\beta$  clearance and reduces inflammatory response through MerTK. 0
- 288 Oxidative stress modulation in neurodegenerative diseases.

- 287 The Molecular Basis of Prion Protein-Mediated Neuronal Damage. **2005**, 407-450
- 286 Gerontopsychiatrie. **2006**, 321-335
- 285 Beta Amyloid and Excitatory Synapses. 151-156
- 284 Cholesterol and A $\beta$  Production: Methods for Analysis of Altered Cholesterol De Novo Synthesis. **2008**, 221-230
- 283 Oral A $\beta$  Vaccine Using a Recombinant Adeno-Associated Virus Vector in an Alzheimer's Disease Mouse Model. **2008**, 265-272
- 282  $\beta$  Secretase And Alzheimer's Disease. **2007**, 89-109
- 281 Alzheimer disease therapy: can the amyloid cascade be halted?. **2003**, 111, 11-8 42
- 280 Neurogenesis in Alzheimer's Disease. **2006**, 359-370
- 279 Mouse Model for Alzheimer's Disease. **2008**, 191-199
- 278 Amyloid  $\beta$  Peptide and Central Cholinergic Neurons: Involvement in Normal Brain Function and Alzheimer's Disease Pathology. **2007**, 159-178
- 277 Physiologic and Neurotoxic Properties of A $\beta$  Peptides. **2007**, 179-197
- 276 Glial Cells and A $\beta$  Peptides in Alzheimer's Disease Pathogenesis. **2007**, 216-233
- 275 Multiple Levels of Synaptic Regulation by NMDA-type Glutamate Receptor in Normal and Disease States. **2008**, 75-87
- 274 Polyphenols as Potential Therapeutic Drugs in Neurodegeneration. 0
- 273 Animal Models for Brain Research. **2021**, 3-55
- 272 [The future of dementia prevention and treatment strategies]. **2020**, 57, 374-396
- 271 Proposition of Potential GSK-3 $\beta$  Inhibitors for the Treatment of Alzheimer's Disease: A Molecular Modeling Study. **2020**, 16, 541-554
- 270 Interactions between beta-amyloid and central cholinergic neurons: implications for Alzheimer's disease. **2004**, 29, 427-41 224



269	L-arginine and Alzheimer's disease. <b>2009</b> , 2, 211-38	36
268	The amyloid beta ion channel hypothesis of Alzheimer's disease. <b>2007</b> , 3, 597-612	51
267	Bioenergetics breakdown in Alzheimer's disease: targets for new therapies. <b>2011</b> , 3, 133-9	11
266	The Association between Sporadic Alzheimer's Disease and the Human ABCA1 and APOE Gene Polymorphisms in Iranian Population. <b>2011</b> , 13, 256-62	6
265	Mycoplasma hyorhinis markedly degrades $\beta$ amyloid peptides in vitro and ex vivo: a novel biological approach for treating Alzheimer's disease?. <b>2013</b> , 5, 634-42	0
264	An information extraction framework for cohort identification using electronic health records. <b>2013</b> , 2013, 149-53	66
263	Identification of microRNAs involved in Alzheimer's progression using a rabbit model of the disease. <b>2014</b> , 3, 33-44	24
262	Metabolomic Identification in Cerebrospinal Fluid of the Effects of High Dietary Cholesterol in a Rabbit Model of Alzheimer's Disease. <b>2012</b> , 2, 109	2
261	Neuronal differentiation of rat hair follicle stem cells: the involvement of the neuroprotective factor Seladin-1 (DHCR24). <b>2014</b> , 18, 136-42	4
260	Neurological and psychiatric disorders as a neuroglial failure. <b>2014</b> , 116, 115-124	11
259	Protein Drug Targets of 'Lavandula angustifolia' on treatment of Rat Alzheimer's Disease. <b>2015</b> , 14, 291-302	16
258	Flavanone glycosides as acetylcholinesterase inhibitors: computational and experimental evidence. <b>2014</b> , 76, 567-70	13
257	Neural stem/progenitor cells in Alzheimer's disease. <b>2016</b> , 89, 23-35	39
256	Amyloid-beta Alzheimer targets - protein processing, lipid rafts, and amyloid-beta pores. <b>2016</b> , 89, 5-21	57
255	Hypoxia increases amyloid- $\beta$ level in exosomes by enhancing the interaction between CD147 and Hook1. <b>2018</b> , 10, 150-163	4
254	Ginsenoside Rb1 inhibit apoptosis in rat model of Alzheimer's disease induced by A $\beta$ <b>2018</b> , 10, 796-805	16
253	Association of G/C (rs638405) Polymorphism in Gene with Alzheimer's Disease. <b>2018</b> , 10, 242-247	
252	SQZ granules, a traditional Chinese herbal, attenuate cognitive deficits in AD transgenic mice by modulating on multiple pathogenesis processes. <b>2018</b> , 10, 3857-3875	4

251	Detection of misfolded protein aggregates from a clinical perspective. <b>2016</b> , 2, 11-26	3
250	Partial Identification of Amyloid- $\beta$ Degrading Activity in Human Serum. <b>2019</b> , 81, 55-64	
249	Delta-Aminolevulinate dehydratase and glutathione peroxidase activity in Alzheimer's disease: a case-control study. <b>2019</b> , 18, 866-875	
248	Phosphoinositide 3-kinase inhibitor AS605240 ameliorates streptozotocin-induced Alzheimer's disease like sporadic dementia in experimental rats. <b>2020</b> , 19, 71-85	3
247	A T231E Mutant that Mimics Pathologic Phosphorylation of Tau in Alzheimer's disease Causes Activation of the Mitochondrial Unfolded Protein Response in touch neurons. <b>2020</b> , 2020,	1
246	Role of caspases, apoptosis and additional factors in pathology of Alzheimer's disease. <b>2022</b> , 69-151	0
245	Differential effects of chronic stress on anxiety-like behavior and contextual fear conditioning in the TgF344-AD rat model of Alzheimer's disease. <b>2022</b> , 418, 113661	
244	ReRF-Pred: predicting amyloidogenic regions of proteins based on their pseudo amino acid composition and tripeptide composition. <b>2021</b> , 22, 545	1
243	Protect Effects of Seafood-Derived Plasmalogens Against Amyloid-Beta (1-42) Induced Toxicity via Modulating the Transcripts Related to Endocytosis, Autophagy, Apoptosis, Neurotransmitter Release and Synaptic Transmission in SH-SY5Y Cells.. <b>2021</b> , 13, 773713	0
242	Sex Differences in Behavior and Molecular Pathology in the 5XFAD Model. <b>2021</b> ,	1
241	Destabilization of the Alzheimer's amyloid- $\beta$ peptide by a proline-rich $\beta$ sheet breaker peptide: a molecular dynamics simulation study. <b>2021</b> , 27, 356	1
240	G-Quadruplexes in Neurobiology and Virology: Functional Roles and Potential Therapeutic Approaches.. <b>2021</b> , 1, 2146-2161	3
239	CRISPR-Cas9-Mediated Gene Therapy in Neurological Disorders. <b>2021</b> , 1	4
238	PrP as a Transducer of Physiological and Pathological Signals. <b>2021</b> , 14, 762918	1
237	Tau activates microglia via the PQBP1-cGAS-STING pathway to promote brain inflammation. <b>2021</b> , 12, 6565	4
236	A Revisit to Etiopathogenesis and Therapeutic Strategies in Alzheimer's Disease. <b>2021</b> ,	0
235	RECENT ADVANCES IN PHARMACOTHERAPY OF ALZHEIMER'S DISEASE. 20-23	
234	Phytosterols: Potential Metabolic Modulators in Neurodegenerative Diseases. <b>2021</b> , 22,	4

- 233 Chemical Constituents from the Wild Koidz and Acetylcholinesterase Inhibitory Activity Evaluation as Well as Molecular Docking Study. **2021**, 26, 0
- 232 Extracellular Vesicles Released from Nprilysin Gene-Modified Human Umbilical Cord-Derived Mesenchymal Stem Cell Enhance Therapeutic Effects in an Alzheimer's Disease Animal Model.. **2021**, 2021, 5548630 0
- 231 Macrocyclic BACE1 inhibitors with hydrophobic cross-linked structures: Optimization of ring size and ring structure. **2021**, 52, 116517
- 230 Comparative Study of the Efficacy of L-Tryptophan Nanoparticles on Motor and Cognitive Behavior in an Alzheimer's Experimental Model. **2021**, 64,
- 229 A Dual-Mechanism-Driven Electrochemiluminescence Aptasensor for Sensitive Detection of  $\beta$ Amyloid Peptide.
- 228 Research Progress of Zhi San Zhen Acupuncture in the Treatment of AD Mild Cognitive Impairment. **2021**, 10, 828-834
- 227 A partial reduction of Drp1 improves cognitive behavior and enhances mitophagy, autophagy and dendritic spines in a transgenic tau mouse model of Alzheimer disease.. **2021**, 0
- 226 Discovery of novel  $\beta$ carboline derivatives as selective AChE inhibitors with GSK-3 $\beta$  inhibitory property for the treatment of Alzheimer's disease.. **2021**, 229, 114095 3
- 225 The novel therapeutic strategy of vilazodone-donepezil chimeras as potent triple-target ligands for the potential treatment of Alzheimer's disease with comorbid depression.. **2021**, 229, 114045 1
- 224 Investigation of Experimental and In Silico Physicochemical Properties of Thiazole-Pyridinium Anti-Acetylcholinesterase Derivatives with Potential Anti-Alzheimer's Activity. **2020**, 27, 366-377 2
- 223 Skin Mirrors Brain: A Chance for Alzheimer's Disease Research.. **2021**, 1339, 371-380 1
- 222 Chemoselective Bioconjugation of Amyloidogenic Protein Antigens to PEGylated Microspheres Enables Detection of  $\beta$ Synuclein Autoantibodies in Human Plasma.. **2022**,
- 221 Mechanistic insights into intramembrane proteolysis by E. coli site-2 protease homolog RseP.
- 220 Mechanistic Link between Vitamin B12 and Alzheimer's Disease.. **2022**, 12, 2
- 219 The role of membranes in function and dysfunction of intrinsically disordered amyloidogenic proteins.. **2022**, 128, 397-434
- 218 Neurodegenerative disease by SRS microscopy. **2022**, 501-514
- 217 Multiscale Entropy Analysis of Retinal Signals Reveals Reduced Complexity in a Mouse Model of Alzheimer's Disease.
- 216 Sodium tanshinone IIA sulfonate improves cognitive impairment via regulating A $\beta$  transportation in AD transgenic mouse model.. **2022**, 1 1

215	A Lycium barbarum extract inhibits $\beta$ amyloid toxicity by activating the antioxidant system and mtUPR in a Caenorhabditis elegans model of Alzheimer's disease.. <b>2022</b> , 36, e22156	3
214	Deep proteome analysis of plasma reveals novel biomarkers of mild cognitive impairment and Alzheimer's disease: A longitudinal study.	0
213	Bioelectrochemical analysis of neurodegeneration: Refocusing efforts. <b>2022</b> , 32, 100924	1
212	Possible association between PM and neurodegenerative diseases: A systematic review.. <b>2021</b> , 208, 112581	2
211	Anti-Amyloidogenic and Fibril-Disaggregating Potency of the Levodopa-Functionalized Gold Nanoroses as Exemplified in a Diphenylalanine-Based Amyloid Model.. <b>2022</b> ,	0
210	Purification of polyphenols from Phyllanthus emblica L. pomace using macroporous resins: Antioxidant activity and potential anti-Alzheimer's effects.. <b>2022</b> ,	0
209	Exosomes Mediate APP Dysregulation APP-miR-185-5p Axis.. <b>2022</b> , 10, 793388	0
208	Drug Design Targeting the Muscarinic Receptors and the Implications in Central Nervous System Disorders.. <b>2022</b> , 10,	2
207	A Review of the Current Mammalian Models of Alzheimer's Disease and Challenges That Need to Be Overcome. <b>2021</b> , 22,	4
206	Alzheimer's Disease. <b>2021</b> , 1-22	
205	Engineering of donor-acceptor-donor curcumin analogues as near-infrared fluorescent probes for imaging of amyloid- $\beta$ species.. <b>2022</b> , 12, 3178-3195	0
204	Nanoparticle-mediated delivery of AChE inhibitors for the treatment of Alzheimer's disease. <b>2022</b> , 223-242	
203	A dual-mechanism-driven electrochemiluminescence aptasensor for sensitive detection of $\beta$ amyloid peptides.. <b>2022</b> ,	
202	The neuroprotective effects of icariin on ageing, various neurological, neuropsychiatric disorders, and brain injury induced by radiation exposure.. <b>2022</b> , 14,	1
201	Effects of Familial Alzheimer's Disease Mutations on the Assembly of a $\beta$ Hairpin Peptide Derived from A $\beta$ <b>2022</b> ,	0
200	A Synergistic Combination of DHA, Luteolin, and Urolithin A Against Alzheimer's Disease.. <b>2022</b> , 14, 780602	3
199	Exercise-Eating Pattern and Social Inclusion (EES) is an Effective Modulator of Pathophysiological Hallmarks of Alzheimer's Disease.	
198	The pathogenic effects of particulate matter on neurodegeneration: a review.. <b>2022</b> , 29, 15	3

197	Early Cellular, Molecular, Morphological and Behavioral Changes in the Humanized Amyloid-Beta-Knock-In Mouse Model of Late-Onset Alzheimer's Disease.. <b>2022</b> , 11,	3
196	Exercise with 40-Hz light flicker improves hippocampal insulin signaling in Alzheimer disease mice.. <b>2022</b> , 18, 20-27	
195	Optogenetics: implications for Alzheimer's disease research and therapy.. <b>2022</b> , 15, 20	1
194	Administration of miR-195 Inhibitor Enhances Memory Function Through Improving Synaptic Degradation and Mitochondrial Dysfunction of the Hippocampal Neurons in SAMP8 Mice.. <b>2021</b> ,	0
193	Neurochemical and cognitive changes precede structural abnormalities in the TgF344-AD rat model.. <b>2022</b> , 4, fcac072	0
192	Plasma Aβ as a biomarker for predicting AβPET status in Alzheimer's disease:a systematic review with meta-analysis.. <b>2022</b> ,	0
191	Getting Into the Brain: The Intranasal Approach to Enhance the Delivery of Nerve Growth Factor and Its Painless Derivative in Alzheimer's Disease and Down Syndrome.. <b>2022</b> , 16, 773347	0
190	Senegenin Inhibits Aβ-Induced PC12 Cells Apoptosis and Oxidative Stress via Activation of the PI3K/Akt Signaling Pathway.. <b>2022</b> , 18, 513-524	1
189	Finding Cures for Alzheimer's Disease. <b>2022</b> , 51-83	
188	Structural Plasticity of the Hippocampus in Neurodegenerative Diseases.. <b>2022</b> , 23,	3
187	Mass spectrometric studies of the variety of beta-amyloid proteoforms in Alzheimer's disease.. <b>2022</b> , e21775	0
186	Effects of subchronic dietary exposure to the engineered nanomaterials SiO and CeO in C57BL/6J and 5xFAD Alzheimer model mice.. <b>2022</b> , 19, 23	1
185	Modulation of amyloid precursor protein cleavage by β-secretase activating protein through phase separation.. <b>2022</b> , 119, e2122292119	1
184	Oleuropein-Rich Olive Leaf Extract Attenuates Neuroinflammation in the Alzheimer's Disease Mouse Model.. <b>2022</b> ,	2
183	β-secretase in Alzheimer's disease.. <b>2022</b> ,	6
182	Dietary consumption of desert olive tree pearls reduces brain Aβ content and improves learning and memory ability in aged mice. <b>2022</b> , 91, 105021	
181	The transmembrane domain of the amyloid precursor protein is required for anti-amyloidogenic processing by β-secretase ADAM10.. <b>2022</b> , 101911	1
180	BACE1 Overexpression Reduces SH-SY5Y Cell Viability Through a Mechanism Distinct from Amyloid-β Peptide Accumulation: Beta Prime-Mediated Competitive Depletion of sAPPβ <b>2022</b> , 86, 1201-1220	

179	Therapeutic strategies for tauopathies and drug repurposing as a potential approach.. <b>2022</b> , 198, 114979	1
178	Exploring the journey of emodin as a potential neuroprotective agent: Novel therapeutic insights with molecular mechanism of action.. <b>2022</b> , 149, 112877	11
177	Advancements in the development of multi-target directed ligands for the treatment of Alzheimer's disease.. <b>2022</b> , 61, 116742	3
176	Biochanin A alleviates cognitive impairment and hippocampal mitochondrial damage in ovariectomized APP/PS1 mice.. <b>2022</b> , 100, 154056	0
175	Enhancing autophagy in Alzheimer's disease through drug repositioning.. <b>2022</b> , 237, 108171	4
174	Pyroglutamate A $\beta$ cascade as drug target in Alzheimer's disease. <b>2021</b> ,	6
173	H detection and dynamic nuclear polarization-enhanced NMR of A $\beta$ fibrils.. <b>2022</b> , 119,	6
172	Cellular and Molecular Mechanisms of Proinflammatory Monocytes Participation in the Pathogenesis of Mental Disorders. Part 3. <b>2021</b> , 19, 125-134	
171	YKL-40 as a Potential Biomarker for the Differential Diagnosis of Alzheimer's Disease.. <b>2021</b> , 58,	1
170	Anti-inflammatory and neuroprotective effects of astragalin isolated from <i>Aster scaber</i> . <b>2021</b> , 28, 1000-1009	1
169	Establishing pre-analytical requirements and maximizing peptide recovery in the analytical phase for mass spectrometric quantification of amyloid- $\beta$ peptides 1-42 and 1-40 in CSF. <b>2021</b> ,	0
168	Arterial stiffness, pulsatile hemodynamics, and the vascular contributions to dementia. <b>2022</b> , 649-663	
167	Protective Effects against the Development of Alzheimer's Disease in an Animal Model through Active Immunization with Methionine-Sulfoxide Rich Protein Antigen.. <b>2022</b> , 11,	
166	Other neurodegenerative conditions I. 249-258	
165	Table_1.PDF. <b>2018</b> ,	
164	Image_1.JPEG. <b>2020</b> ,	
163	Image_2.JPEG. <b>2020</b> ,	
162	DataSheet_1.docx. <b>2020</b> ,	

161 Image\_1.pdf. **2018,**

160 Image\_2.pdf. **2018,**

159 Image\_3.pdf. **2018,**

158 Table\_1.pdf. **2018,**

157 Table\_2.pdf. **2018,**

156 Table\_3.pdf. **2018,**

155 Table\_4.pdf. **2018,**

154 Data\_Sheet\_1.pdf. **2018,**

153 Data\_Sheet\_1.pdf. **2020,**

152 data\_sheet\_1.xlsx. **2018,**

151 data\_sheet\_2.xlsx. **2018,**

150 data\_sheet\_3.xlsx. **2018,**

149 data\_sheet\_4.xlsx. **2018,**

148 data\_sheet\_5.xlsx. **2018,**

147 data\_sheet\_6.xlsx. **2018,**

146 data\_sheet\_7.xlsx. **2018,**

145 data\_sheet\_8.xlsx. **2018,**

144 presentation\_1.PDF. **2018,**

143	Data_Sheet_1.docx. <b>2019</b> ,	
142	Table_1.DOCX. <b>2020</b> ,	
141	Table_2.docx. <b>2020</b> ,	
140	Table_1.DOCX. <b>2019</b> ,	
139	Image1.TIFF. <b>2018</b> ,	
138	Presentation1.PDF. <b>2018</b> ,	
137	Presentation2.PDF. <b>2018</b> ,	
136	Presentation3.PDF. <b>2018</b> ,	
135	Table1.DOCX. <b>2018</b> ,	
134	Table2.DOCX. <b>2018</b> ,	
133	DataSheet_1.zip. <b>2019</b> ,	
132	[Proteolytic cleavage of neuroligins and functions of their cleavage products]. <b>2020</b> , 49, 514-523	1
131	Copper Chelating Cyclic Peptidomimetic Inhibits A $\beta$ Fibrillogenesis.	0
130	Stoichiometric Ratio Controlled Dimension Transition and Supramolecular Chirality Enhancement in a Two-Component Assembly System. <b>2022</b> , 8, 269	0
129	Magnetic resonance elastography of the ageing brain in normal and demented populations: A systematic review.. <b>2022</b> ,	2
128	Multifunctional Anti-Alzheimer $\beta$ Disease Effects of Natural Xanthone Derivatives: A Primary Structure-Activity Evaluation. <b>2022</b> , 10,	1
127	Amyloid- $\beta$ Oligomers: Multiple Moving Targets. <b>2022</b> , 2, 91-110	2
126	Mechanisms of Mitochondrial Malfunction in Alzheimer $\beta$ Disease: New Therapeutic Hope. <b>2022</b> , 2022, 1-28	7



125	Transcriptional Profiling of Hippocampus Identifies Network Alterations in Alzheimer's Disease. <b>2022</b> , 12, 5035	
124	The Correlations of Plasma Liver-Type Fatty Acid-Binding Protein with Amyloid- $\beta$ and Tau Levels in Patients with Alzheimer's Disease. <b>2022</b> , 1-9	
123	Effects of Familial Alzheimer's Disease Mutations on the Folding Free Energy and Dipole-Dipole Interactions of the Amyloid $\beta$ Peptide.	
122	A 512-ch dual-mode microchip for simultaneous measurements of electrophysiological and neurochemical activities.	
121	Altered TIMP-3 Levels in the Cerebrospinal Fluid and Plasma of Patients with Alzheimer's Disease. <b>2022</b> , 12, 827	1
120	Impact of different processing methods on phenolics and neuroprotective activity of <i>Fragaria ananassa</i> Duch. extracts in a D-galactose and aluminum chloride induced rat model of aging.	
119	Allosteric Binding Sites of Ab Peptides on the Acetylcholine Synthesizing Enzyme ChAT as Deduced by In Silico Molecular Modeling. <b>2022</b> , 23, 6073	2
118	Multiscale entropy analysis of retinal signals reveals reduced complexity in a mouse model of Alzheimer's disease. <b>2022</b> , 12,	1
117	Isotope-labeled amyloid- $\beta$ does not transmit to the brain in a prion-like manner after peripheral administration.	1
116	Single Cell/Nucleus Transcriptomics Comparison in Zebrafish and Humans Reveals Common and Distinct Molecular Responses to Alzheimer's Disease. <b>2022</b> , 11, 1807	0
115	Identification of differentially expressed novel tau associated proteins in transgenic AD model of <i>Drosophila</i> - a proteomic and in silico Approach.	
114	N-terminally truncated A $\beta$ -x proteoforms and their relevance for Alzheimer's pathophysiology. <b>2022</b> , 11,	0
113	7,8-Dihydroxycoumarin Alleviates Synaptic Loss by Activated PI3K-Akt-CREB-BDNF Signaling in Alzheimer's Disease Model Mice.	1
112	Pathologie et physiopathologie de la maladie d'Alzheimer. <b>2022</b> , 17-28	
111	Site specific NMR characterization of abeta-40 oligomers cross seeded by abeta-42 oligomers.	1
110	Additions to Alpha-Sheet Based Hypotheses for the Cause of Alzheimer's Disease. <b>2022</b> , 1-10	0
109	Amyloids on Membrane Interfaces: Implications for Neurodegeneration.	0
108	Probiotic <i>Bifidobacterium breve</i> MCC1274 Mitigates Alzheimer's Disease-Related Pathologies in Wild-Type Mice. <b>2022</b> , 14, 2543	2

107	Rational Design of a Theranostic Agent Triggered by Endogenous Nitric Oxide in a Cellular Model of Alzheimer's Disease.		0
106	Identification of sulfonamide-based butyrylcholinesterase inhibitors using machine learning.		
105	The dense-core plaques of Alzheimer's disease are granulomas. <b>2022</b> , 219,		2
104	FTY720 decreases ceramides levels in the brain and prevents memory impairments in a mouse model of familial Alzheimer's disease expressing APOE4. <b>2022</b> , 152, 113240		1
103	The double-layered structure of amyloid- $\beta$ assemblage on GM1-containing membranes catalytically promotes fibrillization.		1
102	Study protocol for the Alzheimer and music therapy study: An RCT to compare the efficacy of music therapy and physical activity on brain plasticity, depressive symptoms, and cognitive decline, in a population with and at risk for Alzheimer's disease. <b>2022</b> , 17, e0270682		0
101	A partial reduction of VDAC1 enhances mitophagy, autophagy, synaptic activities in a transgenic Tau mouse model.		1
100	Biomedical and Potential Therapeutic Aspects of Lithium Carbonate Use. <b>2022</b> , 20, 109-116		
99	Golgi stress induces upregulation of the ER-Golgi SNARE Syntaxin-5, altered APP processing, and Caspase-3-dependent apoptosis in NG108-15 cells. <i>Molecular and Cellular Neurosciences</i> , <b>2022</b> , 103754	4.8	0
98	Black mulberry ( <i>Morus nigra</i> ) fruit extract alleviated AD-Like symptoms induced by toxic A $\beta$ protein in transgenic <i>Caenorhabditis elegans</i> via insulin DAF-16 signaling pathway. <b>2022</b> , 111696		1
97	Protein aggregation rate depends on mechanical stability of fibrillar structure .		1
96	Implementing a Scoring Function Based on Interaction Fingerprint for Autogrow4: Protein Kinase CK1 as a Case Study. 9,		4
95	Sustained high body temperature exacerbates cognitive function and Alzheimer's disease-related pathologies. <b>2022</b> , 12,		1
94	The AICD fragment of APP initiates a FoxO3a mediated response via FANCD2. <i>Molecular and Cellular Neurosciences</i> , <b>2022</b> , 122, 103760	4.8	
93	Selective Detection of Misfolded Tau From Postmortem Alzheimer's Disease Brains. 14,		1
92	A $\beta$ 2 oligomers can seed the fibrillization of A $\beta$ 40 peptides.		
91	Mechanistic insights into intramembrane proteolysis by E. coli site-2 protease homolog RseP. <b>2022</b> , 8,		1
90	Functionalization strategies of polymeric nanoparticles for drug delivery in Alzheimer's disease: Current trends and future perspectives. 16,		1

89	Therapeutic roles of plants for 15 hypothesised causal bases of Alzheimer’s disease. <b>2022</b> , 12,	0
88	Polyphenolic Contents, Free Radical Scavenging and Cholinesterase Inhibitory Activities of <i>Dalbergiella welwitschii</i> Leaf Extracts. <b>2022</b> , 11, 2066	1
87	Reduced VDAC1, Maintained Mitochondrial Dynamics and Enhanced Mitochondrial Biogenesis in a Transgenic Tau Mouse Model of Alzheimer’s Disease. <b>2022</b> , 23, 8561	0
86	Kaempferol as a potential neuroprotector in Alzheimer’s disease.	1
85	Tau liquid-liquid phase separation: At the crossroads of tau physiology and tauopathy.	2
84	Protective effect of apolipoprotein E epsilon 3 on sporadic Alzheimer’s disease in the Chinese population: a meta-analysis. <b>2022</b> , 12,	0
83	Comprehensive review of Ecbarboline alkaloids: Natural products, updated synthesis, and biological activities. 10,	
82	Effects of pramipexole on beta-amyloid1 $\beta$ 2 memory deficits and evaluation of oxidative stress and mitochondrial function markers in the hippocampus of Wistar rat. <b>2022</b> , 92, 91-101	1
81	Synthesis, molecular docking and enzyme inhibitory approaches of some new chalcones engrafted pyrazole as potential antialzheimer, antidiabetic and antioxidant agents. <b>2022</b> , 1269, 133843	3
80	Molecular Insights into the Role of ER Stress in Neurodegenerative Diseases. <b>2022</b> , 219-249	0
79	Mechanistic regulation of Esecretase by their substrates. <b>2022</b> , 24, 19223-19232	0
78	Neuroprotection of Triptolide against Amyloid-Beta1-42-induced toxicity via the Akt/mTOR/p70S6K-mediated Autophagy Pathway. <b>2022</b> , 94,	0
77	Impaired autophagy in amyloid-beta pathology: A traditional review of recent Alzheimer’s research. <b>2022</b> , 37, 1	0
76	Mitochondrial Dysregulation and the Influence in Neurodegenerative Diseases. <b>2022</b> , 109-118	0
75	Pharmacological importance of <i>Bacopa monnieri</i> on Neurological disease (Alzheimer’s Disease) and Diabetic neuropathy - A Concise Review. <b>2022</b> , 3790-3795	0
74	Herpes Simplex Virus Infection Increases Beta-Amyloid Production and Induces the Development of Alzheimer’s Disease. <b>2022</b> , 2022, 1-11	0
73	A Combination Therapy of Urolithin A+EGCG Has Stronger Protective Effects than Single Drug Urolithin A in a Humanized Amyloid Beta Knockin Mice for Late-Onset Alzheimer’s Disease. <b>2022</b> , 11, 2660	2
72	The Feasibility of Early Alzheimer’s Disease Diagnosis Using a Neural Network Hybrid Platform. <b>2022</b> , 12, 753	0

71	Mitochondrial DNA Repair in Neurodegenerative Diseases and Ageing. <b>2022</b> , 23, 11391	1
70	TNF- $\alpha$ and IL-1 $\beta$ Modulate Blood-Brain Barrier Permeability and Decrease Amyloid- $\beta$ Peptide Efflux in a Human Blood-Brain Barrier Model. <b>2022</b> , 23, 10235	3
69	Effects of Familial Alzheimer's Disease Mutations on the Folding Free Energy and Dipole-Dipole Interactions of the Amyloid $\beta$ Peptide. <b>2022</b> , 126, 7552-7566	0
68	Covalent fragment inhibits intramembrane proteolysis. 9,	0
67	Structure of the Blood Brain Barrier and the Role of Transporters in the movement of substrates across the barriers.	0
66	Soft nano and microstructures for the photomodulation of cellular signaling and behavior. <b>2022</b> , 190, 114554	0
65	Alzheimer's disease: genetic and modifiable lifestyle influences. <b>2022</b> ,	0
64	Alzheimer's Disease. <b>2022</b> , 4323-4344	0
63	Telomere-induced senescence increases aberrant intraneuronal amyloid- $\beta$ accumulation by impairing autophagy in a mouse model of Alzheimer's disease.	0
62	Functionalization of Morin-Loaded PLGA Nanoparticles with Phenylalanine Dipeptide Targeting the Brain. <b>2022</b> , 14, 2348	0
61	Potential of Therapeutic Small Molecules in Apoptosis Regulation in the Treatment of Neurodegenerative Diseases: An Updated Review. <b>2022</b> , 27, 7207	1
60	Advancement in Analytical Techniques for Determining the Activity of Site Amyloid Precursor Protein Cleaving Enzyme 1. 1-13	0
59	Phosphorylated Tau in Alzheimer's Disease and Other Tauopathies. <b>2022</b> , 23, 12841	3
58	Amyloid Beta in Aging and Alzheimer's Disease. <b>2022</b> , 23, 12924	5
57	Redox signaling and metabolism in Alzheimer's disease. 14,	0
56	The Interplay between Ghrelin and Microglia in Neuroinflammation: Implications for Obesity and Neurodegenerative Diseases. <b>2022</b> , 23, 13432	2
55	Tooth Loss Induces Memory Impairment and Glial Activation in Young Wild-Type Mice. <b>2022</b> , 6, 663-675	2
54	Amyloidogenesis: What Do We Know So Far?. <b>2022</b> , 23, 13970	2

53	Application of the Loewner Equation for Neurite Outgrowth Mechanism.	0
52	In vitro enzymatic evaluation of some pyrazolo[1,5- a ]pyrimidine derivatives: Design, synthesis, antioxidant, anti-diabetic, anti-Alzheimer, and anti-arthritic activities with molecular modeling simulation.	2
51	Site-Specific Phospho-Tau Aggregation-Based Biomarker Discovery for AD Diagnosis and Differentiation.	0
50	Reduced Expression of Voltage-Gated Sodium Channel Beta 2 Restores Neuronal Injury and Improves Cognitive Dysfunction Induced by A $\beta$ -42. <b>2022</b> , 2022, 1-21	0
49	Depression-related phenotypes at early stages of A $\beta$ and tau accumulation in inducible Alzheimer's disease mouse model: task-oriented and concept-driven interpretations. <b>2022</b> , 114187	0
48	The contribution of an imbalanced redox signalling to neurological and neurodegenerative conditions. <b>2023</b> , 194, 71-83	0
47	Analysis of the time-dependent changes of phospholipids in the brain regions of a mouse model of Alzheimer's disease. <b>2023</b> , 1800, 148197	0
46	Extracting Multiple Nodes in a Brain Region of Interest for Brain Functional Network Estimation and Classification. <b>2022</b> , 10, 3408-3423	0
45	A Review of the Recent Advances in Alzheimer's Disease Research and the Utilization of Network Biology Approaches for Prioritizing Diagnostics and Therapeutics. <b>2022</b> , 12, 2975	1
44	The impact of context on pattern separation for objects among younger and older apolipoprotein E4 carriers and noncarriers. 1-11	0
43	Concentration Effect, Structural Properties, and Driving Force on A $\beta$ 28 Dimerization with and without Zn <sup>2+</sup> Cooperation: Learning from Replica Exchange Sampling**.	0
42	Hexameric Aggregation Nucleation Core Sequences and Diversity of Pathogenic Tau Strains. <b>2022</b> , 11, 1559	0
41	CRISPR: a tool with potential for genomic reprogramming in neurological disorders.	0
40	Multivariate effects of pH, salt, and Zn <sup>2+</sup> ions on A $\beta$ 0 fibrillation. <b>2022</b> , 5,	1
39	Ginsenoside Rg1 ameliorates Alzheimer's disease pathology via restoring mitophagy. <b>2022</b> ,	0
38	Iron-Calcium Crosstalk in Neurodegenerative Diseases. <b>2023</b> , 109-137	0
37	iPSC-Derived PSEN2 (N141I) Astrocytes and Microglia Exhibit a Primed Inflammatory Phenotype.	0
36	A Promising Strategy to Treat Neurodegenerative Diseases by SIRT3 Activation. <b>2023</b> , 24, 1615	0

- 35 Impact of nanoparticles on amyloid beta-induced Alzheimer's disease, tuberculosis, leprosy and cancer: A systematic review. ○
- 34 iPSC-Derived Striatal Medium Spiny Neurons from Patients with Multiple System Atrophy Show Hypoexcitability and Elevated  $\beta$ Synuclein Release. **2023**, 12, 223 ○
- 33 Adipokines and Alzheimer's Disease. **2011**, 130-148 ○
- 32 CELLULAR STRESS RESPONSE (HORMESIS) IN RESPONSE TO BIOACTIVE NUTRACEUTICALS WITH RELEVANCE TO ALZHEIMER DISEASE. ○
- 31 Potential Protective Function of A $\beta$ 2 Monomer on Tauopathies. ○
- 30 Aggregation of Disordered Proteins Associated with Neurodegeneration. **2023**, 24, 3380 1
- 29 Brain targeting based nanocarriers loaded with resveratrol in Alzheimer's disease: A review. ○
- 28 Compensatory remodeling of a septo-hippocampal GABAergic network in the triple transgenic Alzheimer's mouse model. **2023**, 21, ○
- 27 Oxidative stress: A target to treat Alzheimer's disease and stroke. **2023**, 165, 105509 ○
- 26 The pathomimetic  $\alpha$ A $\beta$ 5 $\beta$ 5 model of Alzheimer's disease: Potential for screening of new therapeutic agents. **2023**, 245, 108398 ○
- 25 Gamma secretase inhibition: Effects on fertility and embryo-fetal development in rats. **2023**, 116512 ○
- 24 Relationships between neurotransmitter receptor densities and expression levels of their corresponding genes in the human hippocampus. **2023**, 273, 120095 ○
- 23 Role of UCHL1 in the pathogenesis of neurodegenerative diseases and brain injury. **2023**, 86, 101856 ○
- 22 Lipidomics and proteomics: An integrative approach for early diagnosis of dementia and Alzheimer's disease. 14, ○
- 21 Bilateral Hippocampal Volume Mediated the Relationship Between Plasma BACE1 Concentration and Memory Function in the Early Stage of Alzheimer's Disease: A Cross-Sectional Study. **2023**, 92, 1001-1013 ○
- 20 Intrahippocampal Inoculation of A $\beta$ 2 Peptide in Rat as a Model of Alzheimer's Disease Identified MicroRNA-146a-5p as Blood Marker with Anti-Inflammatory Function in Astrocyte Cells. **2023**, 12, 694 ○
- 19 Neuroanatomical and morphometric study of S100 $\beta$  positive astrocytes in the entorhinal cortex during ageing in the 3xTg-Alzheimer's disease mouse model. **2023**, 802, 137167 ○
- 18 Functional aberration of cortical neuronal network induced by A $\beta$ 2 oligomer. ○

- 17 Alzheimer's Disease and Alzheimer's Disease-Related Dementias in African Americans: Focus on Caregivers. **2023**, 11, 868
- 16 Pharmacological applications of bioactive secondary metabolites from plants. **2023**, 235-248
- 15 Research Progress on the Etiology and Pathogenesis of Alzheimer's Disease from the Perspective of Chronic Stress. **2022**, 0
- 14 Clinical Management in Alzheimer's Disease in the Era of Disease-Modifying Therapies. **2023**, 25, 121-133
- 13 Genetic Phenotypes of Alzheimer's Disease: Mechanisms and Potential Therapy.
- 12 High-Affinity Fluorescent Probes for the Detection of Soluble and Insoluble A $\beta$  Deposits in Alzheimer's Disease.
- 11 Neurotoxicology of metals and metallic nanoparticles in *Caenorhabditis elegans*. **2023**,
- 10 Activation of hypothalamic-enhanced adult-born neurons restores cognitive and affective function in Alzheimer's disease. **2023**, 30, 415-432.e6
- 9 Quinolines: Privileged Scaffolds for Developing New Anti-neurodegenerative Agents. **2023**, 8,
- 8 Differential and substrate-specific inhibition of  $\beta$ secretase by the C-terminal region of ApoE2, ApoE3, and ApoE4. **2023**,
- 7 Geraniol improves passive avoidance memory and hippocampal synaptic plasticity deficits in a rat model of Alzheimer's disease. **2023**, 175714
- 6 Molecular Mind Games: The Medicinal Action of Cyclodextrins in Neurodegenerative Diseases. **2023**, 13, 666
- 5 Design, Synthesis and Evaluation of Catechol-Based Amyloid Beta Aggregation Inhibitors. **2023**, 106, 797
- 4 Brain Region-Specific Differences in Amyloid- $\beta$  Plaque Composition in 5XFAD Mice. **2023**, 13, 1053
- 3 New indole derivatives as multitarget anti-Alzheimer's agents: synthesis, biological evaluation and molecular dynamics. **2023**, 15, 473-495
- 2 A 512-Ch Dual-Mode Microchip for Simultaneous Measurements of Electrophysiological and Neurochemical Activities. **2023**, 13, 502
- 1 TXNIP contributes to induction of pro-inflammatory phenotype and caspase-3 activation in astrocytes during Alzheimer's diseases. **2023**, 63, 102735